var title_f32_20_33088="Mondor disease of the breast";
var content_f32_20_33088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mondor disease of the breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD55JAHNOSJpDk5Ap0MOTnqfWtO2ty2OKipW7F0qHcjtbQcYFa0FmuBntUtnbEda17eEbQMDP8AKuGU2z0IUkiilkBjAwD+lXEsjjir8UOMZx1ycipwickHgVm2bKJmfZipwOc/pTWt3PHUn0rXhh3L0IFXLayLsMZx2qLjsc2ts/TBBqX7G4ye/YV2EWjbgNwAXjqajvbFY1HHHrS5i+RWOOBaH13jvirlnqpQgOwI9TVy5tApYgdeOlZctqHBAw2KpakbHX2uopNEMEE9cetQiMfaiSeTkgelcdFLc2MmYyWTuh7/AEroNN1m3nKiR9jjs3BqXEpSNgq2VyuT39qs20AOFOAO9U01CA/IJF49TTJ9WggBG4MegqXcom1h1t4WK4XAxgd68ztl26lIf4Q5/Xmui1jV98JG4EDP4VySzsshmIPlswBPbr1rWnF2Maklod/pkoi+9tHH1re89TbNvbacZHPSud062k2qWOewAGa2Rp7Mg2/Lzyc81zyOmC0NS1k86y2k5I6buhrPedrK7jkONmcEitC1iFvHtOTke+ar3yoRxwMZ+YZrKTNYnZ6TriSRBX8t8rwWapbqWMB2Rg7MPXpXmMayRzkw+Yig5yOh+ladrrMirtk37h/HRzXJdFLVGnr0nlIBgB2447Vm6trLaVpsFvAvm6hdfLBB/wCzN6L/ADqG4uUw19fOVtIjwo+9Kx6Io9San0/TppmkvdUVTfXGCwA4hQfdjH0HWmrLVil/KcvBaSWkjXFwxn1Kb/WS44HsPapDbXEucsSP7vQV2x01Gy2O3P8AhUH2eNCVUYAOeRxS5rjVrWRz9npu05YYPWtUWIRA3pVxUVTuIOT+tPCmQg7Tj3pXbApWtq4XdOFaQ8gJ0A7Vfit8E5z+XQVPEgcgDIzWlbwYCjHOMVREpXZDbW6jaec9elXfI3LwBxz0qfySo+9wPTrViJV2EAnp1p2MnLqVEgVVxxzUnkjYCMZ6Yq2yYOF5x6jvQiY5JG0dB3FKwubqUBvEhBBxgk89amRflyR8p6ZNOaMB9xOfrTD1KHA9z6VJQrKSHB4yeMdRVC53b3AAIHbpmtF+Dnk57+9ULo4yMcZ5poaZi6hkg89e+ayrdD9oGDnnJArS1D5374PrVSzQeeT0IBNbRWg7lpRiMD7qk8E+tXIBiRT3KdepxTLaLzbAEMNyscEDJP4UWbAK7sVLbdoBHCj0pC3L7LlSSFBJBYkcj/61Z2oArGVzjBOB2rR3s2B1UjqRnn39qztVdY4n4yOgx1z71SQkzkNUudisMYJAHFZMUmWZgQFHenavMEVh1GcgD3rJmutsGTit+XQhz1E1jUAikg/ia891fUmu5WVWPljr/tf/AFqs+IdTa4maGNjtHDH+lYqIzthRk120KPKrvc8/EV3N2WwiqXYBRkmtmxsxGu5x8xpLG0EQDMMtV816FKl1Z5GIxH2YkY+U47U49KHGRSJyMd6320OR6q5dtbUkdK2La3249qltbcBRx2rUt4F69K+flK59XCNiO3iA6j6VfihORx1oii/eLkHGKvRx7SuMc1kzdaEYQ4HcdKmS24wB+FWYoxgdAT71ajjBA4yP50iiC1tSwwMlfY1t2tqFQFuxzUVvEAeB+AqzLKMAAgDoaTJvqKoDScD5RVPUFZAVYjb2rXtShiZmIzisbVpflbLDA7elRY1TObu58EKcdeR1qrGA2SMc/rRPmWRiB1PFS2seCMcVoloZvca9n+7Z9hZz2FVJdIDZLqOfSugtxubDZKnippUH3cAjtxSbsVa5xz6ZKrZjdhjpz0qB9Nu26yNz0zXdx2yFl4FTLZKWwUBA/nS5mg5EcHbeHHZQZXJAP3a3LPw9Dc20trOoVWUqfXHr/WupS1jPJ4FW7Oy+cnlmA4PpUObZSjFI5vwqkybtN1EYu7bIDdBKg6MPwrqVhATdtBHoearaxpR1CGGSFmt7yAl4bgdUYdiO4PcU7S7ua7iaK5gNteRcTQ9v95fVT2/KplrqVG60LKx4TJAHOM54qGWFWUjGT64rorK0Qbi0W4EY5PIPapJLOGNCW+X8KzcW9R+1SdjjPsbwlQXEy8/dXbgUslkoJZ0RYlBYs5wFA7muoltF43LweR3zXL6pG+sasdGiYGztwJL9xxn+5Dn1PU+1Qlqae00KGj27atepqUykWMR/0JGH3j/z1I9+1dIgCrl13d8n+tXzF5MSCNFRVUYVRxj0H+FIsasrHAB6AkdvWqepkpdWUGmbhFwCeTimrCdo749a0xZE+WCMj1Pern9nBxwCMd6aiJzSOfNtliMsSf0qZYdvyn2xxXQtYKicKC2fypJLPJGAM+gquUj2lzKt4VEpGQTjgAVpQR98DPcVKlsAxAXGPQc1NCp2D5cn1PFFieYlWJXJPO6lVAifTkYqWJsJtYEHoKesYJbuc96tIxbZW24K9z/IU5I1LEZwM9ql8vLFh0HAHagqAQxH4iiwXKciAE8gc/lVd1G0jAIHYirkgKkliNo54FV3ZdrEYGayaNYsilbc3GNwHcVVkUCPk/8A6qsoQSR271XvQRGTxn6UFGHdkGY4xwMn3qvbLsidiAdoJ5/lTp2zK44wR3pyg/ZWKkn5Tz71uthNmppMa/2ZC7D7w6bue/aoTAwhYLu29cbcHrWpp6KtjEjAjCcZ7n0+tNnRguSACPQZqbCUtTPkcIuBjCj8j9Kwtaut0LgbT7A/rWhfOOTzkDn61y2pvlxuPB+bOOn1q4ouxyWt3GJWIzyOc1yuv6gYbdURsyNwPb3rY1mTEnpzXC307Xd2zdQDtUe1ehShfU8+vUtdFaNGkcKvJNbVpZiGMEjLetJp9mI13N96rpX0zXp0qXVniYjEa8sWIRgCjGRjvTcc8mlArdHGwPpTD8rU8imvytJoqL1O7iTcB7Vo2sf6c1BagYweTWlCoIJxjP6CvnGfXpWFSPIwBz3q1Fb5I4P1pYYgQOozWhDE24euMVLLRBFHh+SevGKurEAQSM4pUQbwSox0walYKrdgOg4pDHAgKMdOuPWlVBI+BznuaiJLLtB96tWq4yW4FZtjSLNziCwyuADxwK4/U5XccZya3NUumk+UnAxmubumI5AySaa1Y37qKsS5bPbHNXrSPb97GD2qrGuHw341bThaslFjbgZ3d+nSpEIONwJI45qJX3EkmhCC+1SMgdetSWmi5bsTJuBIGMYI4FW1LFQRjJPfvVdAscQGT+HenQxndycg9FPalII6mjDllK5B471oWw2jaxGSMDFU4htUDv3Aq5EcvlV59ulZjJAriPbhjjoeuaGszdbAcxzxcpIvVSex9R7Vct4ySrBQCOfb6CrcUYDhwDn1xRYly7FTTdQMlw2m3KLBqYG4xE/K6/34z3Ht1B61pyYSUSMSFPbGc1na1pFpq8IS7EiSI2+K4ibbJCw6Mp7H26GsaPV9V064istXs572WQkR3lmuVdQOsg/hbpnseT2pvYzWrubWo3EkNvthRXuZspDEDyW9T7Ack1Do+ix6bY/Zoy8zs5kllbAMsjcszVZsIST9rkdfOdRnByEXH3VP8z3q1M6lygU9OT6//XrI0b6IrtGy8ZGQOKSG23c4+VjzkdTU8SBsPnC9ApHOa0LddqlSOWGOetVFJmcpOIllbLkDAx2zyTVuOAklVHyr0BHSpraMRREfkMVaiC5HIx61vGCOaU3cotCuwYXJqCSH5cdCRWtKuewwO+O3pVaYZBwByeacoiUjOkh2EsMjjjmk2HBZsbjjirkiEgZ6dfqaaoUBjt6dPeo5TRS0IghXZ0IHT3qULk45GDmkkBYAMuec04KQpPJ9PemJshUfNgY59O1Dn5QFzknAOKseXtXBxzxnriop0bbgjA6ccUrBfUpSgeYFGRjkgc1VuBuyverZBwVH3vcc1UnyTgcGs2jSLIUUxtkgHAqvf8QOx4BGKtICDg9elU9TI8knnaOualI1ucrJJm4kzjGcEVdMbeQi9N+Bgemax4GEl0wByC+Afxroo4900A25wwBroeiFuzZjIVUDAEngEHGT60lx1QBgPl4DU67yhABy3Q57VQmufMG3oFOOOayi+g+W+ph6iWzKMFc9WXiuf1RQI+O2Rk+ldJeHccnk54xxXLaswAdD82OT7VrA0ex5p4rl8uOQg8ngVz2l224h2H0rY8VKWmjQDG5s4plvGI4gB6V7WEhzK587mFXkuluPGAAB0FNOOadgYyabXoniEdKKDxmkFIvcUimmlbg0lA0eiW7cggYx1FaMLnqBjtWLDN847ZPStKKcbcE5I5r5o+yRtW2AhG4mrsbYAwcd8isWKYKBkjH86vQTblJHTGAKTKSNB5A3Cgc+lIxJGG7e9VY3IZc5/LpVhcuBjPHtWbZooli3UMST+FTSyeSmVJ56j2pufLUH8qpXc/UZ7YrNlWKl05ZizcA+/ArKmYNLgHp0OKt3EgxgHknAqofQDiriZy3HBgB7ipMjA4z3qAHPHvxUqfew2ceppiQ9H3D5cZ9MVNCnlqWHI7io4FwTjntWhZoCxHGCaGyupJGm9fY/pV62Ty1AwTjoO9RLGI2yDgduKuRY5+YYzUsaJog44UdeAav26Hdk/e4wSOlVY2OSM8dTVqASCU4YFCBtBHIPeouDRo28iqSCCzdKmZ2Q7mAwehzVSKZVc449c+v0p0zFgzD8MdTTM2tR29QA0jAbQckt8ox1JNcH4710ahbwWdut79ldhK7QS+SJQOmF6uM8BjgZPGasfETUpbfQYre0I33T+USRn5QCWH49K5uzt2Y2lpBK2yWXzFnc48yRMKEGeDjPB5xnilJ2ElffodJ4e8c2lxdpZ31rdafMx2xNMdyHHYtxz+Fd0pxueUsEUdBxxXlWr2tpeaM890bprk7lErjIndDlmRsY4GBzzXovhoSal4XsD5rIzWyfO/Jxjv8A41CfMrpFt2dma2lzx3ULujZw2cHrj/69ai8YJA9h3rP020S2gAjYHnLP0LVeixsGOD6VcL21Malru2xchkOCvJBGeB0qdTuUcZIqgGbk8Z9KmjPO7+H+dbxkYOJbDAK244B4+lQTkbMZOV6AetIWJUDgkfpVd5CCORz3x1ptiSGuTuwD+RpcEABe59aRW+Uufp9KVSAMAkjpxWZoS7844I96VUJU4H4HtTQcDnkj3qTnA9/TtVEAEx9etQTj5cE4qy3B5+7joO9QyAEbjyOMZ70mC3KMwYMODt9aoTbVOeDyenatK4ckMoAB7GstyEcDj06VnI2iLEN7Zx+J6mszXmEdnI3I4Jwa17Y/wgE98E9a53xqxj0e7dcblQj9KSWpaepzPhxN9vHK2f3jFv1rsdKt/Mfcfmx1K/zrmNEheOxt4wpGEH0rttFjEaBsYzz9K1nvYb0Vx95EckAYIGM5/rXP3UJj3kZ5PXPNdLcg7sHgdaxruPeWB6joPSsbGkGc9ct8mCAOQM965vVCArZwSOmO9dJqKhcjbgLyPeuX1LADkjntW0CpvQ8410btSQfU1ERj8Kl1Qh9Ub2FRGvocIv3aPkMwles0N5xSY4pSRikrqOAjb2pPxpWPNNpGiENL+dGKSkUdlHKDkHBq7bTLswBgDtWUh2irEbjjHWvnGfXo3YGDA4P0qzDMNpGOQegrFhkYDCkc96vwsxHHXpUSNIm1bOGXcrHPTB71dDlE4XI781lwMoAHXvVzzhtHGDismbIuyzcDB+YDmqFw5ZSTgenvSmTIDDHPaq8rblPAJJ5FITKdyfmU9uoHpUakE4Gef0pbgg4x0pokAwAOelUiGPVSGIIPBxmrJX7o65qBOWGSTxxU6gjrnNA0ixCmwbQKu2q4wO3qe9QxLkZbqBVyzQ7QGPA4x/jSYyYqSVOfmzzjvVqHadrcEnuOtRxKACQM54q0kOAGxg5zj3pASxnBIwc+tXlUYyr9s1UiGQOCTn86nk+UjI4XoBSFa5M+AvynLnv6UyWTER3cEHHAqcRkj5gSpNRSWxOAd3y56nNIV0c54w0o63or2kUnlXBIaN+ykdM+xrh3n1ppLG01q01CM2fy27RruRuBkjHHbt1r2KG1U87Mjrn1rUgtA4YAkDoe3NVvoyJNLVHnem+H5vEFjEk0cljYNMsskUh/ezqoxtCD/Vqfc5PpXosduIk2oqpGFAAHYDtWjDYKgV85fGOeanEHHQA+9P2eljJ1Fcz1jwAFzkDnvQsUiqpeRm285bv+VaAtQBhPxHf8aDa/MeMkjGfaj2bJ9oUSTtLEjcOTUkUwYhlJOe56VbNuOA3Ax1NLHANuFzjtxVKLE5KxXVH69cdqhK7pWHOT0x0q+Y9o6nI/lTmgJA2gbW657Cq5SOYpCPCgKN2OpNKyhckZ55x0NWTEQoCjjvRtCkOQxOMfShxDmK8eSpbJIHc1NGoKZJ4PUelKFUcqOvJFOBzlgc9uO1CQ2xrKWB6gDrUZwo2kkn37U8yAqfmGe1MchRnJBPBpMEUbncg561lXKiPBBznritS6BPOSOOnvWbe8xnHTjJ6VmzaLC2k/eqOn0NZHjeHfpNw3XK4P5itGB9kyA4yDwcVH4vjEmg3DKOi5BHbBFJIq9mjF06JgUUZJBAKmuts0KoDgY7qOpH1rF0eIOqkDjAOetdJEB5WEOFI5OMVbWoSkZswIlZjgenvWXfBlDFV6jk9xW3cFQx4575rF1AnlhtAPGKixrGRzeoM2MnGeh4rk9ZbCtuHXmutv5FKkscEjGK4fXZvlcg8dq2pq7CT0OFuTu1CU9hTT1pqNvupmx3qQmvo6CtTSPjcZK9aQ0ikPTFBzQea3OUifrTKe3DGm1JqthAM0Gl4AphOaTKV2dR246U6NxwBwag3c4zgVLEcnH6184z69F+AnOQcVpW78Z6VmQMAPpVyAkc9fas2bRNeCYErz74PYVa84Zz26VmI4HU9KmWT5B/nis2aFyR+BzgVDK2ANvU85zURk3DgA1G7gA56etCJZG7gnGcgdqaGBb1pk0mRkDOBSQYOMd8mqRJfiPIB5xzVuFfmXIqrbAZG7GTx161fTttHQ0hplqNGyAckYzmrsC7QSOP6VDaoc7mIPH5VYiRi2QBspXHuWoEb5eAB1+tXY/lwpGffP86bECARgYGMVIsQkfqMH+6etTcPUnhj3YODyPzFWAny5GQM4P1pqKVwNv/1quIA0gBBx068ChK5DdgRDwEGT2I9PWrFtBtAyzO+c59qezCOMnBDY6e9XrZMIGx25HeqSMpSsRJb/ALxSQMe3FaEaCPbuOMjt1pywhh/EenU4p0SDcwC7h2z1NaqNjKUrk0ZV5CoBLADPbFSBFKAFeM7ee1CAqxYgDPOcZp8bZXkY/pWq8zFibQNyhcjuQaVRk8jkelBOWzjvz/jTx8ueevtRYQvlg8nr057/AIU0oOQcHtz61FNcNDLboY5JRK+0lRwnu3tVjnJyCMZ/L2qlZiaaIynPbgd+3vTW4GGPBqUrtwSCQe2aaVIBPGR2xSaBELr8vccd6iKMEI/lzzUkoJHX5v500E7sMee57VDGRODgAcHufSossMg/ic96lIxndkjrTHjG04I9jWbLWgxsbMsevPtTW+4OBk+/ekdWikyDuTpkjmmsjKuQR2zg/rSKuV5ZFKnJ47Gs2YboA2M5+U+5FaMqHYevPHFU8AxBTjJkIx9e9QzSJlk4YZG0jjrVjVF8/SLmPJIaNvzxkVDKNsrAjg9M+tW7MefA8TYwVPJqUXLuUdFb/Q4MDA2qSe3SukG1o+oyByc9K5fww6m3ERxlSUIHtkflXRpwMd+nHcVqyJblS7O1nJGc+/NYF/IzZJ5H8q27vgkHjPXnNc5qTLgjdkZ3Vm9zaGpz2qyDL4JIA6iuD8QzBY5Oc12Gqy/f44FeceKbgiFsdSMV0UY3Yq0uWJiWR3Bm7k5qwwqG0G2EVMTx0r6SCtFI+LrO82xvtSGnA4prHirMxjdTUTH0qRu+KiNTI0gg60mKfjAptKxon2NtZAT0GasROM8istZADxU8Uvzc5r51o+sUjWjYbgRx7VcSU9BmsaObjjPX16VaSYsc9KzaNYyNpJATyMelWQ+VI9KyYZQcZ6+tXQ5xjkZFZtGqZaDcEGmswIA601D8pPPPWmTP8pUZH0NIYyU5UHPU06A/N7dhUAyWOc+h5qxDgnA/P0qiDWtBnaSBnFaUS7gAc+tZtrwAARn8q0oG+UnPQ8VLKRciQIQMnntV61HTI2jvVO2UsVYjg4rTt0QN8x6UmBYjXLNnjt161YiHlMCMk0RJhgU79Sf5VZjCgfMB9T6+1SJslGXOXwCcGrMOAw29WqHeDkAAnsTVmMbE+YY7496pGTLSP/CRk5weKuW6/MCcZ7mqlrt3A4znsa1YFTIwe3HetEjCTJlAGeobsM9KXIBCZ59R1OBzSnJ4Y8Y54pyqcrgc9eK1sZXHqOgNPVcnHOBTQCVOT7kfj1qQLtyT+XrVpEMjIzgA/SgNtYEfN2PtT2HzZ9e1IACwI7DGKLAKc85wSe9CnouBjFI2dwPJ4p+0gfNjNMBD94gYAprMSc8mmvnjHbj1FOKfLxn/AD70nqA0Zz/exznvTBzkDHNP2vzycYxkdDTGAzznOP8A9VSMjdSMgcY54qNly3UAYwAPWpRnnp1pDhvw9v5Vm0UmQsNwDHHHaoiDsCgHae3rU+zcCMnPXPrxUJUxuQVyM547UbgQTodowQMknHtWXcYjbgqDuDD+tbMmC21sFTxWVdw5+bHsD6VnLQ1gzOvCQ5OM7WHUdM0zTpTFcNk5GcgH0pLvJkfB+Vk29O+eDVOGbF1CeODgj19ahbm1vdM7Trk2/iHUrbJASbeMnswzXZQyYTDYAxjp1NeeeK3/ALL8ZQ3B/wBVcRKCR3IrsdMuRNChbGB3z0zWr2IeupNqJwDzx71yWpsVkYHB46+tdXqLrs5wc/KCfWuO1qTDcHB+v61j1OinscrrEhVGJPbNeZ+IpTJcRx9y2a7vXbjajDtivOJn+06o56hOK9LCQvJHBjqnLBl6NQsS00mpWHAFRuBXvnyV7jeMcUEZBpoPFKeMUAMYYpmMsKkc/NTCdo460i1cR+uBSdqACaDSL20DzsDrinLdKO4qnKRjGKz7po0z8oLGvHVNM+jc2joUuwMEGrdvdbjndxXDhmHRmH41btdQlgOGJdP1FKVBNaDjXaep30E4A6/WtOKcFBlq4yx1OOQfK/PcHrWvbXg9a4502tzrhVT2OmE3yYU9TgVHLLjAPJ68VmRXWSBnAHrUglEhJXkdBzWVjbmLsTEncT19KtwAA59TVW3PPOCSOBV6Ac4yBimBpWv3eOD/ADrSiHBwD7Vl2mN3+etaKKx2AEA5zUlLU2IM4AZcDHFaMS52rkjA61n2SlR87EmtK3OWwOe/B7VBRdtl+X27k1YEe7AOWHcdKjg4woOMdquqF5xkkHkUGbdhkUTbkK8J2zV1IiwJf5u+fSmqo34AAPTA6fWrcUTIcmrSMZSH2sGcBhkk9q1FGB8o4HIGcVWh5OcYyB1q3FjC4PXgDFaxRhJkkYGB1IPrVhEAAzjPrUI4IzU5OBxnJ7CtomTEVj06fh3pWBIweO+Kagy+SPqOxH9Kf69jnpTENOAOc8mmsDtIRsNxyRkCn8lSP1prEBVHG7tikwEPzZzk44+lP+YpyQe1JgE8MenahuoKnBxTAUIApHQk84pQOgB6dqVOmDwe9Kep5HvmnYQ0qBkDoeR6UxowDnipTtCeo96ZtBT09R60mgK7jOOe/wClIV+Y8Z9qlK/MRjaOpIpAqt0Off1rPlLuQKvG0Hn6c0wrkAScg96supI56Ed+1MkXklTg4Ge9K1guUHjDEhlbCng461UuIW2ZUnnkcVpsCSGIIPpmmTj92cfexxx3qJRRUZNHL30TFd20kj04rnr5yswdBwvI/rXY30QMbMckj5Tgd65i9h+Vj/EOcY5rGx1RkZnjGAatoMM0ZUyQ/dPXaareA9YN1am2nbbPEcODxTo5jGZLdiDFLxj0PpXLXpk0PW49QjB8kttnAHT3rWPvKwNWPULpvlIypA6e9cfrbZLHJI7V0huEmtUkTaVIGD2wRXI67KF3DPQcmsktTWL0PPfEt1sWQk4HNcfpCl2MjDliWrW8YT8eWp+8cVW06MRwD34r3MDDqeBmlW0bE7HNMODTvUd6Y5wPevTPBREwxk0rHIFB5poGDQWIxpuMjmnvTPftSKWwnSg8UDrQTSK6mPdXQHCnJrPYliSTkmipIIWlPA47mvNSPdb7kdJWmkaxjGM0NBG/GMVXKRzIzRwcjg1cttQngIG7evv1pk9m8XKjctVqmUejKjLqjo7XWUfAYlG6c10OmzFl69a877V03hu/JXY5+dOOe49a5qtFWvE6qVZ3szvLbBbirsfc+hzWZpsoYBicCr8DFiSORniuOx2qRqWnygZB56mtezG4bmwDxisizIOAOMmtm2TKjHBz2NQzRGpABlSPwFalsqhSx78VQgXG09frV6EeXjd8ykZArNlbl9AVcJgNkdR2q5CQrc4JOMkiq0B4DHKjPIAxU4PzpsGSe59KaMpMvxAFCzcnHbvVyPJYqeh79Ko24bALDOTjA5Oa0IjuOWIP9a0RhInjC+Zt2ngdc9farkarz6n8qrRqAOm5gelWoidpGMMDnNaRMmTLj2Oehqb+EcDH15qJBkcYyaeeAccZPB9a2RkwQcgLjHoae3A+v6UxT83XketSHlQf0zVLYTGMRkg59BUa/MMZGe5qRz649etMJ55HFSxoeqAEHHB6H1pTkA4xjPWm78jvg/pQ5+U7evcn0p6dBDgTkdMjrmnc9+PcVGSc5449T1oHLEH8z/hRcLCP1yvIXgg/0pdxAJOD25oc5+TJ49KbheFwMfXipGK2SMbvmo5A5IpAemAMg96OMEEDIFACPk85yOpPpUQGdoIyBxT5DkjB46c0wZYjJ57EdKl7jI8AZ2qOO1RP8gIUZH8qtNgp7d8VXlBJ2ghevB71LGjOuF3qQMr/AA+tc/fRKIzgYB9K6O5UrLk9x0rPu4wUyRggY4FYSOiDPPtXi2sxGcHn3FZt9ELyyDOisw/duM9fSuj1y3A3MDkfyrn9O2u8sDYGRj6+lOLN2O8LXbx21zpVy2ZbYZiJP3oyeD+B4rN8SSYLZ4BHIFP1WKWykt9QtlPn27Elc/eXoyn6iqXiOdJoBNBzFIu9CepUitFG7uZ3smjy/wAQN52qxoOQoyatIuxFAqpKPM1WVuuDirhPy17+FjywufL5jU5qluwwn5iAabNxikTJcmkkOX57V0nDbUQH1oIyKaevWnelAxrjgDvTCKdJ1pp6UDQmPzpGFO/nTXIXGeaTLW5g21o0mGk4X09avbViwqjAqUU2YZT6Vx8qSPUc3J6kTfepUHIpjHJFSJ2qVuU9i1jIqvPaRyjOMN6irA6UtbOKZyqTi9DGnspIzlfmFRW8z206yLwV6j1HcVvEVQ1C3BG5RWM6dlc6qVbmdmdnptzvthtPykA1vWjBY/6VxHhyYm0jBPOMV2NnkxZJ5AzmvLqRs7Hr05XRt2XJBB/+vXQ2PIx+XtXO2KlYkOeWNdJp6HaGIHPTNc8jpi9DYth+7AbucgetacUZUleDt/vdqzYcghm4B6E1pwDenPL9iazaG2W4l6g8hRnJ6U+Bi0gYL8p4H+NRlDsChgSRz6VZto1WNVAYkADA7UzNsvIxH3u3BFWoz83Ixzz9agQKSUAyvf1q3Go3hlz9KpGUmTxAK2cYB7DufWrkYBXgd8daroeOQPrVpX2gdTx1NaxsYyZMikEkAgj0o2knnrmkRsgEEj2p4HXByD1rZamewbedxHXFO/DPrTMkjHWng5Az37CmhDSFB7Y9OtRsSp+YgD2qXADdTzURI538/wBaTGiPlcLuIx0B5qRz8hzwfSmtgKCQM45qNmJ4BAP1qL2HuPQc4PfPSn4z0OMg1XRs5746mpUIYDrg9fahMLDyCoHOVHf19qaDgcA8U7HpQfrzjpnimAm75TyCe1Rk5JBx0p6DIGRzTWB6574IxSYCk59cjpTC2cnHbn2NSKCVOSeO+KZKwBIyfwHND2BDT0AB/HtVeR8Pzyc84qxIAc49O9QSLsIK8Dvxk1DKRWnyEJVANvPPcVmS9Cd2FHUelak0hAOCMZA4/wAKxr7G8I2Ax4XPUmsZWNqaMXV4/Nt3PXPt3rgo2+z62iZwsh2813t3IArhgMHqc1514oHkvHcxceW4bk9eaIb2OhrQ6i4txLDKrd+RXnd/uthPYuMCImSP/dPUfn/OvTiQywzglkkUc/WuH8dWXlt9pVN4iJyBxuU9Rmtqbs7Gc1dXR5fF/wAfM7H+8anL/LjFRWqjLknqTUh719HSVoI+QxD5qjIwSuW6UgGVz3ol+7Tl+5WhkxuMtTiOKAaM5NAhr4xzUXc05zTRwKTKSshc7RmoSdxzT5GzxTOlRJ9DamralcGh/wDVtRikk+4fpWHQ7upXIPWnoeRSA5Apy1mjVlpegpQaRegpa3RxsWkdAymlo7U3tqJN30LWix7Cij1rsbI5Tbmua0mIg59P511FinIGPrjnmvFqu7PoaSskb1nGcJnPB6etdLZALEuMcHmsG0zgcn5evvW7ZruQM33Rzt7H2rmkdCdjUgKkg4wo9+g9a04WCjLYwB61l2xG/cQSvQDHFaEWPvMTwenXPtUibZbtwS37xznqBjtWnFgleoPJGBVS3RshX6eue3pV+JAWyMheuc9KQmWodrhcbfU1bi5xt4/pVWNcRlT1Ax7GrEZO9TnPr71SMmWQAdwzz0IqVMr15FRL0OcE9akGMHPG7860RmyUN+FSo3GAT6+9Vzxgrwc85qVT8pA7VomQyUcknPToKccEEq2f1FMUg/NkAjjmnHGcAbR6DirWxI18DuRx+dMJJxnAGO9Kx+Xnr796iZjjBHy8YWpbGkPJUpx0FVJXUKS2MVI+QuFHJ5JqjdygnaWyCQCaxlI0jG7LQk3Bdo+uOlTJ1HPJ6VUsw3zZPGTgVYUkEMB1oT6g1rYn78Hg8n6+1PU7SAcVGpwQCM9gKeAQDtxmtEQx2MduTyBmlbBDBvX8qVcjOePWnbeMkcj3rRIlkD5OegP8vekwCfu9u9TKBj73PQUwADr29+1S0O5E44BH/wCqoXwgzgkmrB7gEY/nVadgEbkg4rORcTPvGCnK8MoyCDisS8ui20Bvf6CtK+l8zcJRlR0I65965a/kkjlJOdj8YA6fjXFOeuh6WHpc25T1CZnLlSMDJOO4ritfl862lV+pyK6aaTbK8Ue0tID5YPQH+lcTrc5RJI5Bsk/u9aqjK71Nq9HljdHbeF5WvPCFrOpLNCNjjPYVX8R263Ons6dCuf8A61Q/C26xZfZ5VLQzRtke4ORWjqEYWJlDDBBxW7dmci2PC54Db3M0WOjHFNI4rY8UQ+Vqhb++Kxjk19Fhp89JM+RxtP2deUSKfp0pF5WlnxjikXhRW5zdBp4GKOaX8KaSSaAQ3kmjOBTjxUTUmXHUb15NGOaXGaBUWN7lUGkmb5DSgGmzDKEVg9jsW5GBxQDg01GwMHrTxg1CNWWl6CnU1Puin1ujjYA+tSRKXkVajHWrunxlm3Y61lXnywNcNT56i8jZ06I4UDjjrXSadAAm4/e9BWVp1vgANjpXQWyk4QHp/OvHkz3oo07CP5RkcVsQKdqoo29hntVG1TjBO7HoK1bUbuvQ9AawbNki7AChAwc/rWnb9QoH4sP5VnWy85Iyc8n3rVgXODuzk9BU3Bov2fUHDZ6YI5+taFuOM5Ug9TjtVOziK/OWJJwR6DtWhEv+sOBnoT0wKaMZEyopcsRz3I7/AFqwECpgjDfzqBdqcLyu3ksan3naMZ57VaM3cU7sjJAA6nHSpIycg9R9elQltpO7j2FIHwTk5B9ODRewrXLLyZw3H09akRum3ke/aqvmKYwVPGP8ipIDyCTyOn0q09SLF3OeAMr2J71LjGAO/aoVf8T0pwIJ3E5FbJmY2Q7evIPY1EueeeT0qwwDIBxkg8+lRA7SVI5HvUyWo0R4wM4yM8571iagSkhZeR246VuTbTwp4HXHJrntWbYxDfcb9DXPV0N6OrL9tKXhBXAyM4/rVuE4JPI56ZyawrOZjaxtjBAwMHqK2bY/dbBINODuE42L27JwMAdM06Nt5+QEjODkYqJeeR07EVYRs8DgfzrdasxYuDjOPxoHI5PHv2p6gMOucUmwMpwM881diSNgSVIBB6EU7b8uO2acFLEsM88dacVyT39OaaQXKsqbVxnOP1qldZMLBdrMc/KePyrUaMtyQSMelZt1gFtq8joO596wqxsaU3qcpfecVkMYIccbScc/X0rkda1O6gV/tWweVxuByOf8K6zUzM94wYfuhxtzwc+3rXnPjaPzrxLcSYiOcgfWvPa1PocOvIzrzxVZ3MsEbylNhwGxhQfr71z/AIlvC8gLur7N2HXoQRVbWLdLaYRuj7CpydvA9DWDLJ5BdAcxsCoU8gZ9K6qVNaNGeKqNRaZ6z4ExZWulSt/Gnzfjmul1NQRIwAPX8M1zaYttJ05F4ZQg/lXV3fOnJIQAcdj/AJxSb1OFLRHjvjZQLhGA4BwK5l+FzXWeOgPT+IfzrkmBzivdy53p/M+bziNqyfkRyj5RSDkCiYkLzUQY8Cu88tJtD2yTgUYxQDTXbNAb6DScmmketOBwKaxpM0XZCE46U3Jpe1Iah6mi0KqHikk6UqDjNI+Kw6HctyBxzQOKcwpoPGKzNS8hyopabH90U7ofat0cb3HRrucKO9dFplvwvHSsbTot8hY9BXVWCZK4H4V52Kqc0rdj1cHS5Y37mjZRgnp05rcsowH5J5qjZJj5hyMdBWnZnc2ASO1cDZ6KRrQLkEACtO2j2R5PAPQ+lUbVQwGNwFa9tFkggZ+XJBrJmlixaoGUMS3qT6itO0iAOF/QcCoY0wm45C9D7GtO2jCLgj5e9CM5MngQjk5HQY9DVqJgRgdB1NRRAheeAxwAeoqZflQZ2ogOBjr+NUjKWo9ACSedvp6VIFZm3DBX1Bx+VNChF5PA5AA5+lO6ws3QenvVEC7lDFe5HBqOUMqHj8KWMhUZjyf4eOlVrmQqdvbGSfSpb0KS1LA+6O+3nHenxEk5yeen+NUkkwF7A8cdBTopmZl5GehpcwnE2o2ypxn06U8cY6YHamWq8KVPucf0qUAhQAO/XvXTHYwe4I4D59f0pDzn5ScHkDqKiECJM8yLiWQBWbHLAdKsRZyPX0B6U1rowdlsV5h8uVPBxya5/XVZrdm6BOvH610koDHJwR14HB96zdRti0LhevoehrCtHsa0pWaOc0S48y2ZQwLZwR7+1dDZyu4b1PIHauHtJhaalJAQY1ZshW6g9xXT6dcHzSc5brisqcjorQ1udFDIOMYz3B4qyhGMfxD1rOhbLA45Hp3q7C5K9QWzXXBnHJE4xkKT/wDXqQKAOv09KRDnv19KlQHsOK3ijNsYRtC4PXrShNx46duaeq9N3THrUpC4yTwOPetVC5NyEqRg9uhFZ+qQ5jMgwGrUfGMbRx3qpeKGX0wDwO9Z1Y+60XB2dzitZjICmLDH0z1PtXBeLbV1Md2oxLz5iEfr716HqSAFkOCi8nvtx0/Guf8AFEyG1it/KDu54z6dTXkT0Z72FqWsjxzW9Vjkt5Y5GClhgjuK4kt591FHHllDKMn64r0jxXZWUavJOgJ6KuOpri0tWDiUJsRDu545zgV1YeV9SMa29D0m4cmztwB8q4UH1NdSWH9koXJGRXH6WxuXso1yVX5m9x611Gqy7LDacYI4xWUjGOtjzDx7ICTjpuFcizHotbPjK433QQ9zWOMba97L42pnzWbyTqoY44y1Qk8ipJeeKZiu5nmR2uOHI9BTWxjrSqN3fApCOOKAWjEzxUbHJqTbTStJ3NItIQUgHNOxiipsVcqJ0FNfrTh0pp61zs7luNI4NQjkVM/SoOhqGaIvKMoKUdKSI5QU+Nd0qD3rSTtG5hFc0uU2dNi2ovFdFbuFCjgHp9awLaQR4J7CrcNwzN8vLDjGa8ibPdpx6I6i1mO7t6Zz1rb0/wDeSAYxgZ6VzGnvlljCktjJNdXo3VRkZ75rmcjsjTe50FnACygjLHrW9Zx5banUDlapaXEzoMj5s4HGK3YIfLcjHOOv86lIzm7aBCmAPlPPWr8UBWHc3ODnApyQkBdpBIPOeOKvBFUFgOT1Ga0UTnlIijiIx15HQDtT1AAGVwB2ParEaYUgNyRk+1MMQZgNzAMMe9VymfMRYHyttwe2aV8gxAkL3OaklG0gZ+6OpqMBSQW3EDkH3pMaIiQCQM7+uT0qlcEhsjnPc9asychiG+XHTPSs+eQgMSQT354zWcmaQWoSz7H4HAHH1qxp4+7/AHunHXNYV1Od6gHvz71taGxmZ2AJjTgEHqe+Kyi7yNakeWJ0cAAjVVzx19zVhRljkfWo4hkDOBxzjpUpIwewxyTXoRWh57Y3gv27/hShcOeuPekzwSMHtT1BKnB6daaQhNq524H41WlG07Typ46dP8+tWgMk4IJ9+1I+3nJ46YHBH0pSV0NM4Hx3pZES6jAvzxHEg7kev1FUdJvvM8vcx5GNwruL1N0ZjAEic5BGPzrzLVrWXw/qW3GbN2+Rv7p/un6dvauKa5ZaHoUZc8eVnoFjdcHncOlalrIjdOvXBrh9I1Nd/L4B9eldLaXiOqruw2O/Oa1hMwqU2jooZBjAXbnqRU8bep49ayI7ohRlhu9BV2OUE7sZ+ldcJnK4l8EA57E07cuMcfSqokI5JyB2FNMvBxxWvtEieUtFsk9RVK7kQYGQD1IpfPHIP4CqNxcLgl8D1xzWVSpdFxjqczrwZJSyE5BJ8zsMiuM1KdllZ25Ocr/+qu31gifO0kD/AD1FchrKQWsbGVic9gOtefOKbPWw1W0bHBeIf9JkQSHGTkjuo96yNZXYYbZU27QGK919Affv+NdRJApD3cy7Y1OVU9/c1yMtwZDdXDj55Pu57D1rSmrCrSudT4WBS3EjH5uF/D0rS8TXQhtSrHkjJ9qx9EcQWsak9Bkk9uK53x1r4RW2sCAMADuaag5SsiHNQjc47Wbs3OrPznbS5JUDPFZNkzSSNI5yzHJNahYbcCvoMNHlhY+Wx0nOpcHOKjzzTiB3NIQoPFbs5FYUZPbApDn60oajdTFqJnikzTvlPemEe9DGgoNApDxUl2GyWRUZQkVWeOROoyK6l7UkAdqqXNky42puzXiwxDW59HPDJ7HOSNxzwfeou9dI+mbv4cj0qtJpAPKrg+1bLERe5i8NJbFCA/IKsW+PNHsKa1nNBwBuFJGSrHcCOK2lUjKFkznjRlGom0X/ADCTtBx7+lWbab94qRH5AfxashS0jbQcDua0bWFo2BBwQe/WvPqpJHsYdNs7XQ4naLzJMAHuOtdbpsZEiFMYPANc5oUXmRQB8xoSAxAzj3rv7SKGKNTCoLjuCBn8K4Wnc9VxUYnSaRbEbdwbnHzHua3IrdFfC4+asTSbosnD72UdO+a6CIqVRScYwefWtoJWPJqtp6kxiClVIyvYjuKnSFyDt5XGcdh+NNSSLoOPXjoakWTaP3bAr33VqkjnbY6KHafmXcxxxnH409FKsTjdnlQOw96Qsqnduzj5cdqaZGYF8hCTznvV6EO7GyI3myEqflxjng1BKwKnJGPbtTrmYFC5cgA8HPU1nvcrgseJPpwBWUmjWKbGzSbHBbr124zisi8nAZiCAOpwOppbq8IGTkL9e9c/d3eIGLEAc55rnmzpp0xZrh5bwRW4DTyfIgHQHufoK7jS4UtbZIkbJUAMTxk//XrjvCNmzk6hOvzSjbGpHRPX6nr9K7OE84OMDjg0qas7iru/uo14m2gZJGR0zUm8uAVU4FUUbIK8t+FWkclOBjjP4V1xkcTRISS5Oe34VKHyWGce/aoVbc3yg/NwPbFJkZBY5IHcVadhWJeCCc5yOMjFKSMdOnWowS33uQe2aUPnH9+i4rEbJvznHIrn/EOnJeW0kUsYw45OP19jXRs3zgHBJxyOv4VUuBuUgglaxqRTRpTk07njH+kaTefZboMGAyjEcMvqK6bTNS3AbWGeM+mPWt3xFottqls0cvykDcjjgo3r/nrXm9zHc6Nf/Zrv5WP+rkH3ZR/sn+lc60PQTVRHqFrdqQCXwe1XvtKMnLsAO4PNedWGrEqvJUjt/ntWpHqZXgOeeg6VpzGLou53SXbK3DggDkGj7WuGIJHbGc1yUWpopDktnsSen+NO/tJccFcE5+hp87J9kdVLckg54I6ZrOvLgqCSwbcegNYj6oDy0gAPUA8msy91hYwcNyeMYpOTY1TsTXWo+UzyL83PJ7/SuYvZWuJHluWKoPuIe/uajv8AVkRS0rfMO1cxqOoy3fOdkdJRbN00ibVb1tTkWGH5LWMYZh/F7D/GufvHjkvUtof9Wpy2PQdBS319IE+z233j1Y9hWY8kdlGct8x5Zya3hExnI177VRbW7fOAqjGewrzXV79r+5Lknyx90f1qbWtTe9fYpIgXoPX3rOgQySAV20aXLq9zhrVubToaenRkKKvlcUy1TYnSnnk8V6lOFong1qnNN2GMmTzTgoXpzQQSQKUjHU8VVjPmew3PtS7SR6U7I9KaRz1p2FcTYPWmlQOppxBphBzSZUbvqKWAGBSHmimk1LZoonXoQF4GcdPWpSVwAAcHGc0z5Nmd2Sc/hSL+OPSvnLn1yRJhNx2DtQ65jPA3dRikVSeASDS5ODuPHSlcqxWksxKQB9/t71h69bG2ELkYzlTxXUKoVlbklaxvFR860BAOEORWtOXvIwqw91s5+zG6FmDAY6881t2kkDwgyPmVeuT1+lcxGXU5TkHt6Vo2RkdwFGDW9WF1cMNWtZWPStD1SNljj2Oo2gZOMAV19td5VdhHsB/WvPtGT7OvznLEDmuk0ufy0+c5GeOa8yerPYU1JandaNcMkmUbBJx7Cujgu23bnO7Bx/8AXridJuPm+bBPYGt+GclAWUFsetODaOGtFSZ08V0rIobG05/Cp1uFRQMHCnGBXNxy7Y9yEhgfrVqK6bydzndj25rVSOV0zeeYr9zoeT71AtySXbeo44HoayJL9mx3THrzVYzs6EM20nnAp84lT7mw14JImz9/Gck9ayLu7LA/Nt56VVnvVMbbOXxjA7Vi3N2VJ3MT/Ss2zeFMtXd1ww4AHA561lQxnVL5bZc+Sg3TH/Z7L+NZ91eSSSrFCpaWQ7UQdya7Tw5pAsLbaf3kzcyv6sfT6dqz3NJNQRs2kexQVHbjHYelXoskgenP1qCKNcn5uv6VbjHIB4x2B4qkjkbLUHUKScA84q4u75QTwKrRkEEAnip14xnAroic8iRQAvPQZ570iA+Vh8Z9aXIIyPpnNNDbeo9qskEbg44/lQ2cAj8aA3Q4xznjrSHIBHBB45HNIAZzvz1HTOMVA756Zz1GKmOOjDJ/KoXwWyD+FKRSKlxhsAgE5wccVzmvaVbamjw3kavE3IByCPcHsfeuiuB83A7VVmHQMMnuT3rnkjppy5djyLU9P1Hw7I7usl5pyn/j4QZeMf7aj/0IVLY6tDcRhklVwehz1r0uaHKt/CDx61xGveCLG8ke40+R9OvCfmaEAxuf9pDxn3GKSfc6Oe5XN2xb93jPueKjk1TaMbf8a5690LxTppZhbW+oJ03277XI/wB0/wBKxpfEE1m+zUbK6tWHaSEjFaKN9hcyOtm1Zjyivu9CKz5bq5YliTn1x0rnz4tsOvmKD9DVO58WwMNsAZ29FUnNWqcuxLnHubdwnVp5N2PU1i6jqQY+XEwG0YyO1Zklzq2pEi20+7kHtGQBTf8AhHtcePdcLFZoepZst+VaRgluzKVR/ZQl1qcFlCzFt0revJNYqQXesSb5MxW45571sQaFbwSBpWa4lz95un5Vo7QsTYHHtWyko/CYSUpbnC6tCsMyRRjgZ/GptPtsDJHJqe7h87UGY9Fq0q7EwK9ChT5lzM8nF1uT3Y7j+FGKbkelMJpK7Lnm8o5n4oBJFMNOA4pXbKskhTTfpTuc9aToaBINxprHNOpj8UPQqKTYhNNJpDmjBxWTZulY6iOYEe/TBqyjYwAR9O4rFinUnJq5HPwAK8FxPp4yNRXZDyeRyc0R7ZACpyDWdMzTQsoYhj1PtUumwtCvU464qLGikagxjjBxwfaqWr2yvZuDjJ5FWUyCe+fUdajmcHKsOaS0Y5WasefRHZIynqpxWvaPypx7Vn61C1relwPlapbScYBHIrumueN0efCXs5WZ19lPmLBPzL0Geta+mXG4dfz61yNnKN4PIrdspsfMTwK4ZQsepTqpo7rS7j5QQxHNb0V5hgQxzjGa4Ky1DCqFGSa2Ir7amDjnmo5Whtps7EX2UPlcZ4JBxTH1WOOYRs58wrkJ6iuTj1JTjDHA6e9WFut3JPHqaaViHFHR/a2ZuCQQ27ioZNSyu1j83QYrFF4eWQ7T796qS3iqThhkc59KAskbc96FGSccdfWsHUNRAjOGJ56dyaybzVFUHklifqSa6Dwro7rMl/qSfvRzFET/AKv3b/a/lUtW3KukbPhTRnhYXt4uLqQfKpH+qX0+p712ULZUKOF6Vn2w+UY4NXYMMMZPsScVJhJ3d2Xol45A/wAKs9gAM9s1WtmBwCeR14zira/eXnHv61aRi3qWoxsHHHH1qdeMbuT156fhVccDrx/nFPhK4Xec46g9K2Ri0WHGDn5QB+NNB6ZK0B8lT8vpkUEjcSCOnPpmqZI5DkAgYP0oyOi4yf1poYYyCCDxyaacEZxx25ouFgJyePu01sHnaBmkkOTyefamE8lerAd+alsaRG+Dwenft+FVbgDqBwfXtV3kk9McED0/GqcvIxxx1PaokjSLM+TDA7icHgAdvpVZ2O3HDEcc8VekjwCpUHOO9U5Ew4CcVk0bpopzgbM9Mds1WIyoDLuTsCM/pVuRSNwOMHrVWTC5XPJHFItFKWwsCxdtPtG/3oVP9Khkt7W3+e3treJvVIlX+Qqy7FBtPJHTmsy/ucAgfnTQ7FW9nZhgsSfTPFcnq8nmEqp4rQ1S+IQqDXPM5YsxJ5rWCCSKsiZYdeOlVrr91A30NXHJ6twO1ZWqSqIiAea2jqzCasjnoubiQn1qZ6gtuXY+pqaQ171HSCPmMTrVYw8UgpAacKpGbVgPT3pR0pBSnp71SJA4ptGaAaQ0rBTGx605jiomJqZM0hFi5FIW9KTGaAKi7NbIgS7lT76H6jmrcWpp3O01hx3br94ZFWFuYpOHGD7iuB00+h60ajXU6W31BTgh+a0Yrvdj5+TXGqsR5jYqfY1NHdTQHrvH61jKhfY3jX7napNnncR7ZoD7pPXHQ1zNvqqsMFsH0NaEF6D0asHTktzdVYvYt6rpb30B2gFx0rimMtlOySAjB5Fd5b3rYHPGMVR1rRjqEZngHzgZPvWtKpy6PYzq0uZcy3MWzvFPKmti2uuRyBXIPDLa3GxwyODircN68Z+dT9RWs6SlqjCFZx0Z3FvdKrhlY7q04L4sCC2T0zXC2+pR/wDPQA+h4rQg1JBz5i+/zCsHRZ0xrpnYx3TAbgc49OKsrfgjknJ/nXHDWIUHMyr/AMCoi1SS4bbZwSzn/ZXj86h02ae2R1supgAjdk9+az3v5ruf7PaRtNOw+6nYepPYfWqdnpF3duDqE4gjPWOE5Y/Vv8K7HSba2s4litYUjTuFHLe5Pes5WRak5Evh3Qls2W5vCJr3+8OVi/3ff3rsIJCq/Lgg96yoHyBgjaavwPjntXO22XY1oJCcckc85q/FyowOtY8Lh3GODV9JDlcZx6cYFJEyRrW+1cAcnrnNXUkG3jOe2PWsmEgnjsOParKyY4AIHPWtE7GLV2a0bKTjJ3EdP61LGdxOeg4HzcVmJJ0wee+KuK4AO7senpVpmUkXVcKPvDnjFHGCOcYyQKrlyw7cdmqVXBDDcc+uOKu5FhXG1hyMDrzSMxA5/DjtQAFGABgdRTdwBwCCOmTzQASvwx9utV85Ybc+lSu2N4BB2nBwOtQk7stj6E+lJlIeGbjBxnqT3qCd0Mgx69qSdtrfMcDHrVcScZXnI4FS2NLqJI7BcE5Oee2KrOMgdhTp2+Yhj14wKryNuXjGMc+9Qy0Q3AUfMMFu5qjMQOcZz361bllAXOM1mXUvynGOuM0jSNypdSHPH4Vz+oTfe25yB+ZrSvZ8Bj1rnLpzyx/ChI1WiM67OWAPX+VUiuTgnjNXpVUtnH0FRPHtQnvWyJuZ1y2wdTkc8Vzmpybg3Nb96P3eM+tc5qfGR+NbU1qYVXoZ9r0anSGmW5+Q0rcmvbhpBHzVRXqNgvSpAKaowBS1aMm7i96Qml7UhqmyUhueaKTPNITUXNEgNNNKTxTe1S2aRQUU3mjrUXLsYr20i9ACPaoiCDggitQUjgFeQD+FYcp28xmAkdCR9KkW4lH8WR71I0SknAxTDB6GpLuKbgt95QalhvXjPysR7HmoRbyNnbg4pjRSL95TSsCkblrq7ZAJA9xWrDqUrL8kufxrjKmhuZIj8rZ9jWcqSextGtJbnZQpb6ndR296PLZ+BKexxwfzqrd6XdabMIdQgK5+65GVceqnvR4Xdr66VnQmKM4kPoT0r0+C2ube3MJWO9sWxmKUbhj29K0hRvDzIqVveueZLYW0gyYlz7VNFpFmTzD0969BPhrRr0n7LLPp8x6xsN8f4Z5H51WufBeq22WhiS8j/vW7ZP8A3yea56lOrA3hOnI5a10+zhbi3jz15Ga2rddoXAAX0HFQPavBLsnjaOQcFXUqf1q1HG3Ax+NckpN7nXGKWxcgbJrTtnB4z+XesqIEcHgetXLUkNg//rrJo2RuQzFSpHH0rRt5eMgnbnmsOBsghs+x9K0LZzwM9uvrUMo2IZCHzk1dimZW4YkHg1jxyAEE5q5byM2QpwD60hNG3DMW4x24z2FXI5s9GOT2IrEgk2jA+90z6irqP0Vj82KaZk0bEcu1dvHrk9asxyYX5Tj2zWMkpEo5AGORjrVuGfkZABFUmZSiayy5GDjgdT3p5lxjaTj2rOWbgnjPb2p/nEgc4zwfequRymgH6MTkdCPWlaUY+UEqeKoFyMc5PfninCQFAAfyppicS00uWAx71E0oPPygZI96q+acgEAAe9JJPtGOp9qGxqJJKQQcD8aqyk7eePamSy8dCfxqCSUEd8nrUMtISecqQMqWNVGlwTnk9eaiuZDkKoyO5qpJMcZJB7AVLNVEluJ/kP8AdPBzxWbeTn8falkkYliTmsy53tnqc9qC0iG7fNY1wd3T8fatGYEAA5B9+1RRafcXLbbeCaY5/gjLZPpxVxQpaGUB82evfntUV3IAuAeD+tdXB4L1qfk2RgU9WncR4/OrJ8CqBnUNVhTuUt0Lt9MnArohQqS2RzzxFKO8jzC8k4bIrGFjd6nMY7OFpGP3mA+VB6segAr2hfDGi2q5SzlvHH8Vw/y/XaMVkeJLWebTbi2h228JQ4hhUIvT2rtpYWSfvHHVxKkrRPFoxtBXIbBIyOhp4qOHKpjuOKfuNehHY8eondj+2aKZuoz2q7mXKx2aSkHvRSHawmeaQ9aDSE1LLSAmmk0E03JzUNmiQuaQdKCaQkUi0iqpoc8UnamseKyOmxD3paQ9aKkss23Q1MtQW/Q1MK0iZSEkgjcfMo+oqpJZEcxtn2NXqWhxTEpNHdeA2sx4fto2RUkV2WYHu3978q77T5YY0VAQUx69K8w8N2lwujS3aLugaUgkdUKgcn2Oa7LRoxJbJLuOGBO2topWFdnW/ZIJ8EABvyq1b200BDRSMMdPcVhWryKqkNlW9a2rK8ljUA/Mv8qdguaiSvKojvYIrhPSRA386ik0LQbo/PYG2Y/xQOV/TpVi2vYXA8xMHoTWrAtvIOGGOhFZzpxl8SuVGpKHwuxzcngawlGbPU5Y/wDZnQN+owahb4f6kh/0aayuFHdZNp/Wu2WxQ42gH6VZW0IOVZhXPLB0n0sbRxtVdbnnZ8H65D9/Tpm942V/5Gom0y9tjtns7mI/7UTCvVoo5kA2SHOeKtxS3cfSQ89Qaxll8OkjaOYz6pHjyLhir5BH94YqxFt/vAkehr19mlkwZYopQOMOgJ/UUhtrZ/8AWafZsf8Ariv+FZPLn0kaLMV1ieXQE/KQf161cjDYBX7w6qK9EbS9Mf7+lW2T1wmP5Uv9haORk6bGPoWH9an+zqndD+vQfQ4Fc7/cdKsoeBkEk+ldsNC0delhg9v3jf405dD0gDAs3H/bRv8AGj+z6ndC+uQfRnFqSq4IPuMYqZHbAFdiuiaWMf6PIP8Ato3+NKuiaUMg2jH6yN/jQsBU7oTxcGcgxO0Y6+tIJDs4yBXaDR9MByLL/wAfb/Gl/snTQD/oEeD6k/41X1Cp3QvrUexw8jkcnDEcdaikmXb1XPoDXoS6fZIMJp9uPqgNSLbRLt22lup9oxVf2fJ7yF9biuh5qQWGVyR7c0qWd3OD5VpcSj/ZiavTlMijCBVHoopr+cf4yKpZcushPGvojzb/AIR3Vrg/u7CVc8ZkIT+Zp6eC9Sc5mktIB/tybv0Ar0Bo5Dn5jj60w2qkcknjitFl9Nb3ZDx1Tojio/BUC83WqZY9RDDx+ZNTDwtocONwvLk990m0fkBXWi3RegFI0Kfh61tHCUo/ZMpYqtL7RzkOmaZbEfZNHtg2fvSLvP65qxvu8bYz5Sj7oUbQPwrWeMdQMdarzsigbiM/nWyjGOyOeUpS+J3MWa2ZhmR2I9z3qk9nGMMVyfpWrcXCBTtUP9ayLu4lbcBgL296ZNylfRxxqfMKp6D0rzjxxq5trOdrbIwpBeu01MFIXkYk4GMn3rgPESRXFnPbuMCRSKfQtHkSnIz6nNOApNhQlG6qcGl7cUI5pbi4xR2ozRn2qjPUKQ0UlIpCGkpaacYqWWhuaTNBoqTVCGmmlNJSKSK5pjUUVmbohPWgGiipKLNv0NTL0ooq0ZSHd6KKKohnoHw5dpdF1K3cnylbIA9xzW9YKI7CEL2yo+lFFaxH0NnSxmzjJ68/zrUjUBfpRRTAuxovXHcVdhXa5AJ9aKKJCNC3nkjyFY9BW1a3UpBJbPOKKKnqxM2LeVnfBA/AVfQDPTpRRTYkSKMjqeamA+T8qKKOpQ8DgHv0p4A3AYHWiimhkm0DHHWnIox0FFFAxVQHtS7R6daKKYxxUU3A6UUUAKegpD1FFFAAQM0jdKKKBDDzikYAH1+tFFAEc+EHAHHrVSWRueaKKTIZQmdj1PHpVGYkjJPc0UUmR1KsqjYGxzVKUAoxx70UUAcv4mc4CjgZ7V57rxKykA9Riiim9y1seZXP/H1N/vmojRRQtjmluxKWiigBKDRRSAaelM60UVLNIidjTaKKktCUlFFIs//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mondor disease. Thrombophlebitis of the thoracoepigastric vein causes retraction of the lateral portion of the breast, which crosses to the midline at the inferior areolar margin and is accompanied by a palpable cord.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mulholland MW, Maier RV, et al. Greenfield's Surgery Scientific Principles And Practice, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33088=[""].join("\n");
var outline_f32_20_33088=null;
var title_f32_20_33089="Macintosh laryngoscope";
var content_f32_20_33089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Macintosh laryngoscope blade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Orebaugh SL. Retraction blades for direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33089=[""].join("\n");
var outline_f32_20_33089=null;
var title_f32_20_33090="Hemopneumothorax I PA";
var content_f32_20_33090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of hemopneumothorax due to blunt trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Supine chest radiograph shows hyperexpansion of the left hemithorax with filter effect and veil-like opacification due to dorsal blood and ventral gas. Right panel: After insertion of chest tubes, the dorsal component of blood has been drained, and only the pneumothorax remains. The contused lung is too rigid and noncompliant to completely collapse.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33090=[""].join("\n");
var outline_f32_20_33090=null;
var title_f32_20_33091="Penciclovir: Patient drug information";
var content_f32_20_33091=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Penciclovir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/23/12659?source=see_link\">",
"     see \"Penciclovir: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/19/7475?source=see_link\">",
"     see \"Penciclovir: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Denavir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cold sores.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702697",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to penciclovir or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use at the first sign of a cold sore.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10959 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.80.101-607E99995B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33091=[""].join("\n");
var outline_f32_20_33091=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207403\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012944\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012943\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012948\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012949\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012951\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012946\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012947\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012952\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012953\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/23/12659?source=related_link\">",
"      Penciclovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/19/7475?source=related_link\">",
"      Penciclovir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_20_33092="Melasma";
var content_f32_20_33092=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Melasma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33092/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33092/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33092/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33092/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33092/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33092/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33092/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/20/33092/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melasma is a relatively common disorder of hyperpigmentation that affects sun-exposed areas of skin, most commonly the face. It most often affects women, and is particularly prevalent in women with darker complexions (especially Hispanics) and who live in areas of intense ultraviolet radiation exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise cause of melasma has not been determined. Multiple factors are likely to be involved, including pregnancy, oral contraceptives, genetics, sun exposure, cosmetic use, thyroid dysfunction, and antiepileptic medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Melasma is the most cosmetically disturbing pigmentary change associated with pregnancy, occurring in up to 75 percent of pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with idiopathic melasma (eg, not related to pregnancy or oral contraceptive use) may have hormonal alterations that are consistent with mild ovarian dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Melasma in men shares the same clinical and histologic features as in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/8\">",
"     8",
"    </a>",
"    ]; it is not clear whether hormonal factors play a role in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with melasma exhibit splotchy areas of hyperpigmented macules on the face (",
"    <a class=\"graphic graphic_picture graphicRef75884 graphicRef64109 graphicRef52220 \" href=\"mobipreview.htm?19/48/20234\">",
"     picture 1A-C",
"    </a>",
"    ). Three patterns of involvement are typically seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Centrofacial &mdash; involving the cheeks, forehead, upper lip, nose and chin",
"     </li>",
"     <li>",
"      Malar &mdash; involving the cheeks and nose",
"     </li>",
"     <li>",
"      Mandibular &mdash; involving the ramus of the mandible",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are two main histological patterns: epidermal and dermal. Both patterns have increased numbers of melanocytes. However, patients with the epidermal type will have pigmentary accentuation under a Wood's light, whereas those with dermal melasma will exhibit no enhancement. In addition, some women have a \"mixed\" picture on Wood's light examination, with enhancement in some areas and none in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/2\">",
"     2",
"    </a>",
"    ]. In natural light, epidermal melasma appears light brown, the mixed type looks dark brown, and the dermal pattern is blue or ashen gray. Epidermal melasma seems to be the type most responsive to treatments such as bleaching cream,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1862?source=see_link\">",
"     topical tretinoin",
"    </a>",
"    , or chemical peels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of melasma is based upon clinical appearance. Splotchy hyperpigmentation can also occur as a result of several inflammatory conditions, including acne, eczema, contact dermatitis, and superficial injuries; this may persist for months once the inciting event has resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of melasma can be challenging because of the chronic and persistent nature of this condition. Intermittent long-term topical therapy and strict sun protection are often necessary to control the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/10\">",
"     10",
"    </a>",
"    ]. Melasma due to pregnancy usually regresses within a year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/11\">",
"     11",
"    </a>",
"    ]; however, areas of hyperpigmentation may never completely resolve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bleaching agents and chemical peels are most often recommended for the treatment of melasma. Regardless of the method chosen, therapy must be combined with use of broad spectrum sunscreens (eg, titanium dioxide, micronized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     avobenzone/Parsol",
"    </span>",
"    1789) to maximize their effect; both ultraviolet B and ultraviolet A protection are essential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/13\">",
"     13",
"    </a>",
"    ]. Clothing and hats should also be used for sun protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bleaching agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"     Hydroquinone",
"    </a>",
"    (2 percent over the counter, 4 percent by prescription),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    , and tretinoin are common bleaching agents used to treat melasma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"       Hydroquinone",
"      </a>",
"      exerts its effect by blocking the conversion of dopa to melanin via inhibition of the enzyme tyrosinase. It is applied twice daily for up to three months with subsequent tapering. Concentrations of hydroquinone vary from 2 to 4 percent; the higher concentration is most effective, but may rarely be associated with more severe irritant or allergic contact dermatitis, hypopigmentation of surrounding skin, or rarely hyperpigmentation that resolves on cessation of therapy. The efficacy of hydroquinone may be improved by combining it with a keratolytic agent such as glycolic acid or tretinoin. If no improvement is seen with hydroquinone after two to three months, it should be discontinued.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"       Azelaic acid",
"      </a>",
"      also inhibits tyrosinase and blocks the conversion of dopa to melanin. It is applied twice daily. Adverse reactions include erythema, scaling, pruritus, and burning.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    was demonstrated in a double-blind study involving 329 women with melasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/14\">",
"     14",
"    </a>",
"    ]. Treatment with either 20 percent azelaic acid or 4 percent hydroquinone cream for 24 weeks resulted in good or excellent results in 65 percent of women.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tretinoin 0.1 percent (eg, microgel) is not a true \"bleaching\" agent, although it essentially acts in this manner in patients with melasma. It is applied once daily at bedtime. In a trial of 38 women with melasma who were randomly assigned to apply 0.1 percent tretinoin or vehicle cream once daily for 40 weeks, significantly more tretinoin-treated patients were clinically rated as improved or much improved than those using vehicle (68 versus 5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/15\">",
"       15",
"      </a>",
"      ]. Significant improvement first occurred after 24 weeks of tretinoin treatment. Histologically, epidermal pigment was reduced 36 percent following tretinoin treatment compared with a 50 percent increase with vehicle. Moderate cutaneous side effects, including erythema and desquamation, occurred more often in the tretinoin group (88 versus 29 percent). Thus, while tretinoin is effective, prolonged use is required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Kojic acid, which like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    , blocks the conversion of tyrosine to melanin, also is effective but may be more sensitizing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combinations of treatments, such as tretinoin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    , are increasingly being used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combination of mequinol-tretinoin (Solage&reg;) appears to work as well or better than 3 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"       hydroquinone",
"      </a>",
"      . Mequinol stops the action of chemicals in the skin that create pigmentation or darkening. A randomized trial in 216 adults with solar lentigines found that mequinol-tretinoin appeared to have greater efficacy than hydroquinone for forearm lesions and similar efficacy for clearing facial lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/19\">",
"       19",
"      </a>",
"      ]. However, complete clearing of lesions was uncommon with either treatment, efficacy in melasma as well as long-term efficacy have not been established, and the treatment cannot be used in pregnancy.",
"     </li>",
"     <li>",
"      In a short-term clinical trial, a combination formulation of tretinoin 0.05 percent,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"       hydroquinone",
"      </a>",
"      4.0 percent, and a mid-potency topical steroid,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/22/36192?source=see_link\">",
"       fluocinolone",
"      </a>",
"      acetonide 0.01 percent (Triluma&reg;), appeared to have greater efficacy in treating facial melasma than combinations of two of the components or single components alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Four percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"       hydroquinone",
"      </a>",
"      in combination with 10 percent glycolic acid, antioxidants, and sunscreens (Glyquin&reg;) is effective in decreasing the degree of pigmentation in patients with melasma. Fifteen of twenty patients improved with twice daily application of the combination product compared to 2 of 15 using sunscreen alone. Irritation was frequent but resolved with application of moisturizers and temporary cessation of the cream [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another product containing glycolic acid 2 percent, an active antioxidant system (ascorbyl palmitate and tocopherol acetate), and moisturizers is Lustra-AF&reg;. Lustra-AF also contains a broad spectrum sunscreen. Alustra&reg; contains a stabilized, high concentration of retinol. The above formulations inhibit melanogenesis, stimulate epidermal desquamation, inhibit free radical mediated photodamage and restore the antioxidant reservoir. The addition of retinoids may facilitate epidermal penetration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"       hydroquinone",
"      </a>",
"      and prevent its oxidation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chemical peels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to a dermatologist for chemical peels is indicated in patients with moderate to severe melasma that has not responded to bleaching agents. A chemical peel is a procedure in which a topically applied wounding agent creates smooth, rejuvenated skin by way of an organized repair process and exfoliation. A number of chemical peels are available; glycolic acid peels may be associated with the fewest adverse effects. Patients begin with application of low concentrations of the peeling agent and gradually titrate up on a weekly to monthly basis depending upon results. Topical bleaching agents are frequently used prior to and in between peels, and they appear superior to topical retinoids as priming agents when used in combination with chemical peels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/23\">",
"     23",
"    </a>",
"    ]. Postinflammatory hyperpigmentation may result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laser therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some success with laser therapy for refractory melasma has been reported, but the technique is not yet in widespread use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33092/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9370?source=see_link\">",
"     \"Laser and light therapy for cutaneous hyperpigmentation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Melasma is a relatively common disorder of hyperpigmentation that affects sun-exposed areas of skin, most commonly the face (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Melasma is common during pregnancy but can occur in nonpregnant women and in men (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The diagnosis of melasma is based upon clinical appearance (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features and diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients with melasma should use broad spectrum sun protection including hats (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"       hydroquinone",
"      </a>",
"      cream 4 percent as initial therapy for mild to moderate melasma (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Bleaching agents'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      For more severe melasma or in patients who do not respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"       hydroquinone",
"      </a>",
"      cream after 8 to 12 weeks of therapy, we suggest using a combination bleaching agent such as one containing hydroquinone plus tretinoin, glycolic acid, or retinol. In recalcitrant disease we suggest using a combination that also includes a corticosteroid (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Bleaching agents'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients who do not respond should be referred to a dermatologist for consideration of a chemical peel (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Chemical peels'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/1\">",
"      Kauh YC, Zachian TF. Melasma. Adv Exp Med Biol 1999; 455:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/2\">",
"      Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 1981; 4:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/3\">",
"      Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol 1995; 131:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/4\">",
"      Lutfi RJ, Fridmanis M, Misiunas AL, et al. Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma. J Clin Endocrinol Metab 1985; 61:28.",
"     </a>",
"    </li>",
"    <li>",
"     Wong, RC. Physiologic skin changes in pregnancy. In: Skin changes and diseases in pregnancy, Harahap, M, Wallach, RC (Eds), Marcel Dekker, Inc., New York 1996. p.37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/6\">",
"      P&eacute;rez M, S&aacute;nchez JL, Aguil&oacute; F. Endocrinologic profile of patients with idiopathic melasma. J Invest Dermatol 1983; 81:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/7\">",
"      Hassan I, Kaur I, Sialy R, Dash RJ. Hormonal milieu in the maintenance of melasma in fertile women. J Dermatol 1998; 25:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/8\">",
"      V&aacute;zquez M, Maldonado H, Benmam&aacute;n C, S&aacute;nchez JL. Melasma in men. A clinical and histologic study. Int J Dermatol 1988; 27:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/9\">",
"      Sialy R, Hassan I, Kaur I, Dash RJ. Melasma in men: a hormonal profile. J Dermatol 2000; 27:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/10\">",
"      Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol 2006; 55:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/11\">",
"      Martin AG, Leal-Khouri S. Physiologic skin changes associated with pregnancy. Int J Dermatol 1992; 31:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/12\">",
"      Elling SV, Powell FC. Physiological changes in the skin during pregnancy. Clin Dermatol 1997; 15:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/13\">",
"      V&aacute;zquez M, S&aacute;nchez JL. The efficacy of a broad-spectrum sunscreen in the treatment of melasma. Cutis 1983; 32:92, 95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/14\">",
"      Bali&ntilde;a LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 1991; 30:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/15\">",
"      Griffiths CE, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol 1993; 129:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/16\">",
"      Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg 1999; 25:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/17\">",
"      Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg 1996; 22:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/18\">",
"      Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol 2006; 54:S272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/19\">",
"      Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis 2004; 74:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/20\">",
"      Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003; 72:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/21\">",
"      Guevara IL, Pandya AG. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol 2003; 42:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/22\">",
"      Gupta AK, Ryder JE. Lustra, Lustra-AF and Alustra. Skin Therapy Lett 2003; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/23\">",
"      Nanda S, Grover C, Reddy BS. Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma. Dermatol Surg 2004; 30:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/24\">",
"      Nouri K, Bowes L, Chartier T, et al. Combination treatment of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser: a pilot study. Dermatol Surg 1999; 25:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/25\">",
"      Manaloto RM, Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg 1999; 25:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33092/abstract/26\">",
"      Lee GY, Kim HJ, Whang KK. The effect of combination treatment of the recalcitrant pigmentary disorders with pigmented laser and chemical peeling. Dermatol Surg 2002; 28:1120.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6621 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33092=[""].join("\n");
var outline_f32_20_33092=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bleaching agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chemical peels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laser therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/6621\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/6621|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/56/3973\" title=\"picture 1A\">",
"      Melasma forehead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/53/35666\" title=\"picture 1B\">",
"      Melasma cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/24/8579\" title=\"picture 1C\">",
"      Melasma lip",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9370?source=related_link\">",
"      Laser and light therapy for cutaneous hyperpigmentation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_20_33093="Shoulder anatomy anterior";
var content_f32_20_33093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Anterior view of shoulder anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33093=[""].join("\n");
var outline_f32_20_33093=null;
var title_f32_20_33094="TEE PFO with contrast";
var content_f32_20_33094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/56656/teepfowc_conv.mp4?title=TEE+PFO+with+contrast\" style=\"width:320px;height:236px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiography with contrast of a patent foramen ovale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sequence of images from a transesophageal echocardiography shows the right and left atrium during diastole (panel A); a flap of the atrial septum is seen covering the foramen ovale. There is opacification of the right atrium immediately after the injection of agitated saline (panel B). Panel C shows the contrast passing from the right atrium (RA) into the left atrium (LA) through a patent foramen ovale (PFO) (red arrow). Panel D shows a large amount of contast within the LA (red arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33094=[""].join("\n");
var outline_f32_20_33094=null;
var title_f32_20_33095="Postmastectomy pain syndrome: Clinical manifestations and diagnosis";
var content_f32_20_33095=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postmastectomy pain syndrome: Clinical manifestations and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33095/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33095/contributors\">",
"     Jeannie Shen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33095/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33095/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33095/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33095/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/20/33095/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22470091\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmastectomy pain syndrome (PMPS) is a type of chronic neuropathic pain disorder which can occur following breast cancer procedures, particularly those operations that remove tissue in the upper outer quadrant of the breast",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    axilla, in the absence of an infection or recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain can be severe enough to cause long-term disabilities and interfere with sleep, performance of daily activities, and use of the affected arm, leading to shoulder adhesive capsulitis (frozen shoulder) or complex regional pain syndrome (causalgia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/4,6-10\">",
"     4,6-10",
"    </a>",
"    ]. Altered sensation can also be observed within the distribution of the injured nerve, although not as debilitating as chronic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33912?source=see_link\">",
"     \"Frozen shoulder (adhesive capsulitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1267896\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of PMPS has not been standardized. PMPS is a type of neuropathic pain, a complex chronic pain state that is typically associated with nerve fiber injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16312?source=see_link\">",
"     \"Definition and pathogenesis of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In research studies, various definitions have been used to assess PMPS in patients undergoing a mastectomy with or without reconstruction, partial mastectomy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    axillary dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/1,11-13\">",
"     1,11-13",
"    </a>",
"    ]. For example, in an attempt for uniformity, one series defined PMPS as pain present one-and-a-half years following the operation, located at the operative site or ipsilateral arm, present at least four days per week and with an average intensity of at least three on a numeric rating scale from 0 to 10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/11\">",
"     11",
"    </a>",
"    ]. However, another study adopted the chronic pain definition from the International Association of Study of Pain: &ldquo;pain persisting continuously or intermittently for more than three months after surgery&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22804934\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmastectomy pain syndrome (PMPS) is caused by direct nerve injury (eg, severance, compression, ischemia, stretching, retraction) during the breast cancer operation or from subsequent formation of a traumatic neuroma or scar tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/5,6,14,16-18\">",
"     5,6,14,16-18",
"    </a>",
"    ]. Breast cancer operations can damage the brachial plexus, intercostobrachial, lateral cutaneous branch of the second intercostal, long thoracic, and medial and lateral pectoral nerves that innervate the breast, chest wall, and ipsilateral extremity (",
"    <a class=\"graphic graphic_figure graphicRef54961 \" href=\"mobipreview.htm?42/27/43447\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63143 \" href=\"mobipreview.htm?25/56/26498\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78501 \" href=\"mobipreview.htm?9/6/9315\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/6,16\">",
"     6,16",
"    </a>",
"    ]. In particular, surgical procedures in the upper outer quadrant of the breast and axilla, where major nerves traverse the operative field, are particularly vulnerable to nerve injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. In addition, local radiation treatments and neurotoxic systemic therapy (eg, taxanes, platinum agents, vinca alkaloids) can also exacerbate PMPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/6-8,14,20,21\">",
"     6-8,14,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19710029\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22804946\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of nerve injury or impairment and resultant chronic pain following a breast cancer operation ranges from 20 to 72 percent, in part depending upon the extensiveness of the breast and axillary procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/1,4,6,11-13,16,20,22\">",
"     1,4,6,11-13,16,20,22",
"    </a>",
"    ]. For example, a retrospective review of 55 patients treated at a pain clinic for PMPS after the introduction of the more limited sentinel lymph node dissection (SLND) found that 54 patients had undergone a complete axillary lymph node dissection and one had undergone a total mastectomy without axillary surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/5\">",
"     5",
"    </a>",
"    ]. No patients in this cohort had undergone a SLND.",
"   </p>",
"   <p>",
"    In addition, the wide variation in prevalence rates may be related to a lack of standardization of definition of PMPS, including type, site, and duration of symptoms (eg, chest wall versus ipsilateral arm pain; pain versus paresthesias), as well as the inclusion of patients undergoing immediate or delayed breast reconstructive procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19710037\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is a subjective, multidimensional, and complex phenomenon whose different physiological, sensory, behavioral, socio-cultural, affective, and cognitive components interact to determine pain perception and expression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16312?source=see_link\">",
"     \"Definition and pathogenesis of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon retrospective and prospective studies, the most common variables associated with a higher risk of developing PMPS include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/8,10,20,23\">",
"     8,10,20,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Severe acute postoperative pain",
"      </strong>",
"      &ndash; Patients more likely to develop severe acute postoperative pain include those with preoperative anxiety and age &le;49 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/24\">",
"       24",
"      </a>",
"      ]. Severe acute postoperative pain is a risk factor for developing chronic pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/20,21,24\">",
"       20,21,24",
"      </a>",
"      ]. In a multivariate analysis of 509 breast cancer patients, patients with severe acute postoperative pain were significantly more likely to develop chronic pain in the ipsilateral arm compared with patients with less intense postoperative pain (odds ratio [OR] 1.68, 95% CI 1.34-2.10) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/21\">",
"       21",
"      </a>",
"      ]. Patients with severe pain were also more likely to develop chronic pain in the breast (chest wall) area (OR 1.59, 1.28-1.97).",
"     </li>",
"     <li>",
"      <strong>",
"       Younger age at diagnosis of breast cancer",
"      </strong>",
"      &ndash; It is hypothesized that younger patients are more sensitive to nerve damage, are less likely to tolerate pain, and have increased anxiety, leading to more reports of pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/4\">",
"       4",
"      </a>",
"      ]. However, the effect of age on chronic pain development is poorly understood. More aggressive approaches are commonly offered to younger women, which may influence the prevalence of chronic pain following breast cancer treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Direct comparisons of studies are constrained by varying definitions of &ldquo;younger age&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/20,22,23\">",
"       20,22,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Radiation therapy to the axilla",
"      </strong>",
"      &ndash; Neuropathic pain is a side effect of radiation therapy, frequently identified in patients undergoing postoperative",
"      <span class=\"nowrap\">",
"       breast/axillary",
"      </span>",
"      radiation treatments, and occurring months to years after administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/6-8,14,20,21\">",
"       6-8,14,20,21",
"      </a>",
"      ]. In one series, postoperative radiotherapy and neurotoxic chemotherapy, in conjunction with an axillary lymph node dissection (ALND), were felt to contribute to chronic pain that developed in 21 of 30 patients (70 percent) who were pain free for several months after the operation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The following retrospective studies illustrate the effect of postoperative radiation treatments on chronic pain:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a multivariate analysis of 509 patients, radiation treatments to the breast",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      axilla were associated with increased risk of chronic pain compared with postoperative patients not receiving radiation therapy (OR 2.18, 1.38-3.43 and OR 2.29, 1.47-3.58, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a survey of 569 women undergoing breast cancer procedures, more stage I patients treated with breast conservation therapy (partial mastectomy, axillary node dissection, radiation therapy) had developed chronic pain in the breast scar compared with women undergoing a modified radical mastectomy (total mastectomy with axillary dissection) without radiation treatments (45 versus 32 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/7\">",
"       7",
"      </a>",
"      ]. Women undergoing breast conservation therapy also had more chronic ipsilateral arm pain (37 versus 28 percent), as well as paresthesias in the breast scar (46 versus 35 percent) and ipsilateral arm (51 versus 38 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Extensiveness of axillary procedure",
"      </strong>",
"      &ndash; An axillary node dissection serves as a surrogate for nerve injury contributing to PMPS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/14\">",
"       14",
"      </a>",
"      ]. Patients undergoing a standard ALND frequently have chronic neuropathic symptoms, while a less extensive dissection (ie, sentinel lymph node dissection [SLND]) is associated with less frequent chronic pain complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/5,14,20-25\">",
"       5,14,20-25",
"      </a>",
"      ]. For example, a European Organization for Research and Treatment of Cancer Quality of Life Questionnaire survey of 317 breast cancer patients found that more women undergoing an ALND with breast surgery (n = 105) (ie, mastectomy or partial mastectomy) had chronic pain compared with women not undergoing an ALND (51 versus 23 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/14\">",
"       14",
"      </a>",
"      ]. Some patients not undergoing an ALND did undergo a SLND.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22801901\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83782090\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22801925\">",
"    <span class=\"h3\">",
"     Patient presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PMPS typically present with burning, electric shock, or stabbing pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neuropathic symptoms (eg, numbness, hyperesthesia, paraesthesia) at the operative site",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the ipsilateral arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/3-5,8,9,22,26,27\">",
"     3-5,8,9,22,26,27",
"    </a>",
"    ]. For example, in a survey of 223 women 16 months to 32 years from their original surgery for breast cancer, 65 percent reported pain, 81 percent numbness, and 46 percent paraesthesias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/9\">",
"     9",
"    </a>",
"    ]. Other symptoms include chest wall muscle pain, reduced range of motion of the shoulder, and reduced shoulder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hand grip strength [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion on the critical components of the history for assessing chronic pain is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40296?source=see_link&amp;anchor=H15544409#H15544409\">",
"     \"Evaluation of chronic pain in adults\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22801933\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pertinent findings on the physical examination include sensory changes (eg, hypersensitivity, hyposensitivity) at the operative site",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ipsilateral extremity and decreased range of motion and strength in the ipsilateral arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. For example, intercostobrachial neuralgia pain is typically accompanied by altered sensation in the distribution of the intercostobrachial nerve, whereas neuroma pain is found in the region of the scar, which can be provoked by percussion.",
"   </p>",
"   <p>",
"    In addition to sensory alterations, nerve impairment can result in decreased shoulder strength and range of motion. Methodological differences have resulted in a wide range of reported incidences, ranging from 2 to 51 percent for impairments in range of motion that interfered with normal daily activities, and 17 to 33 percent for decreased muscle strength [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/28-31\">",
"     28-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21967737\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific radiographic findings for PMPS. In the clinical setting of pain confined to the breast, a mammogram, ultrasound, or MRI may identify a fluid collection or evidence of recurrent disease. A plain film of the shoulder and humerus can identify local abnormalities such as a fracture, arthritic changes, metastatic disease, or benign bone cysts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21967745\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific laboratory findings for PMPS. Abnormal laboratory tests (eg, blood count, serologic markers of inflammation, cancer markers) may signify other causes of pain such as rheumatologic, infectious, or oncologic etiologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21967753\">",
"    <span class=\"h2\">",
"     Neurophysiologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurophysiologic testing, principally nerve conduction studies (NCV) and electromyography (EMG), are frequently employed in suspected disorders of the peripheral nervous system. The usual techniques, with surface electrodes for nerve stimulation, measure activity of the largest and fastest conducting sensory and motor myelinated nerve fibers. NCV and EMG studies may be normal in patients with polyneuropathies or focal nerve lesions with only small-fiber involvement. Abnormal findings associated with neuropathy are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/46/1769?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of electromyography\", section on 'Neuropathies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22801909\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PMPS is made based upon characteristic symptoms of a burning, electric, or stabbing pain or paresthesias in the chest wall, axilla,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ipsilateral extremity following a breast cancer operation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    local radiation therapy or chemotherapy, in the absence of an infection or recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The physical examination includes a breast, chest wall, and axillary examination that identifies post-treatment changes (ie, surgical, radiation) in the absence of signs of local recurrence or infection. A detailed sensory and motor neurologic evaluation of the affected sites reveals motor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sensory deficiencies in the distribution of the affected peripheral nerve (eg, intercostal brachial, long thoracic, thoracodorsal nerves).",
"   </p>",
"   <p>",
"    Imaging studies are not necessary or useful for making the diagnosis of PMPS. However, if there is diagnostic uncertainty, imaging studies can be helpful in excluding other disorders in differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22801917\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Locoregional recurrent breast cancer",
"      </strong>",
"      &ndash; Pain is not a common presenting symptom for a local recurrence of breast cancer. A locoregional recurrence is typically identified on the physical examination as a palpable mass or as an abnormality on an imaging study, such as a mammogram. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of locoregional recurrence of breast cancer after mastectomy\", section on 'Presenting signs and symptoms'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34650?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of locoregional recurrence of breast cancer after breast conserving therapy\", section on 'Presenting signs and symptoms'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Metastatic breast cancer",
"      </strong>",
"      &ndash; Bones are a common site of metastasis from breast cancer, and the humerus is the most common upper extremity site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/3\">",
"       3",
"      </a>",
"      ]. Bone pain from metastatic disease is severe and debilitating, and results from destruction of bone tissue. Localized bone pain may indicate a fracture or impending fracture at the site of disease. Diagnosis can be made by imaging studies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35831?source=see_link&amp;anchor=H20#H20\">",
"       \"Metastatic breast cancer: Local treatment\", section on 'Bone metastases'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Infectious etiologies",
"      </strong>",
"      &ndash; Pain accompanied by erythema is a frequent presentation of benign erythematous disorders of the breast, including cellulitis and abscess. An abscess can also occur in the axilla following an axillary dissection. These clinical settings are typically encountered early in the postoperative course. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/857?source=see_link&amp;anchor=H2#H2\">",
"       \"Erythematous disorders of the breast\", section on 'Infectious mastitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9495?source=see_link\">",
"       \"Breast abscess\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Noninfectious erythematous disorders",
"      </strong>",
"      &ndash; Pain can accompany erythema in noninfectious breast disorders, such as postirradiation mastitis and superficial thrombophlebitis of the breast. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/857?source=see_link&amp;anchor=H8#H8\">",
"       \"Erythematous disorders of the breast\", section on 'Noninfectious mastitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Phantom breast pain or phantom sensations",
"      </strong>",
"      &ndash; Chronic pain or chronic sensations can develop as phantom symptoms following a total or partial mastectomy, similar to those that occur after a limb amputation. The postsurgical nonpainful sensations are called phantom breast sensations (PBS) while a painful sensation is called phantom breast pain (PBP). While the symptoms of PBP are similar to those of PMPS, subjectively patients with PBP report the persistence of sensations within their amputated breast.",
"      <br/>",
"      <br/>",
"      PBS includes all sensations that are experienced in the amputated breast, whereas PBP includes sensations so intense that they are experienced as pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. The prevalence of PBS and PBP ranges from 0 to 66 percent, with the wide range most likely attributed to differences in methodologies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/4,10,14,26,32-34\">",
"       4,10,14,26,32-34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Phantom breast sensations &ndash; PBS are characterized by a sensation of persistence of the removed breast after its removal. Phantom breast sensations are distinguishable from pain or other sensory disturbances in or around the scar.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Phantom breast pain &ndash; PBP is characterized by disturbing and painful sensations in the area of the nipple alone or involving the entire breast or segment that was resected, and may persist for years after the operation.",
"      <br/>",
"      <br/>",
"      Etiology includes central nervous system sensitization and cortical reorganization, which are associated with nerve damage, and are considered to have a role in pain chronification [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/8,14\">",
"       8,14",
"      </a>",
"      ]. The injury to neurons results in spontaneous and evoked hyperexcitability. Psychological factors have also been implicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chemical neuropathy",
"      </strong>",
"      &ndash; Chemotherapeutic agents (eg, taxanes, platinum based), heavy metals, and alcohol can produce peripheral neuropathies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/3\">",
"       3",
"      </a>",
"      ]. Presentation includes a distal, symmetric distribution of pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      paresthesias. Electrodiagnostic testing and clinical presentation help establish the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7369?source=see_link&amp;anchor=H6425488#H6425488\">",
"       \"Overview of polyneuropathy\", section on 'Toxic'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lymphedema",
"      </strong>",
"      &ndash; Lymphedema can present as an insidious soft tissue enlargement of the hand and arm. It can occur as a result of injury from an axillary dissection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy or from obstruction of the lymphatic channels (eg, tumor cells, mass effect). Discomfort and the sensation of heaviness is the most common presenting symptom, rather than pain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link\">",
"       \"Clinical manifestations and diagnosis of lymphedema\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Musculoskeletal disorders",
"      </strong>",
"      &ndash; Common musculoskeletal disorders, such as bursitis, adhesive capsulitis (frozen shoulder), tendonitis, or rotator cuff injury can present with shoulder pain and a limited range of motion. Diagnosis can be established based on the history, clinical examination, and radiographic imaging (eg, MRI). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=see_link\">",
"       \"Evaluation of the patient with shoulder complaints\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cervical radiculopathy",
"      </strong>",
"      &ndash; Cervical radiculopathy can present with pain, paresthesias, numbness, or weakness of the shoulders, arms, or hands [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/3\">",
"       3",
"      </a>",
"      ]. Onset of symptoms is most frequently acute when caused by a herniated nucleus pulposus, but may be more indolent when due to spondylosis. Imaging studies, electrodiagnostic studies, and the clinical presentation can help establish the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/19/36152?source=see_link\">",
"       \"Clinical features and diagnosis of cervical radiculopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22470168\">",
"    <span class=\"h1\">",
"     QUALITY OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality of life (QoL) is a multidimensional term that includes the physical, social, and psychological well-being domains. For a cancer patient, the appearance of pain may represent a continuous memory of the treatment and the disease. Additionally, pain may be incorrectly viewed as a sign of recurrent cancer and cause considerable psychological distress and a poor quality of life, even in the absence of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/6,9,14,21-24\">",
"     6,9,14,21-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=see_link\">",
"     \"Overview of cancer pain syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective studies found that PMPS can have a negative impact on an individual&rsquo;s long-term quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/6,10,14,26\">",
"     6,10,14,26",
"    </a>",
"    ]. Persistent, unremitting stress caused by chronic pain can generate detrimental long-term effects, increasing an individual&rsquo;s susceptibility to stress-related physical and mental health problems. A retrospective study of 55 breast cancer patients assessing impairments, disabilities, and health related QoL in women found that pain was the most important factor in predicting health-related QoL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33095/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H747283\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postmastectomy pain syndrome (PMPS) is a chronic neuropathic disorder caused by direct nerve injury (eg, severance, compression, ischemia, stretching, retraction) during the breast cancer operation or the subsequent formation of a traumatic neuroma or scar tissue and possibly exacerbated by local radiation treatments and neurotoxic chemotherapies (eg, taxanes). (See",
"      <a class=\"local\" href=\"#H22804934\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with PMPS typically present with burning, electric shock, or stabbing pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neuropathic symptoms (eg, numbness, hyperesthesia, paraesthesia) at the operative site",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the ipsilateral arm. Other symptoms of patients with PMPS include chest wall muscle pain, reduced range of motion of the shoulder, and reduced shoulder",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hand grip strength. (See",
"      <a class=\"local\" href=\"#H22801925\">",
"       'Patient presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pertinent findings on the physical examination include sensory changes (eg, hypersensitive, hyposensitive) at the operative site",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ipsilateral extremity and decreased range of motion and strength in the ipsilateral arm. (See",
"      <a class=\"local\" href=\"#H22801933\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PMPS is made based upon symptoms of a burning, electric, or stabbing pain or paresthesias in the chest wall, axilla,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ipsilateral extremity following a breast cancer operation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      local radiation therapy or chemotherapy, in the absence of an infection or recurrent disease. (See",
"      <a class=\"local\" href=\"#H22801909\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for PMPS includes recurrent breast cancer, metastatic breast cancer, benign inflammatory disorders, and postradiation and chemotherapy effects. (See",
"      <a class=\"local\" href=\"#H22801917\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/1\">",
"      G&auml;rtner R, Jensen MB, Nielsen J, et al. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 2009; 302:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/2\">",
"      Caviggioli F, Maione L, Forcellini D, et al. Autologous fat graft in postmastectomy pain syndrome. Plast Reconstr Surg 2011; 128:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/3\">",
"      Stubblefield MD, Custodio CM. Upper-extremity pain disorders in breast cancer. Arch Phys Med Rehabil 2006; 87:S96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/4\">",
"      Smith WC, Bourne D, Squair J, et al. A retrospective cohort study of post mastectomy pain syndrome. Pain 1999; 83:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/5\">",
"      Miguel R, Kuhn AM, Shons AR, et al. The effect of sentinel node selective axillary lymphadenectomy on the incidence of postmastectomy pain syndrome. Cancer Control 2001; 8:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/6\">",
"      Caffo O, Amichetti M, Ferro A, et al. Pain and quality of life after surgery for breast cancer. Breast Cancer Res Treat 2003; 80:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/7\">",
"      Tasmuth T, von Smitten K, Hietanen P, et al. Pain and other symptoms after different treatment modalities of breast cancer. Ann Oncol 1995; 6:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/8\">",
"      Bokhari F, Sawatzky JA. Chronic neuropathic pain in women after breast cancer treatment. Pain Manag Nurs 2009; 10:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/9\">",
"      Polinsky ML. Functional status of long-term breast cancer survivors: demonstrating chronicity. Health Soc Work 1994; 19:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/10\">",
"      Macdonald L, Bruce J, Scott NW, et al. Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer 2005; 92:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/11\">",
"      Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer 2008; 99:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/12\">",
"      Vadivelu N, Schreck M, Lopez J, et al. Pain after mastectomy and breast reconstruction. Am Surg 2008; 74:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/13\">",
"      Sclafani LM, Baron RH. Sentinel lymph node biopsy and axillary dissection: added morbidity of the arm, shoulder and chest wall after mastectomy and reconstruction. Cancer J 2008; 14:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/14\">",
"      Steegers MA, Wolters B, Evers AW, et al. Effect of axillary lymph node dissection on prevalence and intensity of chronic and phantom pain after breast cancer surgery. J Pain 2008; 9:813.",
"     </a>",
"    </li>",
"    <li>",
"     IASP: Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain (Suppl 3):S1-S226, 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/16\">",
"      Wallace MS, Wallace AM, Lee J, Dobke MK. Pain after breast surgery: a survey of 282 women. Pain 1996; 66:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/17\">",
"      Vecht CJ, Van de Brand HJ, Wajer OJ. Post-axillary dissection pain in breast cancer due to a lesion of the intercostobrachial nerve. Pain 1989; 38:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/18\">",
"      Jung BF, Ahrendt GM, Oaklander AL, Dworkin RH. Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain 2003; 104:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/19\">",
"      Wong L. Intercostal neuromas: a treatable cause of postoperative breast surgery pain. Ann Plast Surg 2001; 46:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/20\">",
"      Poleshuck EL, Katz J, Andrus CH, et al. Risk factors for chronic pain following breast cancer surgery: a prospective study. J Pain 2006; 7:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/21\">",
"      Tasmuth T, Kataja M, Blomqvist C, et al. Treatment-related factors predisposing to chronic pain in patients with breast cancer--a multivariate approach. Acta Oncol 1997; 36:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/22\">",
"      Hack TF, Cohen L, Katz J, et al. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol 1999; 17:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/23\">",
"      Ververs JM, Roumen RM, Vingerhoets AJ, et al. Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer 2001; 37:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/24\">",
"      Katz J, Poleshuck EL, Andrus CH, et al. Risk factors for acute pain and its persistence following breast cancer surgery. Pain 2005; 119:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/25\">",
"      Glechner A, W&ouml;ckel A, Gartlehner G, et al. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer 2013; 49:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/26\">",
"      Tasmuth T, Blomqvist C, Kalso E. Chronic post-treatment symptoms in patients with breast cancer operated in different surgical units. Eur J Surg Oncol 1999; 25:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/27\">",
"      Rietman JS, Dijkstra PU, Debreczeni R, et al. Impairments, disabilities and health related quality of life after treatment for breast cancer: a follow-up study 2.7 years after surgery. Disabil Rehabil 2004; 26:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/28\">",
"      Sugden EM, Rezvani M, Harrison JM, Hughes LK. Shoulder movement after the treatment of early stage breast cancer. Clin Oncol (R Coll Radiol) 1998; 10:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/29\">",
"      Lauridsen MC, Overgaard M, Overgaard J, et al. Shoulder disability and late symptoms following surgery for early breast cancer. Acta Oncol 2008; 47:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/30\">",
"      Nesvold IL, Dahl AA, L&oslash;kkevik E, et al. Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy. Acta Oncol 2008; 47:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/31\">",
"      Merchant CR, Chapman T, Kilbreath SL, et al. Decreased muscle strength following management of breast cancer. Disabil Rehabil 2008; 30:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/32\">",
"      Dijkstra PU, Rietman JS, Geertzen JH. Phantom breast sensations and phantom breast pain: a 2-year prospective study and a methodological analysis of literature. Eur J Pain 2007; 11:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/33\">",
"      Kr&oslash;ner K, Knudsen UB, Lundby L, Hvid H. Long-term phantom breast syndrome after mastectomy. Clin J Pain 1992; 8:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33095/abstract/34\">",
"      Reuben SS, Makari-Judson G, Lurie SD. Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. J Pain Symptom Manage 2004; 27:133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14973 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33095=[""].join("\n");
var outline_f32_20_33095=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H747283\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22470091\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1267896\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22804934\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19710029\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22804946\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19710037\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22801901\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83782090\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22801925\">",
"      - Patient presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22801933\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21967737\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21967745\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21967753\">",
"      Neurophysiologic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22801909\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22801917\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22470168\">",
"      QUALITY OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H747283\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14973|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/27/43447\" title=\"figure 1\">",
"      Anatomy of the chest wall and axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/56/26498\" title=\"figure 2\">",
"      Completed axillary dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/6/9315\" title=\"figure 3\">",
"      Identification of the thoracodorsal bundle",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9495?source=related_link\">",
"      Breast abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/19/36152?source=related_link\">",
"      Clinical features and diagnosis of cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16312?source=related_link\">",
"      Definition and pathogenesis of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/857?source=related_link\">",
"      Erythematous disorders of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40296?source=related_link\">",
"      Evaluation of chronic pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33912?source=related_link\">",
"      Frozen shoulder (adhesive capsulitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34650?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35831?source=related_link\">",
"      Metastatic breast cancer: Local treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7369?source=related_link\">",
"      Overview of polyneuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_20_33096="Treatment of herpes zoster in the immunocompetent host";
var content_f32_20_33096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of herpes zoster in the immunocompetent host",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33096/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33096/contributors\">",
"     Mary A Albrecht, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33096/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33096/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33096/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33096/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/20/33096/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster virus (VZV) infection causes two clinically distinct forms of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/1\">",
"     1",
"    </a>",
"    ]. Primary infection with VZV results in varicella, also known as chickenpox, characterized by vesicular lesions in different stages of development on the face, trunk and extremities. Herpes zoster, also known as shingles, results from reactivation of endogenous latent VZV infection within the sensory ganglia. This clinical form of the disease is characterized by a painful, unilateral vesicular eruption, which usually occurs in a restricted dermatomal distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/2\">",
"     2",
"    </a>",
"    ]. Although herpes zoster can occur at any age, it is mainly a disease of older adults (&gt;60 years of age).",
"   </p>",
"   <p>",
"    The treatment of herpes zoster will be reviewed here. The clinical manifestations and diagnosis of zoster and the epidemiology, pathogenesis, and sequelae of this infection during pregnancy are discussed separately. Zoster immunization in adults and issues regarding transmission are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=see_link\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=see_link\">",
"     \"Postherpetic neuralgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32200?source=see_link\">",
"     \"Prevention and control of varicella in hospitals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344084\">",
"    <span class=\"h1\">",
"     CLINICAL SEQUELAE OF HERPES ZOSTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting clinical manifestations of herpes zoster include a dermatomal vesicular rash and acute neuritis, which can precede, or occur simultaneously, with the rash; acute neuralgia may persist for weeks after the vesicles have encrusted. The pain of acute neuritis is thought to be related to viral replication, inflammatory changes, and cytokine production leading to neuronal destruction and increased sensitivity of pain receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Post-herpetic neuralgia (PHN) represents a continuum of pain that never resolved following the acute episode of herpes zoster. Uncommonly, after resolution of acute neuritis, there is a recurrence of pain at the same site of the original zoster lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/4\">",
"     4",
"    </a>",
"    ]. Definitions for PHN vary, and are somewhat arbitrary; depending on the clinical trial, PHN may be defined as starting immediately after lesion resolution or one to four months after onset of rash, regardless of when the lesions resolved. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/5\">",
"     5",
"    </a>",
"    ]. Residual neuralgia may be trivial or debilitating, causing significant distress.",
"   </p>",
"   <p>",
"    PHN occurs in approximately 10 to 15 percent of all patients with herpes zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/6\">",
"     6",
"    </a>",
"    ]. The risk of developing PHN is significantly higher in older adults (greater than 50 years of age). Other age-independent risk factors include the severity of neuritis or rash at clinical presentation or a history of prodromal symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/7-14\">",
"     7-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acute and chronic manifestations of herpes zoster infection and the pathophysiology of PHN are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=see_link\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=see_link\">",
"     \"Postherpetic neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important goals of antiviral therapy are to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lessen the severity and duration of pain associated with acute neuritis",
"     </li>",
"     <li>",
"      Promote more rapid healing of skin lesions",
"     </li>",
"     <li>",
"      Prevent new lesion formation",
"     </li>",
"     <li>",
"      Decrease viral shedding to reduce the risk of transmission",
"     </li>",
"     <li>",
"      Prevent post-herpetic neuralgia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3689042\">",
"    <span class=\"h1\">",
"     AVAILABLE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nucleoside analogues",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    are the preferred antivirals for treatment of acute herpes zoster infections. Although oral acyclovir (800 mg five times daily) has been the mainstay of herpes zoster treatment, its poor bioavailability and need for frequent daily dosing prompted the development of later generation antiviral agents (valacyclovir and famciclovir) with improved pharmacokinetics and lower dosing frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/7,17-20\">",
"     7,17-20",
"    </a>",
"    ]. Famciclovir, the prodrug of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/23/12659?source=see_link\">",
"     penciclovir",
"    </a>",
"    , is well absorbed from the gastrointestinal tract and is rapidly converted in the intestinal wall and liver to the active compound penciclovir, which has broad activity against VZV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/14,20\">",
"     14,20",
"    </a>",
"    ]. Valacyclovir is also well absorbed from the gastrointestinal tract and rapidly converted to acyclovir in vivo, thereby providing a three- to fivefold increase in acyclovir bioavailability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/8,20\">",
"     8,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These nucleoside analogs have well-established safety records and are generally well tolerated at the currently recommended doses. Adverse events can include nausea, diarrhea, or headache. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6308?source=see_link\">",
"     \"Famciclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30003?source=see_link\">",
"     \"Valacyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL TRIAL DATA ON ANTIVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several lines of evidence suggest that antiviral therapy hastens resolution of cutaneous lesions and the acute neuritis of herpes zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/7,18,21\">",
"     7,18,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether antiviral therapy prevents post-herpetic neuralgia (PHN) is not as clear because of conflicting study results. However, the evidence is limited by different methodologies of pain assessment, definitions of PHN, and length of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/7,18,21,22\">",
"     7,18,21,22",
"    </a>",
"    ]. Subsequent meta-analyses have also differed in their conclusions depending on which studies were included and the PHN definitions that were used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/18,21,22\">",
"     18,21,22",
"    </a>",
"    ]. One expert suggested that the definitions of acute neuritis and PHN were artificial; it was suggested that the effect of antiviral therapy should be measured as a continuum from the onset of rash to resolution to better determine the impact on the duration of pain, whether acute, subacute, or chronic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trial data regarding the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    within 48 to 72 hours of the onset of rash has demonstrated clinical benefit in the treatment of acute neuritis and in the prevention of post-herpetic neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/7,18\">",
"     7,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of four placebo-controlled trials involving 691 patients (mean age 62 years),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (800 mg five times daily) was associated with a lower prevalence of acute neuritis (HR 1.46; 95% CI 1.1-1.93) and post-herpetic neuralgia, defined as the presence of pain at three and six months after resolution of rash (HR 1.8; 95% CI 1.35-2.43) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/7\">",
"     7",
"    </a>",
"    ]. In a subsequent meta-analysis, which included one additional placebo-controlled trial, antiviral therapy decreased the risk of post-herpetic neuralgia (as defined by any pain at six months) by 46 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Famciclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;A placebo-controlled clinical trial was conducted in 419 immunocompetent adults (mean age 50 years) with uncomplicated zoster to evaluate the efficacy of standard dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    (500 mg three times daily) or high dose famciclovir (750 mg three times daily) for the treatment of acute zoster and prevention of PHN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/14\">",
"     14",
"    </a>",
"    ]. All patients were initiated on the intervention, or placebo, within 72 hours of rash and were treated for seven days. Of note, PHN was defined as any pain occurring after rash resolution. After five months of monthly follow-up, the intention-to-treat analysis demonstrated that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      was associated with modest improvement in lesion healing rates (median five to six days with low- and high-dose famciclovir) compared with placebo (median seven days).",
"     </li>",
"     <li>",
"      There was no difference in the incidence of PHN among the three arms. However, compared with placebo, the median duration of PHN was reduced by approximately two months with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      therapy, regardless of dose (62 and 55 days with low- and high-dose famciclovir, respectively, compared with 119 days with placebo). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although one trial demonstrated comparable rates of resolution of acute neuritis with once-daily dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    (750 mg daily) as compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (800 mg five times daily), no results were reported for the outcome of post-herpetic neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12486538\">",
"    <span class=\"h2\">",
"     Valacyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized, double-blind study of 1141 immunocompetent adults with herpes zoster (mean age 68 years), the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (1000 mg orally three times daily for 7 or 14 days) was compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (800 mg orally five times daily for seven days) over six months of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/8\">",
"     8",
"    </a>",
"    ]. In an intent-to-treat analysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      for 7 or 14 days accelerated the resolution of acute neuritis (median duration of pain 38 and 44 days, respectively) compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (median 51 days).",
"     </li>",
"     <li>",
"      The proportion of patients with pain persisting for six months was modestly lower in the combined",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      arms (19 percent) compared with the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      arm (26 percent). No additional benefit was observed with a longer duration of valacyclovir.",
"     </li>",
"     <li>",
"      Cutaneous lesion resolution occurred at similar rates in all treatment groups",
"     </li>",
"     <li>",
"      Adverse events were similar among all arms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a smaller controlled trial that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , there were no differences in rates of resolution of acute neuritis or PHN; safety profiles were similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344547\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF UNCOMPLICATED HERPES ZOSTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with uncomplicated zoster is discussed below. Herpes zoster can also lead to ophthalmic and central nervous system complications, which are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\", section on 'Complications in immunocompetent patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21288?source=see_link\">",
"     \"Stroke caused by varicella zoster virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345666\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of uncomplicated zoster includes antiviral therapy to hasten healing of cutaneous lesions and to decrease the duration and severity of acute neuritis. Whether antiviral therapy decreases the risk of post-herpetic neuralgia is less clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/7,18,21,22\">",
"     7,18,21,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical trial data on antiviral therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Analgesia is also important for pain control for patients with moderate to severe acute neuritis. There is no clear role for other adjuvant therapies, such as glucocorticoids or tricyclic antidepressants, as discussed below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Analgesia for acute neuritis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'Use of glucocorticoids'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H472008\">",
"     'Use of tricyclic antidepressants'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The treatment of established post-herpetic neuralgia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=see_link&amp;anchor=H7#H7\">",
"     \"Postherpetic neuralgia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344959\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344555\">",
"    <span class=\"h3\">",
"     Patents over 50 years of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend antiviral therapy for patients &gt;50 years of age with uncomplicated herpes zoster who present within 72 hours of clinical symptoms.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    have all demonstrated clinical benefit and safety in the treatment of herpes zoster in immunocompetent patients. However, we prefer valacyclovir or famciclovir compared with acyclovir based on the convenience of less frequent dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/24\">",
"     24",
"    </a>",
"    ]. The selection of drug may also be influenced by cost considerations. The duration of treatment is seven days; dosing is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      800 mg five times daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      500 mg three times daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      1000 mg three times daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344606\">",
"    <span class=\"h3\">",
"     Patients under 50 years of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of antiviral therapy in patients less than 50 years of age has not been as well studied. In the meta-analysis cited above, the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy was seen in all patients, but was greatest in patients older than 50 years of age, in whom the pain of zoster generally persists longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/7,14\">",
"     7,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the risk of adverse events secondary to antiviral therapy is very low, and early treatment can decrease symptoms of acute neuritis and hasten resolution of cutaneous lesions. Thus, we generally give antiviral therapy to patients &lt;50 years of age with herpes zoster who present within 72 hours of clinical symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344906\">",
"    <span class=\"h3\">",
"     Timing of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral therapy should be initiated within 72 hours of clinical presentation in patients greater than 50 years of age to maximize the potential benefits of treatment. The clinical utility of initiating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy more than 72 hours after the onset of lesions in the immunocompetent host is unknown. However, treatment should be considered if new lesions are still appearing at that time of clinical presentation, indicating ongoing viral replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/25\">",
"     25",
"    </a>",
"    ]. There is likely minimal benefit of antiviral therapy in the patient who has lesions that have encrusted.",
"   </p>",
"   <p>",
"    The rapid initiation of therapy is particularly critical in the severely immunocompromised patient, such as the organ transplant recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/26\">",
"     26",
"    </a>",
"    ]. Antiviral therapy should be initiated in all immunocompromised patients, even if they present after 72 hours. Immunocompromised hosts with disseminated zoster should be hospitalized for intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Analgesia for acute neuritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although antiviral therapy reduces pain associated with acute neuritis, pain syndromes associated with herpes zoster can still be severe. Nonsteroidal anti-inflammatory drugs and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    are useful for mild pain, either alone, or in combination with a weak opioid analgesic (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/27\">",
"     27",
"    </a>",
"    ]. For moderate to severe pain that disturbs sleep, stronger opioid analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) may be necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a clinical trial of 87 patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    for a new diagnosis of herpes zoster, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    was not more effective than placebo as adjuvant therapy for acute neuritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Use of glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have been used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    for the treatment of uncomplicated acute herpes zoster in an attempt to improve the quality of life, the time to healing of lesions, and to reduce the incidence of post-herpetic neuralgia. Early trials suggested a modest benefit of glucocorticoids on a limited number of clinical outcomes with an increased risk of adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/19,28-30\">",
"     19,28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a subsequent meta-analysis of five placebo-controlled trials evaluating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    alone compared with acyclovir plus glucocorticoids did not demonstrate any benefit of combination therapy on quality of life or the incidence of post-herpetic neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/31\">",
"     31",
"    </a>",
"    ]. Furthermore, corticosteroids could potentially increase the risk of secondary bacterial skin infection. Thus, we do not recommend the routine use of corticosteroids in addition to antiviral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H472008\">",
"    <span class=\"h2\">",
"     Use of tricyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is unconvincing direct evidence for a role of tricyclic antidepressants in managing acute neuritis or in preventing post-herpetic neuralgia.",
"   </p>",
"   <p>",
"    A placebo-controlled trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    for 90 days among 80 patients with herpes zoster found that the risk of post-herpetic neuralgia was reduced by more than 50 percent among patients who were assigned to the intervention arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/32\">",
"     32",
"    </a>",
"    ]. However, there are multiple limitations to this trial: a) antiviral therapy was prescribed according to the discretion of the practitioner and only a minority of patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ; b) a standardized questionnaire was not used to determine the severity of pain; c) pain symptoms were collected retrospectively, which may have led to recall bias; d) the patients were not stratified at baseline for factors associated with increased risk of post-herpetic neuralgia. Thus, the additive benefit of tricyclics for pain reduction cannot be assessed from this trial.",
"   </p>",
"   <p>",
"    The risk of adverse events related to tricyclic antidepressants is also increased in elderly patients. Thus, we do not recommend the addition of tricyclic antidepressants for the prevention of post-herpetic neuralgia based on the available data.",
"   </p>",
"   <p>",
"    The use of tricyclic antidepressants and other adjuvants in established post-herpetic neuralgia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=see_link&amp;anchor=H7#H7\">",
"     \"Postherpetic neuralgia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1866880\">",
"    <span class=\"h2\">",
"     Viral load monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, there is no indication for monitoring viremia during treatment in patients with acute VZV since the height of the viral load does not correlate with the development of post-herpetic neuralgia or duration of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3374706\">",
"    <span class=\"h2\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, pain management of acute neuritis is integral for patient management. Serial patient monitoring should include standardized pain measures and frequent follow-up to assess efficacy in relief of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, approximately 10 to 15 percent of patients may also develop post-herpetic neuralgia. The management of the pain associated with PHN is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=see_link\">",
"     \"Postherpetic neuralgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40296?source=see_link\">",
"     \"Evaluation of chronic pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1867100\">",
"    <span class=\"h1\">",
"     HERPES ZOSTER DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials examining the role of antiviral therapy in the pregnant woman with herpes zoster infection. However, experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy in both HSV infection and varicella pneumonia suggests that this drug is safe in pregnancy.",
"   </p>",
"   <p>",
"    Although maternal varicella (ie, chickenpox) infection during pregnancy can lead to severe complications, such as congenital varicella with neonatal morbidity, maternal herpes zoster infection has not been associated with the development of congenital varicella. Furthermore, there is no evidence to suggest that the pregnant female is at increased risk for complicated disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link&amp;anchor=H24#H24\">",
"     \"Genital herpes simplex virus infection and pregnancy\", section on 'Safety of antiviral drugs in pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A consensus panel of experts issued management guidelines for the pregnant woman with acute herpes zoster in 2007. These experts suggested initiation of antiviral therapy in a pregnant women with severe zoster rash (eg, &gt;50 lesions) to promote more rapid healing and in those with acute neuritis to lessen the severity and duration of pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1027019\">",
"    <span class=\"h1\">",
"     RECURRENT ZOSTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes of recurrent zoster are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\", section on 'Recurrent zoster'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with recurrent zoster should be treated with antiviral therapy with similar dosing and duration as for a primary episode. In addition, patients who present with recurrent herpes simplex outside of the mouth or genital areas may be misdiagnosed with recurrent zoster. Thus, viral cultures or other detection assays (eg, antigen or DNA detection) should be performed when a diagnosis of recurrent zoster is being considered.",
"   </p>",
"   <p>",
"    There are no data regarding the potential benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    in this scenario. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT OF COMPLICATED HERPES ZOSTER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Herpes zoster ophthalmicus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes zoster ophthalmicus (HZO), a serious sight-threatening condition, has been linked to VZV reactivation within the trigeminal ganglion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Patients can develop conjunctivitis, episcleritis, keratitis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    iritis. Early diagnosis and treatment is critical to prevent progressive corneal involvement and potential loss of vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The standard approach to herpes zoster ophthalmicus is to initiate antiviral therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    ) to limit VZV replication and to use adjunctive topical steroid drops to reduce the inflammatory response and control immune-associated keratitis and iritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. Intravenous acyclovir (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    three times daily for seven days) is suggested in the patient who is immunocompromised or requires hospitalization for sight-threatening disease.",
"   </p>",
"   <p>",
"    As of November 2012, there is a shortage of IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in the United States due to a manufacturing delay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Clinicians should check the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm\">",
"     US Food and Drug Administration's website",
"    </a>",
"    for information about the availability of IV acyclovir. If IV acyclovir is not available, an alternative regimen can be used. Specific recommendations are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link&amp;anchor=H72507949#H72507949\">",
"     \"Acyclovir: An overview\", section on 'Acyclovir shortage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3374933\">",
"    <span class=\"h2\">",
"     Secondary bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be counseled to contact their physician should they observe increased erythema, warmth, or purulence surrounding any lesions, which could suggest secondary bacterial skin infection. Should secondary bacterial infection be suspected, the patient should also receive appropriate staphylococcal and streptococcal antibiotic coverage in addition to antiviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3689599\">",
"    <span class=\"h2\">",
"     Post-herpetic neuralgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients who develop post-herpetic neuralgia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=see_link&amp;anchor=H7#H7\">",
"     \"Postherpetic neuralgia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15364136\">",
"    <span class=\"h1\">",
"     HERPES ZOSTER VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     Herpes zoster vaccine",
"    </a>",
"    is moderately effective in reducing the incidence of herpes zoster and post-herpetic neuralgia (PHN) and is recommended for persons 60 years of age or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/41\">",
"     41",
"    </a>",
"    ]. Preliminary data also suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    reduces herpes zoster and post-herpetic neuralgia in patients ranging in age from 50 to 59. Detailed information regarding vaccine indications and contraindications is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are limited data on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    in patients with a history of prior herpes zoster. The Advisory Committee on Immunization Practices recommends zoster vaccine whether or not the patient has a history of zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33096/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/0/14338?source=see_link\">",
"       \"Patient information: Shingles (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/12/13507?source=see_link\">",
"       \"Patient information: Shingles (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reactivation of latent varicella-zoster virus (VZV) infection within the sensory ganglia results in herpes zoster, or \"shingles.\" This syndrome is usually characterized by a painful, unilateral vesicular eruption in a dermatomal distribution. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of antiviral therapy are to promote more rapid healing of skin lesions, to lessen the severity and duration of pain associated with acute neuritis, and to reduce the incidence or severity of chronic pain, referred to as postherpetic neuralgia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiviral drugs with activity against VZV include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      , all of which are well tolerated. Antiviral therapy leads to faster resolution of cutaneous lesions and acute neuritis compared with no therapeutic intervention. However, it is unclear if treatment of acute herpes zoster decreases the risk or the duration of post-herpetic neuralgia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical trial data on antiviral therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3689042\">",
"       'Available agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend antiviral therapy for all patients &gt;50 years of age with uncomplicated herpes zoster who present within 72 hours of clinical symptoms (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We prefer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (1000 mg three times daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      (500 mg three times daily) because of their lower dosing frequency, compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      . All regimens should be given for seven days. (See",
"      <a class=\"local\" href=\"#H344555\">",
"       'Patents over 50 years of age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefit of antiviral therapy in younger patients (&lt;50 years of age) is less clear since most of the study participants in clinical trials of zoster therapy were older and the risk of prolonged pain is lower in this age group. However, the risk of adverse events secondary to antiviral therapy is low and early treatment can decrease symptoms of acute neuritis and hasten resolution of cutaneous lesions. We recommend antiviral therapy for patients &lt;50 years of age with herpes zoster who present within 72 hours of clinical symptoms (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H344606\">",
"       'Patients under 50 years of age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Analgesic drugs are often needed to control mild to severe pain associated with acute neuritis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Analgesia for acute neuritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no clear role for the use of glucocorticoids or tricyclic antidepressants since clinical benefit has not been demonstrated and there are significant risks associated with these medications. (See",
"      <a class=\"local\" href=\"#H344547\">",
"       'Management of uncomplicated herpes zoster'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no clinical trials examining the role of antiviral therapy in the pregnant woman with herpes zoster infection. However, experience with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      therapy in both HSV infection and varicella pneumonia suggests that this drug is safe in pregnancy. We suggest treatment of herpes zoster in pregnant women with significant cutaneous disease (eg, &gt;50 lesions) or with acute neuritis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1867100\">",
"       'Herpes zoster during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/1\">",
"      Lopez AS, Burnett-Hartman A, Nambiar R, et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. J Infect Dis 2008; 197:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/2\">",
"      Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995; 45:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/3\">",
"      Wood M. Understanding pain in herpes zoster: an essential for optimizing treatment. J Infect Dis 2002; 186 Suppl 1:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/4\">",
"      Schott GD. Triggering of delayed-onset postherpetic neuralgia. Lancet 1998; 351:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/5\">",
"      Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996; 67:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/6\">",
"      Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/7\">",
"      Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/8\">",
"      Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/9\">",
"      Whitley RJ, Weiss HL, Soong SJ, Gnann JW. Herpes zoster: risk categories for persistent pain. J Infect Dis 1999; 179:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/10\">",
"      Dworkin RH, Boon RJ, Griffin DR, Phung D. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998; 178 Suppl 1:S76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/11\">",
"      Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/12\">",
"      Nagasako EM, Johnson RW, Griffin DR, Dworkin RH. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. J Am Acad Dermatol 2002; 46:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/13\">",
"      Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/14\">",
"      Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995; 123:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/15\">",
"      Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/16\">",
"      Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/17\">",
"      Biron KK, Elion GB. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother 1980; 18:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/18\">",
"      Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997; 157:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/19\">",
"      Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996; 125:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/20\">",
"      Gnann JW Jr. New antivirals with activity against varicella-zoster virus. Ann Neurol 1994; 35 Suppl:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/21\">",
"      Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis Suppl 1991; 80:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/22\">",
"      Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009; :CD006866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/23\">",
"      Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004; 29:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/24\">",
"      Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/25\">",
"      Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999; 130:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/26\">",
"      Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant 2007; 7:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/27\">",
"      Dworkin RH, Barbano RL, Tyring SK, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain 2009; 142:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/28\">",
"      Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/29\">",
"      Esmann V, Geil JP, Kroon S, et al. Prednisolone does not prevent post-herpetic neuralgia. Lancet 1987; 2:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/30\">",
"      Benoldi D, Mirizzi S, Zucchi A, Allegra F. Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy. Int J Dermatol 1991; 30:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/31\">",
"      He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2008; :CD005582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/32\">",
"      Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997; 13:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/33\">",
"      Quinlivan ML, Ayres K, Ran H, et al. Effect of viral load on the outcome of herpes zoster. J Clin Microbiol 2007; 45:3909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/34\">",
"      HOPE-SIMPSON RE. THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. Proc R Soc Med 1965; 58:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/35\">",
"      Pavan-Langston D. Herpes zoster ophthalmicus. Neurology 1995; 45:S50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/36\">",
"      Liesegang TJ. Diagnosis and therapy of herpes zoster ophthalmicus. Ophthalmology 1991; 98:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/37\">",
"      Severson EA, Baratz KH, Hodge DO, Burke JP. Herpes zoster ophthalmicus in olmsted county, Minnesota: have systemic antivirals made a difference? Arch Ophthalmol 2003; 121:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33096/abstract/38\">",
"      Herbort CP, Buechi ER, Piguet B, et al. High-dose oral acyclovir in acute herpes zoster ophthalmicus: the end of the corticosteroid era. Curr Eye Res 1991; 10 Suppl:171.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Red Book Online News. Shortage of intravenous acyclovir. file://aapredbook.aappublications.org/site/news#76 (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Current Drug Shortages. file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm (Accessed on January 13, 2012).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/vaccines/recs/schedules/downloads/adult/mmwr-adult-schedule.pdf.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8293 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-201.211.0.116-CB2859D92B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33096=[""].join("\n");
var outline_f32_20_33096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H344084\">",
"      CLINICAL SEQUELAE OF HERPES ZOSTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3689042\">",
"      AVAILABLE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL TRIAL DATA ON ANTIVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acyclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Famciclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12486538\">",
"      Valacyclovir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H344547\">",
"      MANAGEMENT OF UNCOMPLICATED HERPES ZOSTER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H345666\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344959\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H344555\">",
"      - Patents over 50 years of age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H344606\">",
"      - Patients under 50 years of age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H344906\">",
"      - Timing of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Analgesia for acute neuritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H472008\">",
"      Use of tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1866880\">",
"      Viral load monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3374706\">",
"      Pain control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1867100\">",
"      HERPES ZOSTER DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1027019\">",
"      RECURRENT ZOSTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT OF COMPLICATED HERPES ZOSTER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Herpes zoster ophthalmicus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3374933\">",
"      Secondary bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3689599\">",
"      Post-herpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15364136\">",
"      HERPES ZOSTER VACCINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40296?source=related_link\">",
"      Evaluation of chronic pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6308?source=related_link\">",
"      Famciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/12/13507?source=related_link\">",
"      Patient information: Shingles (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/0/14338?source=related_link\">",
"      Patient information: Shingles (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/6/21608?source=related_link\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32200?source=related_link\">",
"      Prevention and control of varicella in hospitals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21288?source=related_link\">",
"      Stroke caused by varicella zoster virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30003?source=related_link\">",
"      Valacyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=related_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_20_33097="Pathogenesis of granulomatosis with polyangiitis (Wegener’s) and related vasculitides";
var content_f32_20_33097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33097/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33097/contributors\">",
"     Stuart M Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33097/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33097/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33097/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33097/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33097/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33097/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/20/33097/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13264519\">",
"    <span class=\"h1\">",
"     NEW TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In January 2011, the Boards of Directors of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism recommended that the name Wegener&rsquo;s granulomatosis be changed to granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This change reflects a plan to gradually shift from honorific eponyms to a disease-descriptive or etiology-based nomenclature. The parenthetic reference to Wegener&rsquo;s will be phased out after several years as the new name becomes more widely known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener&rsquo;s), which can be abbreviated as GPA, is a complex, immune-mediated disorder in which tissue injury results from the interplay of an initiating inflammatory event and a highly specific immune response. Part of this response is directed against previously shielded epitopes of neutrophil granule proteins, leading to high titer autoantibodies known as anti-neutrophil cytoplasmic antibodies (ANCA). The production of ANCA is one of the hallmarks of GPA and related forms of vasculitis. ANCA are directed against antigens present within the primary granules of neutrophils and monocytes; these antibodies produce tissue damage via interactions with primed neutrophils and endothelial cells.",
"   </p>",
"   <p>",
"    ANCA are highly specific for a group of disorders associated with vascular inflammation known as the ANCA-associated vasculitides: GPA, microscopic polyangiitis (MPA), and the Churg-Strauss syndrome. However, the term \"ANCA-associated vasculitis\" may be misleading, since not all patients with clinical (and even histopathologically-proven) diagnoses of GPA, MPA, or the Churg-Strauss syndrome have ANCA.",
"   </p>",
"   <p>",
"    Approximately 85 percent of patients with GPA have ANCA, although the percentage varies according to disease phenotype (patients with limited GPA are less likely to be ANCA positive). Among patients with MPA or Churg-Strauss syndrome, the percentages of patients who are ANCA positive are on the order of 70 percent and 50 percent, respectively.",
"   </p>",
"   <p>",
"    The most commonly identified and evaluated antigens in GPA are the following two proteins:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proteinase 3 (PR3), which is observed in 70 to 80 percent of patients",
"     </li>",
"     <li>",
"      Myeloperoxidase (MPO), which is the target in approximately 10 percent of patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ANCA directed against these antigens are known as PR3-ANCA and MPO-ANCA, respectively. More limited data suggest that antibodies directed against another ANCA subtype, lysosome associated membrane protein-2 (LAMP-2), are pathogenetically important and, via molecular mimicry, may provide a link between ANCA-associated disease and infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Anti-LAMP-2 antibodies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    ANCA that target other antigens (eg, lactoferrin, cathepsin G, elastase, and bactericidal permeability inhibiting protein) are frequently observed in immune-mediated disorders not typically associated with vasculitis (eg, ulcerative colitis). These other ANCA are of uncertain clinical and pathological significance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upon immunofluorescence testing of serum using ethanol-fixed neutrophils as the substrate, sera containing PR3-ANCA cause a cytoplasmic pattern of neutrophil staining (a \"C-ANCA\" pattern). In contrast, sera containing MPO-ANCA lead to a perinuclear (\"P-ANCA\") pattern of staining. For unclear reasons, sera from patients with ANCA-associated vasculitis usually contain either PR3-ANCA or MPO-ANCA, although occasionally both may be present.",
"   </p>",
"   <p>",
"    The mechanisms by which ANCA arise, and the role of these autoantibodies in causing disease remains unclear. One possibility is that these antibodies are epiphenomena (eg, the by-product of more primary pathological processes). However, in the majority of GPA cases and particularly in patients with generalized disease, ANCA appear, at minimum, to be involved directly in the widespread tissue damage that is the hallmark of this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of GPA and related vasculitides and the evidence supporting a pathogenetic role for ANCA will be reviewed here. The clinical spectrum of ANCA, the clinical manifestations, diagnosis, and initial and maintenance therapy of GPA and MPA, and issues related to Churg-Strauss syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND POSSIBLE INITIATING EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The events leading to the initiation of granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, are obscure. Infectious, genetic, and environmental risk factors (and combinations of all three) have been entertained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the symptoms of GPA at disease onset overlap substantially with those due to infectious processes, research efforts have focused upon the identification of pathogens that may precipitate GPA in individuals of the proper genetic background. Limited data demonstrating a higher rate of nasal carriage among patients with GPA have implicated Staphylococcus aureus as a possible inciting factor for relapse of GPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], an effect that may involve the staphylococcal toxic shock syndrome toxin-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anti-LAMP-2 antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subtype of ANCA antibodies are directed against lysosome associated membrane protein 2 (LAMP-2) and are present in over 90 percent of patients with ANCA-positive pauci-immune necrotizing glomerulonephritis, at least according to one as yet unconfirmed report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/4\">",
"     4",
"    </a>",
"    ]. These antibodies frequently coexist with anti-PR3 and anti-MPO antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-LAMP-2 antibodies activate neutrophils, injure vascular endothelial cells without the need for neutrophils, and recognize a human LAMP-2 epitope with 100 percent homology to the bacterial adhesin FimH, with which they crossreact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence of pathogenicity comes from the observation that rats immunized with FimH develop a pauci-immune necrotizing glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, infection with bacteria that express FimH (most often Escherichia coli) occurred in 9 of 13 patients (69 percent) in the 12 weeks before the clinical presentation of ANCA-positive focal necrotizing glomerulonephritis, suggesting the presence of molecular mimicry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1551282\">",
"    <span class=\"h2\">",
"     Anti-Plasminogen antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-plasminogen antibodies have been identified in 25 percent of patients with ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].The presence of anti-plasminogen antibodies correlates with both venous thromboembolic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/15\">",
"     15",
"    </a>",
"    ] and with characteristic glomerular histologic lesions and reduced renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to define genetic risk factors have met with limited success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. The MHC class II allele HLA-DRB1-15 markedly increases the risk of PR3-associated ANCA vasculitis among African-Americans and also contributes to disease risk among Caucasians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/21\">",
"     21",
"    </a>",
"    ]. A single nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22), has been associated with both ANCA disease and rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=see_link&amp;anchor=H8#H8\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\", section on 'RA susceptibility genes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of drugs (rifampicin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    , aminoguanidine, as examples) have been reported to cause ANCA seroconversion, particularly thiol and hydrazine containing compounds. Whether these drugs actually cause a vasculitis is not always clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/22\">",
"     22",
"    </a>",
"    ], but in some situations a causal relationship is very clear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Drug-induced ANCA-associated vasculitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Alpha-1 antitrypsin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because alpha-1 antitrypsin (AAT) is the primary in vivo inhibitor of PR3, the observation that patients with AAT deficiency are at increased risk for GPA suggests a potential pathogenic role in this disease for deficient PR3 clearance from sites of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Decreased local concentrations of AAT caused by genetic polymorphisms or alterations in the enzyme's functionality induced by inflammation may therefore lead to",
"    <span class=\"nowrap\">",
"     protease/anti-protease",
"    </span>",
"    imbalance in the disease microenvironment. Although unproven, these events may be responsible for generating immunogenic forms of PR3 in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the frequency with which the first symptoms of GPA occur in the respiratory tract, exposure to noninfectious agents or toxins via the inhalational route is another possible inciting event. One such candidate is silica dust. The odds ratio of exposure to silica dust has been reported to be 4.4 times higher for patients with ANCA-associated vasculitis than in a comparison group of patients with renal disease caused by lupus or other conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/26\">",
"     26",
"    </a>",
"    ]. Another case-control study reported a similarly increased risk of ANCA-associated vasculitis associated with exposure to silica [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mercury and lead exposure have also been proposed as potential etiologic agents in the development of GPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, exact relationships between such environmental exposures and vasculitis are complicated by difficulties in obtaining reliable measurements of exposures, the likelihood of recall bias among patients who are diagnosed with ANCA-associated vasculitis, and the choice of appropriate control groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ANCA PRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The autoantibody response that produces ANCA is probably generated against newly exposed epitopes (ie, cryptic sites) of the target autoantigen. Following the production of ANCA, the antibody response may generalize to the rest of the molecule or to other components of a macromolecular protein complex via the process of epitope spreading. With ANCA-associated vasculitis, these neoepitopes may arise at the sites of initial tissue injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Autoantigen complementarity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies are also generated against complementary peptides that are translated from the antisense RNA that encodes PR3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/15,30,31\">",
"     15,30,31",
"    </a>",
"    ]. This has lead to the hypothesis that the antigen that initiates the cascade of immunologic events in granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, and related vasculitides is NOT the autoantigen or mimic, but the complementary protein of the autoantigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Antibodies to these complementary proteins elicit anti-idiotypic antibodies that may react with the autoantigen or to other unrelated antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/15,32\">",
"     15,32",
"    </a>",
"    ]. As an example of the latter, antibodies generated to peptides complementary to PR3 also react with plasminogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H1551282\">",
"     'Anti-Plasminogen antibodies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ROLE OF T CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since it is an antigen-driven process, the disease may heavily depend upon help from T cells. This hypothesis is supported by the finding that mononuclear cells have a significant role in ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/33-40\">",
"     33-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with active granulomatosis with polyangiitis (Wegener&rsquo;s), which can be abbreviated as GPA, have much higher levels of CD4+ T cell and monocytic activation than do patients in remission or healthy controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/33-35\">",
"       33-35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Very high levels of the Th1 cytokines TNF-alpha and interferon (IFN)-gamma are also observed in patients with active GPA. Monocytes from these patients release large quantities of interleukin (IL)-12, a major inducer of Th1 cytokines.",
"     </li>",
"     <li>",
"      Population-based studies of GPA patients reveal a diminished frequency of a major inhibitory CTLA-4 allele [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/40\">",
"       40",
"      </a>",
"      ]. This may contribute to increased T cell activation in these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that IL-10, a known antagonist of monocyte activation, may inhibit the Th1 pathway in this disease by impairing the production of IL-12. In one study, for example, IL-10 treatment of peripheral blood mononuclear cells from active GPA patients impaired the production of IFN-gamma in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another finding that supports a likely role for cellular immunity in disease pathophysiology is the report of a study of five patients with very low cell surface expression of HLA class I molecules (caused by impaired expression of the transporter associated with antigen presentation genes) and with clinical and pathologic findings that resembled GPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/37\">",
"     37",
"    </a>",
"    ]. Close examination of the granulomatous lesions revealed a large percentage of activated natural killer cells, a subpopulation of non-MHC restricted mononuclear cells. Similar findings suggesting a prominent role for the Th1 lymphocyte pathway and mononuclear cells have been observed in patients with giant cell arteritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NEUTROPHIL ACTIVATION AND ANCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant role for mononuclear cells in granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, does not exclude an important role for ANCA. Since Th1 cytokines are effective stimuli of both neutrophils and monocytes, the production of ANCA may further enhance tissue injury by augmenting the damage caused by mononuclear cells.",
"   </p>",
"   <p>",
"    The effects of ANCA are determined by the state of neutrophil activation. PR3 and MPO, located in the cytosol, may be relatively inaccessible to antibody binding. However, neutrophils \"primed\" with tumor necrosis factor (TNF) as well as those undergoing apoptosis have enhanced expression of membrane-associated PR3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/7,38\">",
"     7,38",
"    </a>",
"    ]. In some individuals, a higher proportion of nonactivated neutrophils may express membrane-associated PR3, which may be a risk factor for vasculitis, or for more severe manifestations of vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/41\">",
"     41",
"    </a>",
"    ]. Genes that encode both PR3 and MPO have been shown to be abnormally upregulated in the peripheral neutrophils of patients with ANCA-associated glomerulonephritis, possibly due to silencing defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once neutrophils have been activated by priming, ANCA are able to bind relevant membrane-bound antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/39,44\">",
"     39,44",
"    </a>",
"    ], causing abnormal constitutive activation via either the crosslinking of MPO or PR3 or the binding of Fc receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. ANCA binding to neutrophils can enhance neutrophil-endothelial cell interactions and subsequent microvascular injury, explaining a possible pathogenetic role for ANCA in systemic vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/7,49\">",
"     7,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate at which primed neutrophils degranulate and release chemoattractants and cytotoxic oxygen free-radical species into the local tissue environment is also increased by ANCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/50-57\">",
"     50-57",
"    </a>",
"    ]. In addition, primed neutrophils can adhere to and damage vascular endothelial cells and attract additional neutrophils to the site of damage, thereby creating an auto-amplifying loop specific to the microenvironment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/38,55,56\">",
"     38,55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with ANCA-associated vasculitis have increased numbers of primed neutrophils in renal biopsy specimens as well as increased expression of neutrophil-specific genes, paralleling the activity of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/50,58\">",
"     50,58",
"    </a>",
"    ]. In addition, persistent membrane expression of PR3 during periods of disease remission is associated with an increased risk of relapse in GPA patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/56\">",
"     56",
"    </a>",
"    ]. Enhanced generation of reactive oxygen species by circulating neutrophils in these patients compared to controls may also occur.",
"   </p>",
"   <p>",
"    GPA patients in remission frequently experience disease flares following systemic bacterial or viral infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/7,59\">",
"     7,59",
"    </a>",
"    ]. One potential explanation for this observation is that an infection or other inflammatory process can lead to suprathreshold neutrophil (and perhaps monocyte) priming in those with circulating ANCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/60\">",
"     60",
"    </a>",
"    ]. This process then sets off the amplifying cascade described above, which ultimately leads to vascular injury. The release of MPO, PR3, elastase and other proteases from the activated neutrophils can also contribute directly to the local inflammatory process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevention of antecedent infections may explain the purported ability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    to maintain disease remissions in selected patients, particularly those with disease limited to the upper airways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32727?source=see_link\">",
"     \"Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ANCA associated activation may induce neutrophil actin polymerization, resulting in increased neutrophil rigidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/62\">",
"     62",
"    </a>",
"    ]. Such activated neutrophils may become sequestered in small sized vessels since they are unable to adapt morphologically to arterioles; this may help explain the predilection for small blood vessels in ANCA-associated disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     NET formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a killing strategy against invading pathogens, neutrophils release webs of decondensed chromatin called neutrophil extracellular traps (NETs) into the extracellular space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/63\">",
"     63",
"    </a>",
"    ]. NETs may also contribute to the pathogenesis of ANCA-associated vasculitides. NETs containing PR3 and MPO autoantigens are released by ANCA-stimulated neutrophils and have been demonstrated in the kidneys of patients with ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     THE ROLE OF THE ENDOTHELIAL CELL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early stages of ANCA-associated vasculitis, endothelial cells may recruit inflammatory cells and enhance their adhesion to sites of vascular injury. The subsequent release of PR3 and other neutrophil proteases may induce endothelial synthesis and secretion of interleukin-8, a potent neutrophil chemoattractant, thereby attracting additional neutrophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PR3 released by neutrophils may also enhance the adhesion of accumulating neutrophils and mononuclear cells to the endothelial surface via the induction of adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The potential significance of adhesion via VCAM-1 is supported by the observation of enhanced in situ expression of this molecule in the affected glomerular tufts of patients with ANCA-associated vasculitis, particularly PR3-ANCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether endothelial cells produce PR3 and display this molecule upon activation is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/70-75\">",
"     70-75",
"    </a>",
"    ]. The contradictory results may be due in part to differences in experimental techniques.",
"   </p>",
"   <p>",
"    The soluble endothelial protein C receptor binds activated neutrophils via interactions with PR3. This provides a link between neutrophil priming, vascular inflammation, and the coagulation cascade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/76\">",
"     76",
"    </a>",
"    ], and may explain in part the increased risk of venous thrombotic events in granulomatosis with polyangiitis (Wegener's), abbreviated as GPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also evidence for organ-specific antiendothelial antibodies (AECAs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/75\">",
"     75",
"    </a>",
"    ]. The exact antigens and their role in disease development are unclear, but one possible target is the 60 kilodalton heat-shock protein, which plays a role in protein assembly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     THE PARTICIPATION OF B CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;B cells may also play an important role in ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/79\">",
"     79",
"    </a>",
"    ]. In the early 1980s, studies with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    indicated that, among lymphocytes, its greater effect may be upon B cells rather than T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/80\">",
"     80",
"    </a>",
"    ]. Subsequently, it was shown that the number of activated B cells in circulation (but not the number of activated T cells) correlates with disease activity scores in ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/81\">",
"     81",
"    </a>",
"    ]. A compassionate use study of B cell depletion therapy in ANCA-associated vasculitis showed encouraging results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/82\">",
"     82",
"    </a>",
"    ]. The ability to deplete B cells precisely with anti-CD20 therapies may offer new insights into the pathophysiology of ANCA-associated vasculitis.",
"   </p>",
"   <p>",
"    The rationale for why B cell depletion may be effective in ANCA-associated vasculitis is not clear, but possibilities include the complete removal or substantial reduction of ANCA production; diminution of the contribution of B cells to antigen presentation and cytokine production; and the inhibition of B",
"    <span class=\"nowrap\">",
"     cell/T",
"    </span>",
"    cell cross-talk.",
"   </p>",
"   <p>",
"    Ten patients with refractory granulomatosis with polyangiitis (Wegener's), which can be abbreviated as GPA, were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus high-dose glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/83\">",
"     83",
"    </a>",
"    ]. All patients in the trial achieved disease remission on this treatment regimen. PR3-ANCA levels declined in all patients following this treatment and became negative in six patients. Two patients remained ANCA negative even after their peripheral B cell numbers had returned to normal.",
"   </p>",
"   <p>",
"    Data from this trial are consistent with a number of other case reports and small case series of patients with ANCA-associated vasculitis treated with B cell depletion. Thus, ANCA titers appear to decline in most patients treated with B cell depletion strategies, but ANCA tests do not become negative in all patients. Understanding of the full impact of B cell depletion on the disease process in ANCA-associated vasculitis awaits the completion of ongoing randomized clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     LOCATION OF ANCA ANTIGENS IN RENAL TISSUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergence of ANCA-associated antigens in the renal tissue of patients with glomerulonephritis may contribute to the underlying disease process. PR3, MPO, and elastase have been observed within the glomeruli, crescents, and tubular epithelial cells in renal disorders associated with neutrophilic infiltrates, but not in normal kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/50,84\">",
"     50,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to enhancing the antineutrophil activity of ANCA, the proinflammatory activity of TNF and other cytokines (such as interleukin-6) may also contribute directly to renal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/59,77\">",
"     59,77",
"    </a>",
"    ]. Local TNF production by infiltrating mononuclear cells and intrinsic renal cells has been demonstrated in active renal vasculitic lesions in ANCA-positive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/77\">",
"     77",
"    </a>",
"    ]. The mechanism by which these cells become activated to release TNF is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ANCA ISOTYPES AND THE ROLE OF FC RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In theory, the isotype of ANCA in a given individual may have pathophysiological importance. Most patients with ANCA-associated vasculitis, for example, produce isotype-switched IgG ANCA, implying a secondary immune response driven by T-cells. However, studies regarding the relative importance of IgG subtypes and other types of ANCA (eg, IgM, IgA) have been inconclusive and contradictory. At present, there is no unequivocal evidence that particular ANCA isotypes influence the susceptibility to or clinical expression of ANCA-associated vasculitis.",
"   </p>",
"   <p>",
"    The magnitude of enhanced neutrophil activation by ANCA may also be influenced by antibody specificity for different PR3 epitopes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/28,85\">",
"     28,85",
"    </a>",
"    ], IgG subclass, and the type of Fcgamma-R engaged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/40,46,48,86,87\">",
"     40,46,48,86,87",
"    </a>",
"    ]. The Fcgamma-RIIIB allele polymorphism NA1, which allows more efficient neutrophil activation by ANCA, is overrepresented in patients with severe forms of granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANIMAL MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two murine models of ANCA-associated vasculitis reveal that adoptive transfer of autoantibody alone is sufficient to induce a necrotizing vasculitis that closely resembles human disease. Development of these models involved two types of genetically altered mice: the MPO knockout mouse, and the recombinase-activating gene 2 (RAG-2) deficient mouse. The latter species lacks both T- and B-cells.",
"   </p>",
"   <p>",
"    These models provide in vivo evidence for the pathogenic potential of ANCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/90\">",
"     90",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first model, MPO knockout mice were initially immunized with mouse MPO, resulting in the formation of anti-MPO splenocytes and anti-MPO antibodies within immunized mice. RAG-2 deficient mice were subsequently injected with either anti-MPO splenocytes or control splenocytes which did not produce anti-MPO antibodies. RAG-2 mice that received anti-MPO splenocytes developed clinical features of ANCA-associated vasculitides, including crescentic glomerulonephritis and systemic necrotizing vasculitis. By comparison, RAG-2 mice that received non-MPO antibody producing splenocytes displayed only a relatively mild immune complex glomerulonephritis.",
"     </li>",
"     <li>",
"      In the second disease model, RAG-2 deficient and wild-type mice were injected with anti-MPO or control immunoglobulins. Only mice receiving anti-MPO antibodies developed a pauci-immune glomerulonephritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another model described above, rats immunized with FimH, which has 100 percent homology to a human LAMP-2 epitope, develop a pauci-immune necrotizing glomerulonephritis. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Anti-LAMP-2 antibodies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     HUMAN MODEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first direct evidence in humans that ANCA is pathogenic was provided by a newborn in which the placental transmission of maternal anti-MPO antibodies resulted in the pulmonary-renal syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33097/abstract/91\">",
"     91",
"    </a>",
"    ]. After treatment with glucocorticoids and supportive therapy, the syndrome completely resolved over time in conjunction with the eventual disappearance of maternal ANCA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2358526\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Granulomatosis with polyangiitis (Wegener&rsquo;s), which can be abbreviated as GPA, is a complex, immune-mediated disorder in which tissue injury results from the interplay of an initiating inflammatory event and a highly specific immune response. Part of this response is directed against previously shielded epitopes of neutrophil granule proteins, leading to autoantibodies known as anti-neutrophil cytoplasmic antibodies (ANCA). Approximately 85 percent of patients with GPA have ANCA. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most commonly identified and evaluated antigens in GPA are proteinase 3 (PR3), observed in 70 to 80 percent of patients and myeloperoxidase (MPO), observed in 10 percent of patients. Other antibodies, such as those directed against lysosome associated membrane protein-2 (LAMP-2), may also be pathogenetically important. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Anti-LAMP-2 antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The events that may lead to the initiation of GPA include infection genetic factors and environmental factors, including drugs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors and possible initiating events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The autoantibody response that produces ANCA is probably generated against newly exposed epitopes (ie, cryptic sites) of the target autoantigen. Antibodies are also generated against complementary peptides that are translated from the antisense RNA that encodes PR3. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mechanisms of anca production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since it is an antigen-driven process, GPA pathogenesis may also be T-cell dependent. The activation of neutrophils, endothelial cells and B cells may also play roles. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Role of T cells'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Neutrophil activation and anca'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'The role of the endothelial cell'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'The participation of b cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Murine models of ANCA-associated vasculitis provide in vivo evidence for the pathogenic potential of ANCA. Evidence of the pathogenicity of ANCA was also provided by a case report of a newborn in which the placental transmission of maternal anti-MPO antibodies resulted in the pulmonary-renal syndrome. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Animal models'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Human model'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/1\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/2\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis 2011; 70:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/3\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol 2011; 22:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/4\">",
"      Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/5\">",
"      Kain R, Matsui K, Exner M, et al. A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995; 181:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/6\">",
"      Kallenberg CG, Brouwer E, Weening JJ, Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/7\">",
"      Jennette JC. Pathogenic potential of anti-neutrophil cytoplasmic autoantibodies. Lab Invest 1994; 70:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/8\">",
"      Muller Kobold AC, van der Geld YM, Limburg PC, et al. Pathophysiology of ANCA-associated glomerulonephritis. Nephrol Dial Transplant 1999; 14:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/9\">",
"      Savage CO, Harper L, Holland M. New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2002; 14:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/10\">",
"      de Lind van Wijngaarden RA, van Rijn L, Hagen EC, et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol 2008; 3:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/11\">",
"      Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/12\">",
"      Popa ER, Tervaert JW. The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions. Intern Med 2003; 42:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/13\">",
"      Popa ER, Stegeman CA, Abdulahad WH, et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/14\">",
"      Salama AD, Pusey CD. Shining a LAMP on pauci-immune focal segmental glomerulonephritis. Kidney Int 2009; 76:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/15\">",
"      Bautz DJ, Preston GA, Lionaki S, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol 2008; 19:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/16\">",
"      Berden AE, Nolan SL, Morris HL, et al. Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis. J Am Soc Nephrol 2010; 21:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/17\">",
"      Huang D, Giscombe R, Zhou Y, Lefvert AK. Polymorphisms in CTLA-4 but not tumor necrosis factor-alpha or interleukin 1beta genes are associated with Wegener's granulomatosis. J Rheumatol 2000; 27:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/18\">",
"      Zhang L, Jayne DR, Zhao MH, et al. Distribution of MHC class II alleles in primary systemic vasculitis. Kidney Int 1995; 47:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/19\">",
"      Cotch MF, Fauci AS, Hoffman GS. HLA typing in patients with Wegener granulomatosis. Ann Intern Med 1995; 122:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/20\">",
"      Jagiello P, Aries P, Arning L, et al. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 2005; 52:4039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/21\">",
"      Cao Y, Schmitz JL, Yang J, et al. DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol 2011; 22:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/22\">",
"      Choi HK, Slot MC, Pan G, et al. Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis Rheum 2000; 43:2488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/23\">",
"      Audrain MA, Sesbo&uuml;&eacute; R, Baranger TA, et al. Analysis of anti-neutrophil cytoplasmic antibodies (ANCA): frequency and specificity in a sample of 191 homozygous (PiZZ) alpha1-antitrypsin-deficient subjects. Nephrol Dial Transplant 2001; 16:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/24\">",
"      Elzouki AN, Segelmark M, Wieslander J, Eriksson S. Strong link between the alpha 1-antitrypsin PiZ allele and Wegener's granulomatosis. J Intern Med 1994; 236:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/25\">",
"      Mahr AD, Edberg JC, Stone JH, et al. Alpha���-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis Rheum 2010; 62:3760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/26\">",
"      Hogan SL, Satterly KK, Dooley MA, et al. Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J Am Soc Nephrol 2001; 12:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/27\">",
"      Beaudreuil S, Lasfargues G, Lau&eacute;riere L, et al. Occupational exposure in ANCA-positive patients: a case-control study. Kidney Int 2005; 67:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/28\">",
"      Albert D, Clarkin C, Komoroski J, et al. Wegener's granulomatosis: Possible role of environmental agents in its pathogenesis. Arthritis Rheum 2004; 51:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/29\">",
"      Johnson RJ. The mystery of the antineutrophil cytoplasmic antibodies. Am J Kidney Dis 1995; 26:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/30\">",
"      Pendergraft WF 3rd, Preston GA, Shah RR, et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/31\">",
"      Yang J, Bautz DJ, Lionaki S, et al. ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int 2008; 74:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/32\">",
"      Pendergraft WF 3rd, Pressler BM, Jennette JC, et al. Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease. J Mol Med (Berl) 2005; 83:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/33\">",
"      L&uacute;dv&iacute;ksson BR, Sneller MC, Chua KS, et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998; 160:3602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/34\">",
"      Muller Kobold AC, Kallenberg CG, Tervaert JW. Monocyte activation in patients with Wegener's granulomatosis. Ann Rheum Dis 1999; 58:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/35\">",
"      Marinaki S, K&auml;lsch AI, Grimminger P, et al. Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis. Nephrol Dial Transplant 2006; 21:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/36\">",
"      Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CG. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int 2006; 70:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/37\">",
"      Moins-Teisserenc HT, Gadola SD, Cella M, et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet 1999; 354:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/38\">",
"      Masutani K, Tokumoto M, Nakashima H, et al. Strong polarization toward Th1 immune response in ANCA-associated glomerulonephritis. Clin Nephrol 2003; 59:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/39\">",
"      Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992; 41:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/40\">",
"      Zhou Y, Huang D, Paris PL, et al. An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. Arthritis Rheum 2004; 50:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/41\">",
"      Schreiber A, Otto B, Ju X, et al. Membrane proteinase 3 expression in patients with Wegener's granulomatosis and in human hematopoietic stem cell-derived neutrophils. J Am Soc Nephrol 2005; 16:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/42\">",
"      Yang JJ, Pendergraft WF, Alcorta DA, et al. Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J Am Soc Nephrol 2004; 15:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/43\">",
"      Ciavatta DJ, Yang J, Preston GA, et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest 2010; 120:3209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/44\">",
"      Van Rossum AP, van der Geld YM, Limburg PC, Kallenberg CG. Human anti-neutrophil cytoplasm autoantibodies to proteinase 3 (PR3-ANCA) bind to neutrophils. Kidney Int 2005; 68:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/45\">",
"      Kettritz R, Jennette JC, Falk RJ. Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol 1997; 8:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/46\">",
"      Mulder AH, Heeringa P, Brouwer E, et al. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol 1994; 98:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/47\">",
"      Porges AJ, Redecha PB, Kimberly WT, et al. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol 1994; 153:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/48\">",
"      Hewins P, Williams JM, Wakelam MJ, Savage CO. Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18. J Am Soc Nephrol 2004; 15:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/49\">",
"      Little MA, Smyth CL, Yadav R, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005; 106:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/50\">",
"      Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990; 87:4115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/51\">",
"      Brouwer E, Huitema MG, Mulder AH, et al. Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int 1994; 45:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/52\">",
"      Cockwell P, Brooks CJ, Adu D, Savage CO. Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int 1999; 55:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/53\">",
"      Kettritz R, Choi M, Butt W, et al. Phosphatidylinositol 3-kinase controls antineutrophil cytoplasmic antibodies-induced respiratory burst in human neutrophils. J Am Soc Nephrol 2002; 13:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/54\">",
"      Schreiber A, Luft FC, Kettritz R. Membrane proteinase 3 expression and ANCA-induced neutrophil activation. Kidney Int 2004; 65:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/55\">",
"      Pendergraft WF 3rd, Rudolph EH, Falk RJ, et al. Proteinase 3 sidesteps caspases and cleaves p21(Waf1/Cip1/Sdi1) to induce endothelial cell apoptosis. Kidney Int 2004; 65:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/56\">",
"      Rarok AA, Stegeman CA, Limburg PC, Kallenberg CG. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/57\">",
"      Williams JM, Savage CO. Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies. J Am Soc Nephrol 2005; 16:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/58\">",
"      Alcorta DA, Barnes DA, Dooley MA, et al. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int 2007; 72:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/59\">",
"      Arimura Y, Minoshima S, Kamiya Y, et al. Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. Clin Nephrol 1993; 40:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/60\">",
"      Nowack R, Schwalbe K, Flores-Su&aacute;rez LF, et al. Upregulation of CD14 and CD18 on monocytes In vitro by antineutrophil cytoplasmic autoantibodies. J Am Soc Nephrol 2000; 11:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/61\">",
"      Stegeman, CA, Cohen Tervaert, JW, de Jong, PE, Kallenberg, CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/62\">",
"      Tse WY, Nash GB, Hewins P, et al. ANCA-induced neutrophil F-actin polymerization: implications for microvascular inflammation. Kidney Int 2005; 67:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/63\">",
"      Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol 2009; 30:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/64\">",
"      Kessenbrock K, Krumbholz M, Sch&ouml;nermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/65\">",
"      Berger SP, Seelen MA, Hiemstra PS, et al. Proteinase 3, the major autoantigen of Wegener's granulomatosis, enhances IL-8 production by endothelial cells in vitro. J Am Soc Nephrol 1996; 7:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/66\">",
"      Mayet WJ, Meyer zum B&uuml;schenfelde KH. Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 1993; 94:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/67\">",
"      Mayet WJ, Schwarting A, Orth T, et al. Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule-1 (VCAM-1). Clin Exp Immunol 1996; 103:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/68\">",
"      Rastaldi MP, Ferrario F, Tunesi S, et al. Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-1 alpha expression in 15 cases of antineutrophil cytoplasmic autoantibody-associated renal vasculitis. Am J Kidney Dis 1996; 27:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/69\">",
"      Arrizabalaga P, Sol&eacute; M, Iglesias C, et al. Renal expression of ICAM-1 and VCAM-1 in ANCA-associated glomerulonephritis--are there differences among serologic subgroups? Clin Nephrol 2006; 65:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/70\">",
"      Mayet WJ, Csernok E, Szymkowiak C, et al. Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood 1993; 82:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/71\">",
"      King WJ, Adu D, Daha MR, et al. Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3. Clin Exp Immunol 1995; 102:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/72\">",
"      De Bandt M, Meyer O, Dacosta L, et al. Anti-proteinase-3 (PR3) antibodies (C-ANCA) recognize various targets on the human umbilical vein endothelial cell (HUVEC) membrane. Clin Exp Immunol 1999; 115:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/73\">",
"      Pendergraft WF, Alcorta DA, Segelmark M, et al. ANCA antigens, proteinase 3 and myeloperoxidase, are not expressed in endothelial cells. Kidney Int 2000; 57:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/74\">",
"      Tervaert JW. Proteinase 3: A cofactor for the binding of antineutrophil cytoplasm antibodies (ANCA) to endothelial cells? Kidney Int 2000; 57:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/75\">",
"      Holm&eacute;n C, Christensson M, Pettersson E, et al. Wegener's granulomatosis is associated with organ-specific antiendothelial cell antibodies. Kidney Int 2004; 66:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/76\">",
"      Kurosawa S, Esmon CT, Stearns-Kurosawa DJ. The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol 2000; 165:4697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/77\">",
"      Noronha IL, Kr&uuml;ger C, Andrassy K, et al. In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993; 43:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/78\">",
"      Jamin C, Dugu&eacute; C, Alard JE, et al. Induction of endothelial cell apoptosis by the binding of anti-endothelial cell antibodies to Hsp60 in vasculitis-associated systemic autoimmune diseases. Arthritis Rheum 2005; 52:4028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/79\">",
"      Pallan L, Savage CO, Harper L. ANCA-associated vasculitis: from bench research to novel treatments. Nat Rev Nephrol 2009; 5:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/80\">",
"      Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/81\">",
"      Popa ER, Stegeman CA, Bos NA, et al. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999; 103:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/82\">",
"      Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/83\">",
"      Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/84\">",
"      Mrowka C, Csernok E, Gross WL, et al. Distribution of the granulocyte serine proteinases proteinase 3 and elastase in human glomerulonephritis. Am J Kidney Dis 1995; 25:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/85\">",
"      Sommarin Y, Rasmussen N, Wieslander J. Characterization of monoclonal antibodies to proteinase-3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies. Exp Nephrol 1995; 3:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/86\">",
"      Mulder AH, Stegeman CA, Kallenberg CG. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA. Clin Exp Immunol 1995; 101:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/87\">",
"      Holland M, Hewins P, Goodall M, et al. Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin Exp Immunol 2004; 138:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/88\">",
"      Tse WY, Abadeh S, Jefferis R, et al. Neutrophil FcgammaRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin Exp Immunol 2000; 119:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/89\">",
"      Kocher M, Edberg JC, Fleit HB, Kimberly RP. Antineutrophil cytoplasmic antibodies preferentially engage Fc gammaRIIIb on human neutrophils. J Immunol 1998; 161:6909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/90\">",
"      Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33097/abstract/91\">",
"      Schlieben DJ, Korbet SM, Kimura RE, et al. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 2005; 45:758.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3074 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33097=[""].join("\n");
var outline_f32_20_33097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2358526\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13264519\">",
"      NEW TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS AND POSSIBLE INITIATING EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anti-LAMP-2 antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1551282\">",
"      Anti-Plasminogen antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Exposures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MECHANISMS OF ANCA PRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Autoantigen complementarity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ROLE OF T CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NEUTROPHIL ACTIVATION AND ANCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NET formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      THE ROLE OF THE ENDOTHELIAL CELL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      THE PARTICIPATION OF B CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      LOCATION OF ANCA ANTIGENS IN RENAL TISSUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ANCA ISOTYPES AND THE ROLE OF FC RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANIMAL MODELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HUMAN MODEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2358526\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32727?source=related_link\">",
"      Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=related_link\">",
"      HLA and other susceptibility genes in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_20_33098="Overview of acquired peripheral neuropathies in children";
var content_f32_20_33098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of acquired peripheral neuropathies in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33098/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33098/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33098/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33098/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33098/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/20/33098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/20/33098/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/20/33098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy is a disorder of the peripheral nerves of any cause. It typically is characterized by symmetric distal sensory loss, dysesthesias such as burning, or weakness. Most peripheral nerve disorders in children are hereditary (",
"    <a class=\"graphic graphic_figure graphicRef81219 \" href=\"mobipreview.htm?0/54/878\">",
"     figure 1",
"    </a>",
"    ). However, many systemic illnesses, drugs, and toxins affect the peripheral nervous system (",
"    <a class=\"graphic graphic_table graphicRef69751 \" href=\"mobipreview.htm?43/47/44798\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An overview of acquired peripheral neuropathies is presented here. Hereditary peripheral neuropathies and specific disorders that affect the peripheral nerves are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most peripheral nerve disorders have a gradual and slowly progressive course. Acute presentation may occur with toxic exposure or inflammatory conditions.",
"   </p>",
"   <p>",
"    Most peripheral neuropathies show bilateral, symmetric, predominantly distal involvement. The injury is related directly to axon length; thus, longer axons are affected first, resulting in symptoms that typically have an earlier presentation and are more prominent in the lower extremities. Most have combined sensory and motor involvement. However, some disorders have only motor or sensory abnormalities.",
"   </p>",
"   <p>",
"    The most common motor symptom is weakness. It may present as clumsiness, difficulty with running or climbing stairs, or impaired fine motor skills such as writing, buttoning clothes, or tying shoes. Sensory symptoms may include numbness, dysesthesias such as burning pain, or ataxia.",
"   </p>",
"   <p>",
"    Autonomic symptoms such as abnormal sweating, cardiac arrhythmias, hypotension, or bowel and bladder dysfunction may accompany peripheral neuropathy. The central nervous system may be involved in some disorders, but this occurs more often with the hereditary neurodegenerative diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characterization of a peripheral nerve disorder involves a careful neurologic examination, evaluation of family members (to detect an inherited condition), and a nerve conduction study (NCS) with electromyography (EMG) that includes a needle examination of select muscles. Nerve conduction studies are performed on accessible nerves in the extremities that are usually mixed motor and sensory. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/31/2554?source=see_link\">",
"     \"Overview of nerve conduction studies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/46/1769?source=see_link\">",
"     \"Overview of electromyography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Predominantly sensory nerves that are commonly tested include the sural, superficial peroneal, and superficial radial nerves. The EMG typically examines the distal muscles of the hands and feet, but more proximal muscles may be tested depending upon the disorder and neurologic abnormalities.",
"   </p>",
"   <p>",
"    Electrodiagnostic studies can determine if the disorder is caused by a nerve (neuropathy) or muscle disorder (myopathy). If it is a neuropathy,",
"    <span class=\"nowrap\">",
"     EMG/NCS",
"    </span>",
"    can help differentiate whether it is axonal or demyelinating in character.",
"   </p>",
"   <p>",
"    Electrodiagnostic features of demyelinating disorders include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Slow nerve conduction velocity",
"     </li>",
"     <li>",
"      Dispersion of evoked compound motor or nerve action potentials",
"     </li>",
"     <li>",
"      Conduction block (decreased amplitude of muscle compound action potentials on proximal compared with distal nerve stimulation)",
"     </li>",
"     <li>",
"      Marked prolongation of distal latencies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, axonal neuropathies are characterized by a reduced amplitude of evoked compound action potentials with relative preservation of the nerve conduction velocity.",
"   </p>",
"   <p>",
"    Determining if the neuropathy affects sensory or motor nerves and is primarily a disorder of demyelination or axonal degeneration can assist in generating a differential diagnosis of the primary disease or toxic exposure. Further testing may be required to establish the cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some systemic disorders present with signs and symptoms of peripheral neuropathy. In many cases, peripheral nerve involvement is asymptomatic and detectable only with thorough neurologic examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrodiagnostic testing. In these cases, demonstration and characterization of a peripheral neuropathy may help establish the cause of an undiagnosed systemic or toxic illness. However, sensory symptoms of pain and dysesthesias are often early complaints, and may trigger a search for systemic cause.",
"   </p>",
"   <p>",
"    The major causes of acquired peripheral neuropathies and their general clinical features are described here. Specific disorders are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathies are associated with a variety of infections. With the exception of Lyme disease, these conditions are rare in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lyme disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease is a multisystem inflammatory disease caused by spirochetes, known collectively as Borrelia burgdorferi, which are spread by the bite of infected Ixodes ticks. Adults with Lyme disease can develop a painful radiculitis manifested by neuropathic symptoms such as numbness, tingling, and burning. This radiculoneuropathy may affect the limbs (upper greater than lower extremity) or trunk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14681?source=see_link&amp;anchor=H10939468#H10939468\">",
"     \"Nervous system Lyme disease\", section on 'Radiculoneuritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to their prevalence in affected adults, meningoradiculitis and peripheral neuropathy occur rarely in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In a series of 97 cases of Lyme disease in children, new neurologic signs occurred in 32 percent; 76 percent were accounted for by facial nerve palsy and aseptic meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/2\">",
"     2",
"    </a>",
"    ]. Chronic peripheral neuropathy, which occurs in adults, has not been reported in children. With appropriate treatment, prognosis for recovery is good. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7225?source=see_link\">",
"     \"Lyme disease: Clinical manifestations in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chagas disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chagas disease (American trypanosomiasis) is caused by infection with the protozoan parasite, Trypanosoma cruzi. It can be asymptomatic, or can result in acute and chronic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/32/19975?source=see_link\">",
"     \"Pathology and pathogenesis of Chagas disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/551?source=see_link\">",
"     \"Chagas disease: Natural history and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical features of acute symptomatic infection are fever, swollen face or eyelids (Roma&ntilde;a's sign), peripheral edema, conjunctivitis, hepatosplenomegaly, and lymphadenopathy. Myocarditis and meningoencephalitis also can develop.",
"   </p>",
"   <p>",
"    In chronic Chagas disease, peripheral nerve involvement can occur, resulting in diminished or absent deep tendon reflexes and sensory impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/3\">",
"     3",
"    </a>",
"    ]. In a study of 511 patients with chronic Chagas disease and with other causes of neurologic impairment excluded, 10 percent had signs and symptoms of mixed peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/4\">",
"     4",
"    </a>",
"    ]. Electrophysiologic features seen in approximately 30 percent included reduced number of functional motor units in the thenar, hypothenar, soleus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extensor digitorum brevis muscles; slow sensory and motor nerve conduction velocities; low sensory action potential amplitude; impairment of neuromuscular transmission; and reduction in single motor unit action potentials with increased polyphasic activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diphtheria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diphtheria is an acute respiratory or cutaneous illness caused by Corynebacterium diphtheriae, a pleomorphic gram-positive bacillus. Toxigenic strains of C. diphtheriae produce respiratory disease that typically consists of pseudomembranous pharyngitis. A generalized motor-sensory demyelinating polyneuropathy caused by the exotoxin produced by C. diphtheriae is a common complication of severe infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=see_link\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11046?source=see_link\">",
"     \"Diagnosis and treatment of diphtheria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical course of diphtheritic polyneuropathy was described in 50 adults in Riga, Latvia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/5\">",
"     5",
"    </a>",
"    ]. Neurologic complications occurred in 15 percent of patients hospitalized with diphtheria, usually in those with severe pharyngeal infection. Neurologic signs typically developed in two phases. Bulbar symptoms occurred first in 49 of 50 patients at a median of 10 (range two to 50) days after onset of pharyngitis. Bulbar function typically improved after approximately 30 days, then deteriorated in 19 of the patients. Limb symptoms affected 45 patients, beginning at 37 (range 12 to 63) days. Achilles tendon reflexes were lost in 78 percent of patients with neuropathy, and 48 percent were unable to walk unaided. Early treatment with antitoxin was associated with a good prognosis, although chronic disability occurred in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24346520\">",
"    <span class=\"h2\">",
"     Leprosy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leprosy (Hansen disease) is a chronic disease caused by Mycobacterium leprae. It involves mainly the skin, mucosa of the upper respiratory tract, and peripheral nerves. Most cases in the United States occur in immigrants from areas in which leprosy is endemic, especially Southeast Asia and Mexico. The disease is classified on the basis of the skin, motor, and sensory changes, and biopsy findings as: indeterminate, tuberculoid, borderline, and lepromatous. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/43/18105?source=see_link&amp;anchor=H21480360#H21480360\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy\", section on 'Classification and terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral neuropathy is caused by bacterial invasion of the Schwann cells in the peripheral nerves. Both segmental demyelination and axonal degeneration occur. Motor and sensory nerve conduction is slow in both clinically involved and unaffected nerves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/6\">",
"     6",
"    </a>",
"    ]. Nerve biopsy shows loss of axons and myelin with swollen Schwann cells that contain the organism.",
"   </p>",
"   <p>",
"    Sensory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    motor loss generally will occur in the distribution of nerves in the vicinity of a tuberculoid lesion, whereas nerve damage may become more generalized in borderline and lepromatous disease. Nerve damage occurs later in the disease toward the lepromatous end of the spectrum, and sensory loss usually involves the distal extremities first. Nerves commonly involved include the ulnar and median (claw hand), the common peroneal (foot drop), the posterior tibial (claw toes and plantar insensitivity), facial, radial cutaneous, and great auricular. Although relatively uncommon today, advanced cases may demonstrate loss of eye brows and lashes, nasal septal perforation with collapsed nose, and hoarseness (laryngeal involvement).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Rabies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies virus is endemic in wildlife in the United States. Important sources of infection for humans and domestic animals include raccoons, skunks, foxes, coyotes and bats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/7\">",
"     7",
"    </a>",
"    ]. The virus is present in saliva; transmission occurs by bites or contamination of skin lesions or mucosa. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29624?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of rabies\", section on 'Transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infection with rabies virus results in an acute rapidly progressive illness characterized by encephalitis, anxiety, dysphagia, and seizures. Some patients develop paralysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    focal neurologic signs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29624?source=see_link&amp;anchor=H4962713#H4962713\">",
"     \"Clinical manifestations and diagnosis of rabies\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral neuropathy, with weakness and loss of deep tendon reflexes, occurs in approximately 20 percent of children with paralysis caused by rabies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/8\">",
"     8",
"    </a>",
"    ]. The neuropathy is caused by axonal degeneration with segmental demyelination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/9\">",
"     9",
"    </a>",
"    ]. Some patients develop an ascending paralysis with bulbar dysfunction similar to that of Guillain-Barr&eacute; syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/10\">",
"     10",
"    </a>",
"    ]. The disease nearly always is fatal once symptoms have developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rabies diagnosis, treatment, and prophylaxis are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29624?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rabies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2393?source=see_link\">",
"     \"Rabies immune globulin and vaccine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INFLAMMATORY DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory neuropathies include Guillain-Barr&eacute; syndrome and chronic inflammatory demyelinating polyneuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Guillain-Barr&eacute; syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute immune-mediated polyneuropathies are classified under the eponym Guillain-Barr&eacute; syndrome (GBS), after the authors of early descriptions of the disease. Historically, GBS was considered a single disorder, but it is now known to be a heterogeneous syndrome with several variant forms.",
"   </p>",
"   <p>",
"    Most often, GBS presents as an acute monophasic paralyzing illness known as acute inflammatory demyelinating polyneuropathy (AIDP) that is provoked by a preceding infection. Additional demyelinating forms of GBS are Miller-Fisher syndrome and polyneuritis cranialis. Axonal forms of GBS are now well-recognized; these are acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN). Guillain-Barr&eacute; syndrome is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27705?source=see_link\">",
"     \"Overview of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41781?source=see_link\">",
"     \"Treatment of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chronic inflammatory demyelinating polyneuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare acquired disorder of peripheral nerves and nerve roots. Both the cellular and humoral components of the immune system appear to be involved in the pathogenesis of CIDP and its variants. However, the precise cause is unclear. There is a temporal continuum between acute inflammatory demyelinating polyneuropathy (AIDP), the demyelinating form of Guillain-Barr&eacute; syndrome, and CIDP.",
"   </p>",
"   <p>",
"    Although the incidence of CIDP is unknown, it is thought to be the most common acquired treatable polyneuropathy in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/12\">",
"     12",
"    </a>",
"    ]. The classic form of CIDP is fairly symmetric, and motor involvement is greater than sensory. Weakness is present in both proximal and distal muscles. Most patients also have sensory involvement and globally diminished or absent reflexes. Cranial nerve and bulbar involvement occur in a minority. A slowly progressive course is most frequent, but a relapsing-remitting course is noted in at least one-third. Increased cerebrospinal fluid protein without pleocytosis is present in over 90 percent of patients with CIDP. In a series of 13 children, the most common presentation was lower extremity weakness with difficulty walking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the initial diagnosis of CIDP is clinical, peripheral nerve demyelination must be demonstrated by either electrodiagnostic testing or by nerve biopsy. The pathogenesis, clinical features, and diagnosis of CIDP are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40472?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mainstays of treatment for CIDP are intravenous immune globulin (IVIG), glucocorticoids, and plasma exchange. These treatments appear to be equally effective. Approximately two-thirds of patients with CIDP will initially respond to any single standard therapy (IVIG, glucocorticoid, and plasma exchange), while about 10 to 15 percent of patients are resistant to all of these. While the long-term prognosis of CIDP is generally favorable, data are limited, and up to 15 percent of patients may be severely disabled despite treatment. The treatment and prognosis of CIDP are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17385?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RHEUMATIC DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy can be seen in many rheumatic diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24346812\">",
"    <span class=\"h2\">",
"     Churg-Strauss syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Churg-Strauss syndrome (allergic granulomatosis and angiitis) is a multisystem disorder characterized by allergic rhinitis, asthma, and prominent peripheral blood eosinophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/14\">",
"     14",
"    </a>",
"    ]. The most common organ involved is the lung, followed by the skin. Churg-Strauss syndrome, however, can affect any organ system, including the cardiovascular, gastrointestinal, and central and peripheral nervous systems. The disorder is rare, but approximately 20 percent of cases occur in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic involvement is common in Churg-Strauss syndrome, and typically manifests as a peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In one series of 47 affected patients, peripheral neuropathy was present in 25 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/16\">",
"     16",
"    </a>",
"    ]. This included multiple mononeuropathy in 17, distal symmetric polyneuropathy in seven, and asymmetric polyneuropathy in one.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24346908\">",
"    <span class=\"h2\">",
"     Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Henoch-Sch&ouml;nlein purpura (IgA vasculitis) is a systemic vasculitis with a prominent cutaneous component. The clinical manifestations include a classic tetrad that can occur in any order and at any time over a period of several days to several weeks: rash, arthralgias, abdominal pain, and renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral neuropathy is rare in children with Henoch-Sch&ouml;nlein purpura (IgA vasculitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/18\">",
"     18",
"    </a>",
"    ]. Acute mononeuropathy can affect the femoral or sciatic nerve. The pathogenesis is not known, although suggested mechanisms include immune disease, mechanical compression, or metabolic disturbance. Henoch-Sch&ouml;nlein purpura (IgA vasculitis), including neurologic signs, typically resolves completely in most cases, although recurrences can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24346996\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel disease is comprised of two major disorders: ulcerative colitis and Crohn disease. These disorders have distinct pathologic and clinical characteristics, but their pathogenesis remains poorly understood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4650?source=see_link\">",
"     \"Treatment of ulcerative colitis in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24693?source=see_link\">",
"     \"Clinical manifestations of Crohn's disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic involvement is uncommon in inflammatory bowel disease, occurring in 3 percent of 638 patients with ulcerative colitis or Crohn disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/19\">",
"     19",
"    </a>",
"    ]. In this series, peripheral neuropathy occurred in six patients with ulcerative colitis and none with Crohn disease.",
"   </p>",
"   <p>",
"    Peripheral neuropathy may occur in adolescent males with long-standing Crohn disease. Extraintestinal manifestations often include large joint arthritis and uveitis. Affected patients often have a family history of collagen vascular disease.",
"   </p>",
"   <p>",
"    Peripheral neuropathy is a rare primary manifestation of Crohn disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. It usually occurs in affected patients who have vitamin B12 deficiency due to malabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/23\">",
"     23",
"    </a>",
"    ] or have been treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Juvenile idiopathic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy is a rare feature of juvenile idiopathic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The mechanism may be vasculitis involving the vaso nervorum that results in an axonal neuropathy with secondary demyelination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24346703\">",
"    <span class=\"h2\">",
"     Polyarteritis nodosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarteritis nodosa is a systemic necrotizing vasculitis that typically affects the small and medium-sized muscular arteries. A mononeuropathy multiplex (or asymmetric polyneuropathy) with motor and sensory deficits is one of the most common findings in patients with polyarteritis nodosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. With time, additional nerve branches may be affected, possibly resulting in the appearance of a distal polyneuropathy. Cranial nerves are less commonly involved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nerve conduction studies in affected patients show slowed conduction. Pathologic examination of peripheral nerve demonstrates arteritis with nerve infarction and demyelination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24346564\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is a multisystem disorder of unknown etiology characterized by the accumulation of T lymphocytes, mononuclear phagocytes, and noncaseating granulomas in involved tissues. The lungs are affected in approximately 90 percent of patients and account for most of the morbidity and mortality. Other tissues commonly involved include the skin, eyes, and lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 5 percent of adults with sarcoidosis have neurologic involvement, which can on occasion be the presenting symptom. The protean manifestations of CNS involvement usually occur in the early phase of the disease, whereas peripheral nerve and skeletal muscle involvement characteristically are seen in the more chronic stages. Neurologic involvement is uncommon in children with sarcoidosis and peripheral neuropathy has not been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Sj&ouml;gren syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren syndrome is a chronic inflammatory disorder characterized primarily by diminished lacrimal and salivary gland secretions resulting in symptoms of dry eyes and dry mouth, the so-called \"sicca complex.\" Like many connective tissue diseases, Sj&ouml;gren syndrome is thought to be an autoimmune disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic disease is common in Sj&ouml;gren syndrome, occurring in 25 to 60 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/30\">",
"     30",
"    </a>",
"    ]. In one series, 33 of 50 (66 percent) affected patients had neurologic abnormalities. Both the central and peripheral nervous systems were involved in 19, only peripheral in nine, and only central in five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/31\">",
"     31",
"    </a>",
"    ]. The incidence of peripheral neuropathy in affected children is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neuropathy is highly variable and may present in various forms, including cranial, distal sensory, distal sensory-motor, or pure sensory neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/33\">",
"     33",
"    </a>",
"    ]. It may be difficult to differentiate this disorder from Guillain-Barr&eacute; syndrome or chronic inflammatory demyelinating polyradiculoneuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A peripheral \"glove and stocking\" neuropathy affects as many as 10 percent of adult patients with Sj&ouml;gren syndrome. It usually is a symmetric, sensorimotor polyneuropathy in which the sensory features (eg, dysesthesias) predominate. The patient thus presents with anesthesia and dysesthesias of the extremities. The course generally is slowly progressive although some patients may benefit from steroids.",
"   </p>",
"   <p>",
"    Other neuropathies may be found, usually in subjects who already have a peripheral neuropathy. These include the trigeminal nerve, the most common cranial nerve defect; other cranial nerves VII, VIII, III, IV, or VI; and autonomic nerves.",
"   </p>",
"   <p>",
"    Confirmation of peripheral nerve involvement requires nerve conduction studies and sural nerve biopsy. Biopsy of affected nerves shows axonal degeneration and a perivascular inflammatory infiltrate, suggesting an underlying vasculitic cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/35\">",
"     35",
"    </a>",
"    ]. Antibodies to extractable nuclear antigens",
"    <span class=\"nowrap\">",
"     (anti-Ro/SSA,",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-La/SSB,",
"    </span>",
"    anti-Sm, and anti-RNP) often are negative. Additional tests of ocular or salivary gland involvement often are required to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H137453\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic lupus erythematosus (SLE) is a chronic inflammatory disease of unknown cause which can affect the skin, joints, kidneys, lungs, nervous system, serous membranes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other organs of the body. Distinct immunologic abnormalities, especially the production of numerous antinuclear antibodies, are another prominent feature. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=see_link\">",
"     \"Systemic lupus erythematosus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral neuropathy affects 2 to 27 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Peripheral neuropathy is rare in affected children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Pathologic findings include vasculitis and axonal degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/41\">",
"     41",
"    </a>",
"    ]. Findings in mixed connective tissue disease are similar to those in SLE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24346615\">",
"    <span class=\"h2\">",
"     Wegener granulomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wegener granulomatosis is a systemic vasculitis of the medium and small arteries, as well as the venules, arterioles, and occasionally large arteries. \"Classic\" Wegener granulomatosis is a form of systemic vasculitis that primarily involves the upper and lower respiratory tracts and the kidneys. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral neuropathy is common in this disorder, occurring in 17 and 43 percent of adult patients in two series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Patients typically had distal symmetrical polyneuropathy or mononeuropathy multiplex. In a series of 23 children with the disease, nine percent had neurologic disease that was predominantly peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ORGAN FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy may be associated with organ failure, such as renal or hepatic failure, or with critical illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfunction of the peripheral nervous system induced by uremia commonly occurs in patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/45\">",
"     45",
"    </a>",
"    ]. Peripheral polyneuropathy generally develops only in advanced renal failure and is an indication to initiate dialysis. However, patients already being dialyzed adequately are also at some risk, although the neural dysfunction is often subclinical and detectable only by electrophysiologic studies.",
"   </p>",
"   <p>",
"    Uremic peripheral neuropathy is a distal, symmetrical, mixed sensorimotor neuropathy. It occurs more commonly in males and is independent of the underlying disease. As with other neuropathies, symptoms are more prominent in the lower extremities. The sensory symptoms&mdash;paresthesias, burning sensations, and pain&mdash;tend to precede the motor symptoms.",
"   </p>",
"   <p>",
"    The initial finding is loss of position and vibration sense in the toes and decreased deep tendon reflexes, beginning with the Achilles reflex. Clinical involvement of the hands typically is delayed until the sensory defects have moved to or above the knees. Electrophysiologic studies are the most sensitive way to detect uremic neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14773?source=see_link\">",
"     \"Uremic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications commonly occur after liver transplantation and predominantly affect the CNS. Some cases are attributed to immunosuppressive therapy.",
"   </p>",
"   <p>",
"    In a series of 427 consecutive orthotopic liver transplantations in 391 patients, 19 percent developed neurologic complications, of which encephalopathy comprised 59 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/47\">",
"     47",
"    </a>",
"    ]. Other complications included seizures, peripheral neuropathy, stroke, and CNS infections. Encephalopathy occurred with similar frequency in adults and children, although only 1 of 16 cases of brachial plexus and peripheral nerve injuries occurred in children. Mortality rate was higher in children with than without neurologic complications (50 versus 7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Bone marrow transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inflammatory neuropathy may occur after bone marrow transplantation. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The disorder was associated with graft-versus-host disease, and improved as graft-versus-host disease resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Critical illness polyneuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critical illness polyneuropathy occurs in patients with multiple organ failure who receive prolonged intensive care treatment. This condition occurs predominantly in adults, but children also may be affected. The disorder is associated with multiple organ dysfunction, prolonged mechanical ventilation, and sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/50\">",
"     50",
"    </a>",
"    ]. Critical illness polyneuropathy has been reported in children but appears to be rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43976?source=see_link\">",
"     \"Neuromuscular weakness related to critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected patients have flaccid paralysis and areflexia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/51\">",
"     51",
"    </a>",
"    ]. The diagnosis should be considered in a flaccid child who is difficult to wean from ventilator support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nerve conduction studies show a generalized axonal neuropathy and electromyography may show varied abnormalities. Often, evidence of ongoing denervation (fibrillation potentials and positive sharp waves) is seen in conjunction with normal appearing motor units. Occasionally, electromyography shows myopathic changes; this observation correlates with pathologic studies that demonstrate a myopathy. Cerebrospinal fluid is normal. Motor function returns slowly over several months.",
"   </p>",
"   <p>",
"    Peripheral neuropathy with myopathy may occur after prolonged neuromuscular blockade with nondepolarizing neuromuscular blocking agents including",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/49/43797?source=see_link\">",
"     vecuronium",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/15/42229?source=see_link\">",
"     atracurium",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/0/34821?source=see_link\">",
"     pancuronium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Affected patients developed pronounced weakness without sensory loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/53\">",
"     53",
"    </a>",
"    ]. The condition delayed weaning from the ventilator and recovery of strength took several months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     OTHER DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with endocrine abnormalities (eg, diabetes mellitus, hypothyroidism), disorders of the gastrointestinal tract (eg, celiac disease), and enzyme deficiencies (eg, porphyria) may develop peripheral neuropathies. Peripheral neuropathy associated with malignancy may be caused by the underlying illness or its treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy is a common complication of diabetes. The mechanism is uncertain but is thought to be mediated by the effects of hyperglycemia on the peripheral nerve (",
"    <a class=\"graphic graphic_table graphicRef71576 \" href=\"mobipreview.htm?13/45/14045\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41928?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis and prevention of diabetic polyneuropathy\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetic polyneuropathy primarily is a symmetrical sensory neuropathy, initially affecting the distal lower extremities. With disease progression, sensory loss ascends and, when reaching approximately mid-calf, becomes clinically apparent in the hands. This gradual evolution causes the typical \"stocking-glove\" sensory loss. This pattern reflects preferential damage according to axon length; the longest axons are affected first. Motor involvement with frank weakness occurs in the same pattern, but only later and in more severe cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18551?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"    </a>",
"    .) Autonomic dysfunction also is common in diabetic children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuropathy may be present at the time of diagnosis. Abnormalities were detected in 25 percent of children at their initial presentation by measurement of reduced nerve conduction velocities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/57\">",
"     57",
"    </a>",
"    ]. In another study of 102 adolescents, peripheral nerve function, assessed by determining the thermal threshold for heat and cold at the wrist and foot and the vibration threshold at the great toe and medial malleolus, was abnormal in 28 percent at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with established disease are affected, although most abnormalities are subclinical. In one report, electrophysiologic studies were performed on median, peroneal, and sural nerves in 75 patients seven to 20 years of age with diabetes longer than three years' duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/59\">",
"     59",
"    </a>",
"    ]. Measurements of motor and sensory conduction velocity and sensory nerve action potential were abnormal in 57 percent. However, only three patients had signs or symptoms of neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism may result in abnormalities of the peripheral and central nervous system, although the latter is more likely to be affected. In one study, clinical and electrophysiologic measurements were performed in 23 patients, 17 to 64 years of age, with hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/60\">",
"     60",
"    </a>",
"    ]. Abnormalities of the peripheral nervous system occurred in 52 percent, including entrapment neuropathy, axonal neuropathy, and myopathy. CNS abnormalities occurred in 78 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is a malabsorption disorder in which there is abnormal small intestinal mucosa that improves morphologically when treated with a gluten-free diet and relapses when gluten is reintroduced.",
"   </p>",
"   <p>",
"    A number of reports have described an association of celiac disease with neurologic disorders, including cerebellar ataxia, progressive myoclonic ataxia, peripheral neuropathy, myopathy, and seizures. These complications have generally been reported in adults. However, the diagnosis of celiac disease was frequently based only upon anti-gliadin antibodies (which lack specificity for celiac disease) and not all studies have detected these associations, making the relationship to celiac disease unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H18#H18\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Neuropsychiatric disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with celiac disease, clinically apparent neurologic disorders are uncommon, and the evidence supporting the association with celiac disease is weak. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\", section on 'Neurologic disease and behavioral symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While data are limited, the prevalence of neuropathy in children with celiac disease is probably low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Nevertheless, there are case reports suggesting the existence of a reversible neuropathy related to celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Porphyria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The porphyrias are genetic or acquired deficiencies in the activity of enzymes in the heme biosynthetic pathway. Peripheral neuropathy is a common feature of acute intermittent porphyria, although it also occurs in hereditary coproporphyria, and variegate porphyria.",
"   </p>",
"   <p>",
"    Muscle weakness often begins proximally in the legs but may involve the arms or the distal extremities. Reflexes are lost. Motor neuropathy also may involve the cranial nerves or lead to bulbar paralysis, respiratory impairment, and death. Some patients develop sensory, patchy neuropathy. Autonomic dysfunction may lead to colicky abdominal pain, diarrhea or constipation, and bladder dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10439?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute intermittent porphyria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/45/41687?source=see_link\">",
"     \"Hereditary coproporphyria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/51/825?source=see_link\">",
"     \"Variegate porphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy is an uncommon paraneoplastic complication of lymphoma in adults that has been reported in a few cases in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/568?source=see_link\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The neuropathy may be acute or chronic and can present as sensory or sensorimotor abnormalities. Sensory symptoms include paresthesias, dysesthesias, pain, or sensory ataxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/66\">",
"     66",
"    </a>",
"    ]. Acute motor neuropathy may resemble Guillain-Barr&eacute; with distal ascending weakness. Chronic neuropathy typically presents as distal weakness with loss of reflexes and may be relapsing.",
"   </p>",
"   <p>",
"    The neuropathy is thought to be immune-mediated, resulting in axonal degeneration. Malignant infiltration of peripheral nerves also may occur. Segmental demyelination is seen in the relapsing form.",
"   </p>",
"   <p>",
"    Chemotherapeutic agents also can cause peripheral neuropathy (",
"    <a class=\"graphic graphic_table graphicRef69751 \" href=\"mobipreview.htm?43/47/44798\">",
"     table 1",
"    </a>",
"    ). Neuropathy associated with malignancy thus may be caused by the treatment as well as the underlying disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     VITAMIN DEFICIENCY OR EXCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin deficiency or excess may result in peripheral neuropathy. Symptoms usually resolve with correction of the deficiency or elimination of the excess vitamin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Vitamin B1 (thiamine) deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiamine, formerly known as vitamin B1, serves as a catalyst in the conversion of pyruvate to acetyl CoA and is involved in many other cellular metabolic activities. Thiamine has a role in the initiation of nerve impulse propagation that is independent of its coenzyme functions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28650?source=see_link\">",
"     \"Overview of water-soluble vitamins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    B1 deficiency typically is seen in areas where polished rice is a major portion of the diet. Breast-fed infants of thiamine-deficient mothers may develop encephalopathy, seizures, diarrhea, and cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thiamine deficiency results in beriberi, a fulminant cardiac syndrome with cardiomegaly, tachycardia, a loud piercing cry, cyanosis, dyspnea, and vomiting, and neurologic abnormalities, including altered sensorium, hoarseness caused by laryngeal nerve paralysis and considered a classic sign, and peripheral neuropathy. The latter may be obscured by the CNS and systemic symptoms. If the deficiency is prolonged, a patchy, demyelinating neuropathy may develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24346188\">",
"    <span class=\"h2\">",
"     Vitamin B2 (riboflavin) deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Riboflavin is an essential component of coenzymes involved in multiple cellular metabolic pathways, including the energy-producing respiratory pathways. Deficiency occurs most often in patients with malabsorption syndromes, anorexia nervosa, inborn errors in riboflavin synthesis, and long-term use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    (which may impair riboflavin function), and in those who avoid dairy products (a good source of riboflavin). It also may occur in developing countries if access to food is limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28650?source=see_link\">",
"     \"Overview of water-soluble vitamins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs of significant B2 deficiency include sore throat, hyperemia of pharyngeal mucous membranes, edema of mucous membranes, cheilitis, stomatitis, glossitis, normocytic-normochromic anemia, and seborrheic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/68\">",
"     68",
"    </a>",
"    ]. Because riboflavin deficiency usually is accompanied by deficiencies of other water-soluble vitamins that can cause similar symptoms, it is uncertain whether these result from riboflavin deficiency alone. Sensory and sensory-motor neuropathy due to nutritional deficiency of thiamine and riboflavin comprised 10 percent of a series of 358 cases of peripheral neuropathy in Nigerians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Vitamin B6 (pyridoxine) deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyridoxine plays a role in amino acid metabolism, gluconeogenesis, conversion of tryptophan to niacin, sphingolipid biosynthesis, neurotransmitter synthesis, immune function, and steroid hormone modulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28650?source=see_link\">",
"     \"Overview of water-soluble vitamins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dietary pyridoxine deficiency is rare. Clinical features include seborrheic dermatitis, glossitis and stomatitis. A microcytic hypochromic anemia is common. Peripheral neuropathy may occur in adolescents, although not in younger children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/70\">",
"     70",
"    </a>",
"    ]. The latter develop encephalopathy with seizures.",
"   </p>",
"   <p>",
"    The neuropathy was investigated in an experimental model of rats fed a diet deficient in B6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/71\">",
"     71",
"    </a>",
"    ]. The deficient rats developed abnormal walking patterns, which resolved with B6 supplementation. Morphometric analysis of the sciatic and posterior tibial nerves in the deficient animals showed a normal total number of myelinated nerve fibers, significantly decreased nerve fiber density, and increased axon-to-myelin ratio, compared to controls.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/24/38278?source=see_link\">",
"     Isoniazid",
"    </a>",
"    , used to treat tuberculosis, inhibits pyridoxine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/72\">",
"     72",
"    </a>",
"    ]. As a result, pyridoxine supplementation may be needed to prevent neuropathy in these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19142?source=see_link&amp;anchor=H14#H14\">",
"     \"Isoniazid: An overview\", section on 'Neurologic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Vitamin B6 (pyridoxine) toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive doses of pyridoxine may cause peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. A few cases of peripheral neuropathy, dermatoses, photosensitivity, dizziness, and nausea have been reported with long-term use of large doses of pyridoxine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/73\">",
"     73",
"    </a>",
"    ]. Cases of acute intoxication typically present with paresthesias, generalized sensory loss and autonomic dysfunction, without weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/74\">",
"     74",
"    </a>",
"    ]. The clinical picture is similar to that of animal models of pyridoxine toxicity and may be caused by a sensory ganglion neuronopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/75\">",
"     75",
"    </a>",
"    ]. In a patient treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/24/38278?source=see_link\">",
"     isoniazid",
"    </a>",
"    and high dose pyridoxine who developed a severe sensory neuropathy, sural nerve biopsy showed loss of large myelinated fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24346287\">",
"    <span class=\"h2\">",
"     Vitamin B12 (cobalamin) deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiency of cobalamin (vitamin B12), a cofactor for DNA synthesis, can occur in exclusively breast-fed infants of vegetarian mothers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/77,78\">",
"     77,78",
"    </a>",
"    ] or genetic disorders, such as defective cobalamin ileal transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/79\">",
"     79",
"    </a>",
"    ]. Deficiency of cobalamin produces megaloblastic anemia and neurologic changes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms of neuropathy associated with B12 deficiency include areflexia and loss of vibration and position sense, but they are difficult to detect in young children. Affected infants develop irritability, anorexia, and failure to thrive, with developmental regression and poor brain growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/80\">",
"     80",
"    </a>",
"    ]. Lethargy and coma can occur in severe cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/81\">",
"     81",
"    </a>",
"    ]. In general, CNS abnormalities and peripheral neuropathy accompany anemia or macrocytosis, although neurologic disease can occur without hematologic findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24346414\">",
"    <span class=\"h2\">",
"     Vitamin E (tocopherol) deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E is a generic term for a group of fat-soluble compounds, of which alpha-tocopherol is most important. These compounds function as free radical scavengers at the cellular level. Vitamin E deficiency is uncommon in humans except in unusual circumstances because of the abundance of tocopherols in our diet. Deficiency may occur in patients with fat malabsorption and steatorrhea and in those with certain genetic disorders, including abetalipoproteinemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21736?source=see_link\">",
"     \"Overview of vitamin A\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major features of vitamin E deficiency are skeletal myopathy, spinocerebellar ataxia, and pigmented retinopathy with loss of vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/83\">",
"     83",
"    </a>",
"    ]. Sensory-motor neuropathy occurs late in the course of vitamin E deficiency and is manifested by loss of vibration and position sense, loss of reflexes, and generalized weakness. Pathologic findings on nerve biopsy include accumulation of lipofuscin in peripheral Schwann cell cytoplasm and selective loss of large myelinated fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The progressive course of the neurologic disorder in vitamin E deficiency was described in a series of children with either chronic forms of intrahepatic neonatal cholestasis or extrahepatic biliary atresia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/35\">",
"     35",
"    </a>",
"    ]. All patients had normal neurologic function before reaching one year of age. Among those with vitamin E deficiency, neurologic abnormalities occurred in one-half between one and three years of age and in all after three years. Areflexia was the first abnormality noted and occurred before the patients reached four years of age; truncal and limb ataxia, peripheral neuropathy, and ophthalmoplegia developed when they were between three and six years. Most of children became disabled by neurologic dysfunction by the time they were 8 to 10 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy is a side effect of many medications (",
"    <a class=\"graphic graphic_table graphicRef69751 \" href=\"mobipreview.htm?43/47/44798\">",
"     table 1",
"    </a>",
"    ). The most common associations are listed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24347344\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic agents have been associated with peripheral nerve disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/86\">",
"     86",
"    </a>",
"    ]. These agents include penicillin, sulfonamide,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/35/4664?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/24/38278?source=see_link\">",
"     isoniazid",
"    </a>",
"    . Symptoms consist of paresthesias, motor weakness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sensory abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Antiretroviral agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of human immunodeficiency virus (HIV) with antiretroviral agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/55/27512?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/9/33942?source=see_link\">",
"     stavudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/0/36871?source=see_link\">",
"     lamivudine",
"    </a>",
"    ) may result in toxic neuropathies. These disorders are characterized predominantly by sensory symptoms that include spontaneous or evoked pain and follow a subacute or chronic course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/87\">",
"     87",
"    </a>",
"    ]. Pathologic features include degeneration of long axons in distal regions, loss of unmyelinated fibers, and infiltration of macrophages in peripheral nerves and dorsal root ganglia. The mechanism is thought to be interference with mitochondrial DNA synthesis and mitochondrial toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24347380\">",
"    <span class=\"h2\">",
"     Chemotherapeutic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy is an important complication of chemotherapeutic agents, including",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/8/34949?source=see_link\">",
"     cisplatin",
"    </a>",
"    , cytosine arabinoside, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/3/33846?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. In some cases, this toxicity may limit the use of these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Phenytoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy associated with the use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    has been well described. In one report, nerve conduction studies were abnormal in 15 of 21 children with epilepsy receiving long-term phenytoin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/91\">",
"     91",
"    </a>",
"    ]. The most frequent abnormalities were slowed motor conduction velocity of the ulnar and posterior tibial nerves and slowed sensory conduction velocity of the sural nerve. The total dose and duration of therapy with phenytoin correlated with reduced motor conduction velocity in the posterior tibial nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/42/42664?source=see_link\">",
"     Thalidomide",
"    </a>",
"    , which inhibits tumor necrosis factor and angiogenesis, has been used in disorders including Crohn disease, graft-versus-host-disease, HIV complications, and multiple myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/92\">",
"     92",
"    </a>",
"    ]. In addition to its sedative and embryopathic effects, thalidomide can cause an irreversible toxic peripheral neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     TOXINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxins that cause peripheral neuropathy include heavy metals and industrial or environmental substances (",
"    <a class=\"graphic graphic_table graphicRef69751 \" href=\"mobipreview.htm?43/47/44798\">",
"     table 1",
"    </a>",
"    ). These toxins primarily affect the axon with secondary myelin involvement. Chronic exposure is usually required, although abnormalities can occur after acute exposure. The diagnosis is confirmed by identification of the toxic substance in blood, urine, or body tissues (eg, hair or nails).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Arsenic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic exposure to arsenic may result from environmental sources such as contaminated water or accidental ingestion of pesticides, particularly ant poison. Chronic exposure is rare and usually is the result of deliberate poisoning. Arsenic exposure and toxicity are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8730?source=see_link\">",
"     \"Arsenic exposure and poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical features of arsenic poisoning include changes in skin pigmentation, palmar and plantar hyperkeratosis, and white striae of the nails (Mees lines or transverse leukonychia). Systemic signs include anemia, gastrointestinal symptoms (vomiting, bloody diarrhea, and abdominal pain), and liver disease. Peripheral neuropathy typically develops after one to three weeks and is characterized by a distal motor-sensory neuropathy (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8730?source=see_link&amp;anchor=H10#H10\">",
"     \"Arsenic exposure and poisoning\", section on 'Neurologic manifestations'",
"    </a>",
"    ). Paresthesia and numbness occur in the fingers and toes and ascend proximally. Autonomic symptoms, such as sweating, tachycardia, and hypotension, occur early.",
"   </p>",
"   <p>",
"    Treatment and prevention of arsenic poisoning are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8730?source=see_link&amp;anchor=H22#H22\">",
"     \"Arsenic exposure and poisoning\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8730?source=see_link&amp;anchor=H27#H27\">",
"     \"Arsenic exposure and poisoning\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Lead",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead toxicity can occur after acute or chronic exposure. The characteristic neurologic manifestations of lead poisoning range from developmental delay and loss of milestones to encephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    .) Neuropathy occurs infrequently, and sensory symptoms are minimal.",
"   </p>",
"   <p>",
"    Neuropathy, when it occurs, usually presents in children as distal ankle weakness with foot drop. In contrast, the arms are more likely to be affected in adults, who often develop wrist drop. The peripheral neuropathy is caused by axonal degeneration of the large myelinated fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Mercury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxicity may occur from exposure to either organic (eg, eating contaminated fish) or inorganic mercury (eg, antiseptic solutions, occupational exposures). The principal organ systems affected by mercury poisoning are the CNS and the kidneys. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34295?source=see_link\">",
"     \"Epidemiology and toxicity of mercury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral motor neuropathy, characterized by weakness and areflexia, may result from acute toxicity. Sensory findings may include distal paresthesias. Residual neurologic deficits may persist many years after the initial exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     N-hexane (glue sniffing)",
"    </span>",
"    &nbsp;&mdash;&nbsp;N-hexane is a neurotoxin that causes giant axonal changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/95\">",
"     95",
"    </a>",
"    ]. Products such as solvents, glues, spray paints, coatings and silicones contain n-hexane, a petroleum distillate and aliphatic hydrocarbon. Toxicity can result from industrial exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/96\">",
"     96",
"    </a>",
"    ] or addictive inhalation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33753?source=see_link\">",
"     \"Inhalant abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral neuropathy caused by n-hexane presents as distal weakness and muscle atrophy, mainly in the hands and feet. Sensory symptoms are minimal and consist of numbness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/98\">",
"     98",
"    </a>",
"    ]. Other solvents such as 2, 5-hexanedione and methyl-n-butylketone cause a similar neuropathy. After elimination of the exposure, recovery is slow and may be incomplete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24348432\">",
"    <span class=\"h2\">",
"     Organophosphorus esters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poisoning from organophosphorus esters can occur through their use in insecticides. However, insecticide exposure causes symptoms in less than 10 percent of cases and rarely results in peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute intoxication results from inhibition of acetylcholinesterase. Muscarinic effects include salivation, lacrimation, bronchoconstriction, sweating, abdominal cramps, diarrhea, constricted pupils, mental confusion, and muscle cramps with fasciculations. Nicotinic effects may be seen in the subacute phase, with muscle weakness affecting both proximal muscles and respiratory muscles secondary to post-synaptic neuromuscular block.",
"   </p>",
"   <p>",
"    A specific syndrome known as organophosphorus-induced delayed polyneuropathy (OPIDP) may occur after industrial exposure or contamination of foods, drinks, or cooking oil with tri-ortho-cresyl phosphate, used in the manufacture of plastics and as a high temperature lubricant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. Leg cramps and burning dysesthesias of the feet and hands develop approximately three weeks after exposure. Distal weakness, foot drop, spasticity, hyperreflexia, and ataxia typically occur. There is no treatment for this condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24347507\">",
"    <span class=\"h2\">",
"     Thallium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thallium is used in rodenticides and insecticides in some countries, despite recommendation against its use by the World Health Organization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/102\">",
"     102",
"    </a>",
"    ]. Intoxication can occur through inhalation, ingestion, or introduction through the skin. Clinical features include alopecia, black deposits at the base of hairs, glossitis, and Mees&rsquo; lines (white lines in the fingernails). Abdominal pain with nausea and vomiting occur in the acute phase.",
"   </p>",
"   <p>",
"    A painful, rapidly progressive, and usually ascending peripheral neuropathy typically begins two to five days after acute exposure and dominates the clinical picture in the second or third week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/102\">",
"     102",
"    </a>",
"    ]. Motor findings include distal weakness primarily affecting the lower extremities. Sensory findings include paresthesias and pain of the lower extremities and numbness of the fingers and toes. Nerve fibers show axonal degeneration and demyelination.",
"   </p>",
"   <p>",
"    Other neurologic abnormalities include tremor, ataxia, seizures, and coma. Optic nerve atrophy may result in visual changes.",
"   </p>",
"   <p>",
"    Treatment consists of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/39/31347?source=see_link\">",
"     ferric hexacyanoferrate",
"    </a>",
"    (Prussian blue), which binds thallium and prevents reabsorption. &nbsp;Chelating agents are not effective. Thallium poisoning case fatality rates range from 0 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/20/33098/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24347550\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most peripheral nerve disorders have a gradual and slowly progressive course. However, acute presentation may occur with toxic exposure or inflammatory conditions. Many systemic illnesses, drugs, and toxins affect the peripheral nervous system (",
"      <a class=\"graphic graphic_table graphicRef69751 \" href=\"mobipreview.htm?43/47/44798\">",
"       table 1",
"      </a>",
"      ). Peripheral neuropathies typically develop with bilateral, symmetric, predominantly distal involvement. Combined sensory and motor involvement is most common, but motor or sensory abnormalities may predominate in some cases, and autonomic symptoms may also occur. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Characterization of a peripheral nerve disorder involves a careful neurologic examination, evaluation of family members (to detect an inherited condition), and a nerve conduction study (NCS) with electromyography (EMG) that includes a needle examination of select muscles. Electrodiagnostic studies can determine if the disorder is caused by a nerve (neuropathy) or muscle disorder (myopathy). If it is a neuropathy,",
"      <span class=\"nowrap\">",
"       EMG/NCS",
"      </span>",
"      can help differentiate whether it is axonal or demyelinating in character. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral neuropathies are associated with a variety of infections, including Lyme disease, Chagas disease, diphtheria, leprosy, and rabies. With the exception of Lyme disease, these conditions are rare in the United States. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inflammatory neuropathies include Guillain-Barr&eacute; syndrome and chronic inflammatory demyelinating polyneuropathy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Inflammatory disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral neuropathy can be seen in many rheumatic diseases, including the following (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Rheumatic diseases'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </li>",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </li>",
"     <li>",
"      Inflammatory bowel disease (ulcerative colitis and Crohn disease)",
"     </li>",
"     <li>",
"      Juvenile idiopathic arthritis",
"     </li>",
"     <li>",
"      Polyarteritis nodosa",
"     </li>",
"     <li>",
"      Sarcoidosis",
"     </li>",
"     <li>",
"      Sj&ouml;gren syndrome",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus",
"     </li>",
"     <li>",
"      Wegener granulomatosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral neuropathy may be associated with organ failure, such as renal or hepatic failure, or with critical illness. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Organ failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with endocrine abnormalities (eg, diabetes mellitus, hypothyroidism), disorders of the gastrointestinal tract (eg, celiac disease), and enzyme deficiencies (eg, porphyria) may develop peripheral neuropathies. Peripheral neuropathy associated with malignancy may be caused by the underlying illness or its treatment. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Other disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin deficiency or excess may result in peripheral neuropathy. Symptoms usually resolve with correction of the deficiency or elimination of the excess vitamin. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Vitamin deficiency or excess'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral neuropathy is a side effect of many medications (",
"      <a class=\"graphic graphic_table graphicRef69751 \" href=\"mobipreview.htm?43/47/44798\">",
"       table 1",
"      </a>",
"      ). The most common associations involve antibiotics, antiretroviral agents, chemotherapeutic agents,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/42/42664?source=see_link\">",
"       thalidomide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H42\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Toxins that cause peripheral neuropathy include heavy metals and industrial or environmental substances such as arsenic, lead, mercury, n-hexane, organophosphorus esters, and thallium (",
"      <a class=\"graphic graphic_table graphicRef69751 \" href=\"mobipreview.htm?43/47/44798\">",
"       table 1",
"      </a>",
"      ). These toxins primarily affect the axon with secondary myelin involvement. Chronic exposure is usually required, although abnormalities can occur after acute exposure. (See",
"      <a class=\"local\" href=\"#H48\">",
"       'Toxins'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/1\">",
"      Belman AL, Iyer M, Coyle PK, Dattwyler R. Neurologic manifestations in children with North American Lyme disease. Neurology 1993; 43:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/2\">",
"      Blanco SB, Segura EL, Cura EN, et al. Congenital transmission of Trypanosoma cruzi: an operational outline for detecting and treating infected infants in north-western Argentina. Trop Med Int Health 2000; 5:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/3\">",
"      Genovese O, Ballario C, Storino R, et al. Clinical manifestations of peripheral nervous system involvement in human chronic Chagas disease. Arq Neuropsiquiatr 1996; 54:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/4\">",
"      Sica RE, Gonzalez Cappa SM, Sanz OP, Mirkin G. Peripheral nervous system involvement in human and experimental chronic American trypanosomiasis. Bull Soc Pathol Exot 1995; 88:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/5\">",
"      Logina I, Donaghy M. Diphtheritic polyneuropathy: a clinical study and comparison with Guillain-Barr&eacute; syndrome. J Neurol Neurosurg Psychiatry 1999; 67:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/6\">",
"      Wilder-Smith A, Wilder-Smith E. Electrophysiological evaluation of peripheral autonomic function in leprosy patients, leprosy contacts and controls. Int J Lepr Other Mycobact Dis 1996; 64:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/7\">",
"      Krebs JW, Mandel EJ, Swerdlow DL, Rupprecht CE. Rabies surveillance in the United States during 2004. J Am Vet Med Assoc 2005; 227:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/8\">",
"      Chopra JS, Banerjee AK, Murthy JM, Pal SR. Paralytic rabies: a clinico-pathological study. Brain 1980; 103:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/9\">",
"      Tangchai P, Vejjajiva A. Pathology of the peripheral nervous system in human rabies. A study of nine autopsy cases. Brain 1971; 94:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/10\">",
"      Sheikh KA, Ramos-Alvarez M, Jackson AC, et al. Overlap of pathology in paralytic rabies and axonal Guillain-Barre syndrome. Ann Neurol 2005; 57:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/11\">",
"      Hattwick MA. Reactions to rabies. N Engl J Med 1972; 287:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/12\">",
"      Sladky JT. Neuropathy in childhood. Semin Neurol 1987; 7:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/13\">",
"      Nevo Y, Pestronk A, Kornberg AJ, et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 1996; 47:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/14\">",
"      Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/15\">",
"      Farooki ZQ, Brough AJ, Green EW. Necrotizing arteritis. Am J Dis Child 1974; 128:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/16\">",
"      Sehgal M, Swanson JW, DeRemee RA, Colby TV. Neurologic manifestations of Churg-Strauss syndrome. Mayo Clin Proc 1995; 70:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/17\">",
"      Solans R, Bosch JA, P&eacute;rez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001; 40:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/18\">",
"      Bulun A, Topaloglu R, Duzova A, et al. Ataxia and peripheral neuropathy: rare manifestations in Henoch-Sch&ouml;nlein purpura. Pediatr Nephrol 2001; 16:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/19\">",
"      Lossos A, River Y, Eliakim A, Steiner I. Neurologic aspects of inflammatory bowel disease. Neurology 1995; 45:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/20\">",
"      Nemni R, Fazio R, Corbo M, et al. Peripheral neuropathy associated with Crohn's disease. Neurology 1987; 37:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/21\">",
"      Duval L, Lucidarme D, Delalande I, et al. [Sensorimotor polyneuropathy in a flare-up of Crohn disease]. Rev Med Interne 1997; 18:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/22\">",
"      Humbert P, Monnier G, Billerey C, et al. Polyneuropathy: an unusual extraintestinal manifestation of Crohn's disease. Acta Neurol Scand 1989; 80:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/23\">",
"      Neund&ouml;rfer B. [Neurologic concomitant diseases in Crohn disease]. Fortschr Neurol Psychiatr 1992; 60:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/24\">",
"      Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985; 88:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/25\">",
"      Peyronnard JM, Charron L, Beaudet F, Couture F. Vasculitic neuropathy in rheumatoid disease and Sj&ouml;gren syndrome. Neurology 1982; 32:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/26\">",
"      McCombe PA, Klestov AC, Tannenberg AE, et al. Sensorimotor peripheral neuropathy in rheumatoid arthritis. Clin Exp Neurol 1991; 28:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/27\">",
"      Ohkoshi N, Mizusawa H, Oguni E, Shoji S. Sural nerve biopsy in vasculitic neuropathies: morphometric analysis of the caliber of involved vessels. J Med 1996; 27:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/28\">",
"      Tervaert JW, Kallenberg C. Neurologic manifestations of systemic vasculitides. Rheum Dis Clin North Am 1993; 19:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/29\">",
"      Moore PM. Neurological manifestation of vasculitis: update on immunopathogenic mechanisms and clinical features. Ann Neurol 1995; 37 Suppl 1:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/30\">",
"      Alexander E. Central nervous system disease in Sj&ouml;gren's syndrome. New insights into immunopathogenesis. Rheum Dis Clin North Am 1992; 18:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/31\">",
"      Molina R, Provost TT, Alexander EL. Peripheral inflammatory vascular disease in Sj&ouml;gren's syndrome. Association with nervous system complications. Arthritis Rheum 1985; 28:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/32\">",
"      Anaya JM, Ogawa N, Talal N. Sj&ouml;gren's syndrome in childhood. J Rheumatol 1995; 22:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/33\">",
"      Kaplan JG, Rosenberg R, Reinitz E, et al. Invited review: peripheral neuropathy in Sjogren's syndrome. Muscle Nerve 1990; 13:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/34\">",
"      Mochizuki H, Kamakura K, Masaki T, et al. Motor dominant neuropathy in Sj&ouml;gren's syndrome: report of two cases. Intern Med 2002; 41:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/35\">",
"      Mellgren SI, Conn DL, Stevens JC, Dyck PJ. Peripheral neuropathy in primary Sj&ouml;gren's syndrome. Neurology 1989; 39:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/36\">",
"      Grant IA, Hunder GG, Homburger HA, Dyck PJ. Peripheral neuropathy associated with sicca complex. Neurology 1997; 48:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/37\">",
"      Omdal R, L&oslash;seth S, Torbergsen T, et al. Peripheral neuropathy in systemic lupus erythematosus--a longitudinal study. Acta Neurol Scand 2001; 103:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/38\">",
"      Huynh C, Ho SL, Fong KY, et al. Peripheral neuropathy in systemic lupus erythematosus. J Clin Neurophysiol 1999; 16:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/39\">",
"      Steinlin MI, Blaser SI, Gilday DL, et al. Neurologic manifestations of pediatric systemic lupus erythematosus. Pediatr Neurol 1995; 13:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/40\">",
"      Parikh S, Swaiman KF, Kim Y. Neurologic characteristics of childhood lupus erythematosus. Pediatr Neurol 1995; 13:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/41\">",
"      McCombe PA, McLeod JG, Pollard JD, et al. Peripheral sensorimotor and autonomic neuropathy associated with systemic lupus erythematosus. Clinical, pathological and immunological features. Brain 1987; 110 ( Pt 2):533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/42\">",
"      Nishino H, Rubino FA, DeRemee RA, et al. Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993; 33:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/43\">",
"      de Groot K, Schmidt DK, Arlt AC, et al. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 2001; 58:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/44\">",
"      Rottem M, Fauci AS, Hallahan CW, et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr 1993; 122:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/45\">",
"      Fraser CL, Arieff AI. Nervous system complications in uremia. Ann Intern Med 1988; 109:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/46\">",
"      Makkar RK, Kochar DK. Somatosensory evoked potentials (SSEPs); sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) in chronic renal failure. Electromyogr Clin Neurophysiol 1994; 34:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/47\">",
"      Menegaux F, Keeffe EB, Andrews BT, et al. Neurological complications of liver transplantation in adult versus pediatric patients. Transplantation 1994; 58:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/48\">",
"      Amato AA, Barohn RJ, Sahenk Z, et al. Polyneuropathy complicating bone marrow and solid organ transplantation. Neurology 1993; 43:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/49\">",
"      Adams C, August CS, Maguire H, Sladky JT. Neuromuscular complications of bone marrow transplantation. Pediatr Neurol 1995; 12:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/50\">",
"      Leijten FS, De Weerd AW, Poortvliet DC, et al. Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator. Intensive Care Med 1996; 22:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/51\">",
"      Petersen B, Schneider C, Strassburg HM, Schrod L. Critical illness neuropathy in pediatric intensive care patients. Pediatr Neurol 1999; 21:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/52\">",
"      Wijdicks EF, Litchy WJ, Harrison BA, Gracey DR. The clinical spectrum of critical illness polyneuropathy. Mayo Clin Proc 1994; 69:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/53\">",
"      Gooch JL, Suchyta MR, Balbierz JM, et al. Prolonged paralysis after treatment with neuromuscular junction blocking agents. Crit Care Med 1991; 19:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/54\">",
"      Watling SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med 1994; 22:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/55\">",
"      Verrotti A, Giuva PT, Morgese G, Chiarelli F. New trends in the etiopathogenesis of diabetic peripheral neuropathy. J Child Neurol 2001; 16:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/56\">",
"      Verrotti A, Chiarelli F, Blasetti A, Morgese G. Autonomic neuropathy in diabetic children. J Paediatr Child Health 1995; 31:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/57\">",
"      Solders G, Thalme B, Aguirre-Aquino M, et al. Nerve conduction and autonomic nerve function in diabetic children. A 10-year follow-up study. Acta Paediatr 1997; 86:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/58\">",
"      Donaghue KC, Fung AT, Fairchild JM, et al. Prospective assessment of autonomic and peripheral nerve function in adolescents with diabetes. Diabet Med 1996; 13:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/59\">",
"      Hyllienmark L, Brismar T, Ludvigsson J. Subclinical nerve dysfunction in children and adolescents with IDDM. Diabetologia 1995; 38:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/60\">",
"      Khedr EM, El Toony LF, Tarkhan MN, Abdella G. Peripheral and central nervous system alterations in hypothyroidism: electrophysiological findings. Neuropsychobiology 2000; 41:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/61\">",
"      Zelnik N, Pacht A, Obeid R, Lerner A. Range of neurologic disorders in patients with celiac disease. Pediatrics 2004; 113:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/62\">",
"      Ruggieri M, Incorpora G, Polizzi A, et al. Low prevalence of neurologic and psychiatric manifestations in children with gluten sensitivity. J Pediatr 2008; 152:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/63\">",
"      Kaplan JG, Pack D, Horoupian D, et al. Distal axonopathy associated with chronic gluten enteropathy: a treatable disorder. Neurology 1988; 38:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/64\">",
"      Kurczynski TW, Choudhury AA, Horwitz SJ, et al. Remote effect of malignancy on the nervous system in children. Dev Med Child Neurol 1980; 22:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/65\">",
"      ROWLAND LP, SCHNECK SA. NEUROMUSCULAR DISORDERS ASSOCIATED WITH MALIGNANT NEOPLASTIC DISEASE. J Chronic Dis 1963; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     McCloud JG, Walsh JC. Peripheral neuropathy associated with lymphomas and other reticuloses. In: Peripheral Neuropathy, 2nd, Dyck PJ, Thomas PK, Lambert EH, Bunge R, (Eds), WB Saunders, Philadelphia 1984. Vol 2, p.2192.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/67\">",
"      COCHRANE WA, COLLINS-WILLIAMS C, DONOHUE WL. Superior hemorrhagic polioencephalitis (Wernicke's disease) occurring in an infant-probably due to thiamine deficiency from use of a soya bean product. Pediatrics 1961; 28:771.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson JA. Vitamin deficiency and excess. In: Harrison's Principles of Internal Medicine, 14th, Fauci AS, Braunwald E, Isselbacher K (Eds), McGraw-Hill, New York 1998. p.481.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/69\">",
"      Bademosi O, Osuntokun BO. Diseases of peripheral nerves as seen in the Nigerian African. Afr J Med Med Sci 1981; 10:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/70\">",
"      Snodgrass SR. Vitamin neurotoxicity. Mol Neurobiol 1992; 6:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/71\">",
"      Dellon AL, Dellon ES, Tassler PL, et al. Experimental model of pyridoxine (B6) deficiency-induced neuropathy. Ann Plast Surg 2001; 47:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/72\">",
"      Snider DE Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980; 61:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/73\">",
"      Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 1983; 309:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/74\">",
"      Albin RL, Albers JW, Greenberg HS, et al. Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology 1987; 37:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/75\">",
"      Windebank AJ, Low PA, Blexrud MD, et al. Pyridoxine neuropathy in rats: specific degeneration of sensory axons. Neurology 1985; 35:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/76\">",
"      Santoro L, Ragno M, Nucciotti R, et al. Pyridoxine neuropathy. A four-year electrophysiological and clinical follow-up of a severe case. Acta Neurol (Napoli) 1991; 13:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/77\">",
"      Grattan-Smith PJ, Wilcken B, Procopis PG, Wise GA. The neurological syndrome of infantile cobalamin deficiency: developmental regression and involuntary movements. Mov Disord 1997; 12:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/78\">",
"      Renault F, Verstichel P, Ploussard JP, Costil J. Neuropathy in two cobalamin-deficient breast-fed infants of vegetarian mothers. Muscle Nerve 1999; 22:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/79\">",
"      Mackenzie IL, Donaldson RM Jr, Trier JS, Mathan VI. Ileal mucosa in familial selective vitamin B 12 malabsorption. N Engl J Med 1972; 286:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/80\">",
"      Graham SM, Arvela OM, Wise GA. Long-term neurologic consequences of nutritional vitamin B12 deficiency in infants. J Pediatr 1992; 121:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/81\">",
"      Matthews DM, Linnell JC. Cobalamin deficiency and related disorders in infancy and childhood. Eur J Pediatr 1982; 138:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/82\">",
"      Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988; 318:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/83\">",
"      Guggenheim MA, Ringel SP, Silverman A, Grabert BE. Progressive neuromuscular disease in children with chronic cholestasis and vitamin E deficiency: diagnosis and treatment with alpha tocopherol. J Pediatr 1982; 100:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/84\">",
"      Werlin SL, Harb JM, Swick H, Blank E. Neuromuscular dysfunction and ultrastructural pathology in children with chronic cholestasis and vitamin E deficiency. Ann Neurol 1983; 13:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/85\">",
"      Rosenblum JL, Keating JP, Prensky AL, Nelson JS. A progressive neurologic syndrome in children with chronic liver disease. N Engl J Med 1981; 304:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/86\">",
"      Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med 1984; 101:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/87\">",
"      Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 2001; 6:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/88\">",
"      Dalakas MC. Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 2001; 6:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/89\">",
"      Hilkens PH, ven den Bent MJ. Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 1997; 2:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/90\">",
"      Beinert T, Masuhr F, Mwela E, et al. Neuropathy under chemotherapy. Eur J Med Res 2000; 5:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/91\">",
"      Mochizuki Y, Suyehiro Y, Tanizawa A, et al. Peripheral neuropathy in children on long-term phenytoin therapy. Brain Dev 1981; 3:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/92\">",
"      Eriksson T, Bj&ouml;rkman S, H&ouml;glund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001; 57:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/93\">",
"      Behse F, Carlsen F. Histology and ultrastructure of alterations in neuropathy. Muscle Nerve 1978; 1:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/94\">",
"      Letz R, Gerr F, Cragle D, et al. Residual neurologic deficits 30 years after occupational exposure to elemental mercury. Neurotoxicology 2000; 21:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/95\">",
"      Korobkin R, Asbury AK, Sumner AJ, Nielsen SL. Glue-sniffing neuropathy. Arch Neurol 1975; 32:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/96\">",
"      Centers for Disease Control and Prevention (CDC). n-Hexane-related peripheral neuropathy among automotive technicians--California, 1999-2000. MMWR Morb Mortal Wkly Rep 2001; 50:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/97\">",
"      Kuwabara S, Kai MR, Nagase H, Hattori T. n-Hexane neuropathy caused by addictive inhalation: clinical and electrophysiological features. Eur Neurol 1999; 41:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/98\">",
"      Herskowitz A, Ishii N, Schaumburg H. N-hexane neuropathy. A syndrome occurring as a result of industrial exposure. N Engl J Med 1971; 285:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/99\">",
"      JENKINS RB, TOOLE JF. POLYNEUROPATHY FOLLOWING EXPOSURE TO INSECTICIDES. TWO CASES OF POLYNEUROPATHY WITH ALBUMINOCYTOLOGIC DISSOCIATION IN THE SPINAL FLUID FOLLOWING EXPOSURE TO DDD AND ALDRIN AND DDT AND ENDRIN. Arch Intern Med 1964; 113:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/100\">",
"      Lotti M, Becker CE, Aminoff MJ. Organophosphate polyneuropathy: pathogenesis and prevention. Neurology 1984; 34:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/101\">",
"      Senanayake N, Johnson MK. Acute polyneuropathy after poisoning by a new organophosphate insecticide. N Engl J Med 1982; 306:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/102\">",
"      Galv&aacute;n-Arzate S, Santamar&iacute;a A. Thallium toxicity. Toxicol Lett 1998; 99:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/20/33098/abstract/103\">",
"      Centers for Disease Control and Prevention (CDC). Thallium poisoning from eating contaminated cake--Iraq, 2008. MMWR Morb Mortal Wkly Rep 2008; 57:1015.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6166 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-77.94.48.4-CE85A84A2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33098=[""].join("\n");
var outline_f32_20_33098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24347550\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diphtheria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24346520\">",
"      Leprosy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Rabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INFLAMMATORY DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Guillain-Barr&eacute; syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chronic inflammatory demyelinating polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RHEUMATIC DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24346812\">",
"      Churg-Strauss syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24346908\">",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24346996\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24346703\">",
"      Polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24346564\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Sj&ouml;gren syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H137453\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24346615\">",
"      Wegener granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ORGAN FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Bone marrow transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Critical illness polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      OTHER DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Porphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      VITAMIN DEFICIENCY OR EXCESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Vitamin B1 (thiamine) deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24346188\">",
"      Vitamin B2 (riboflavin) deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Vitamin B6 (pyridoxine) deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Vitamin B6 (pyridoxine) toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24346287\">",
"      Vitamin B12 (cobalamin) deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24346414\">",
"      Vitamin E (tocopherol) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24347344\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Antiretroviral agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24347380\">",
"      Chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Phenytoin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      TOXINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Arsenic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Lead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Mercury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      N-hexane (glue sniffing)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24348432\">",
"      Organophosphorus esters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24347507\">",
"      Thallium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24347550\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6166\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6166|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/54/878\" title=\"figure 1\">",
"      Etiology peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6166|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/47/44798\" title=\"table 1\">",
"      Polyneuropathy drugs toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/45/14045\" title=\"table 2\">",
"      Pathogenesis diab neuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8730?source=related_link\">",
"      Arsenic exposure and poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/551?source=related_link\">",
"      Chagas disease: Natural history and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40472?source=related_link\">",
"      Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17385?source=related_link\">",
"      Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18551?source=related_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29624?source=related_link\">",
"      Clinical manifestations and diagnosis of rabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24693?source=related_link\">",
"      Clinical manifestations of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/568?source=related_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11046?source=related_link\">",
"      Diagnosis and treatment of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34295?source=related_link\">",
"      Epidemiology and toxicity of mercury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/43/18105?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/45/41687?source=related_link\">",
"      Hereditary coproporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33753?source=related_link\">",
"      Inhalant abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19142?source=related_link\">",
"      Isoniazid: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14681?source=related_link\">",
"      Nervous system Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43976?source=related_link\">",
"      Neuromuscular weakness related to critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27705?source=related_link\">",
"      Overview of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/31/2554?source=related_link\">",
"      Overview of nerve conduction studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21736?source=related_link\">",
"      Overview of vitamin A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41928?source=related_link\">",
"      Pathogenesis and prevention of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6376?source=related_link\">",
"      Pathogenesis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/32/19975?source=related_link\">",
"      Pathology and pathogenesis of Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2393?source=related_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41781?source=related_link\">",
"      Treatment of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4650?source=related_link\">",
"      Treatment of ulcerative colitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14773?source=related_link\">",
"      Uremic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/51/825?source=related_link\">",
"      Variegate porphyria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_20_33099="Liver diseases and HPS";
var content_f32_20_33099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Liver diseases associated with the hepatopulmonary syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Cryptogenic cirrhosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postnecrotic cirrhosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcoholic cirrhosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Autoimmune cirrhosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Primary biliary cirrhosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic active hepatitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Primary sclerosing cholangitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alpha-1-antitrypsin deficiency (associated with Z and M-malton alleles)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Wilson's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sarcoidosis*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hemochromatosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Biliary atresia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Non-cirrhotic portal hypertension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tyrosinemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gaucher disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Schistosomiasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nodular regenerative hyperplasia of the liver",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatic allograft rejection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Langerhans-cell histiocytosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatic graft-versus-host disease following bone marrow transplantation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * From Patel, A. South Med J 2009; 102:844.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Krowka, MJ. Semin Liver Dis 1993; 13:414.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33099=[""].join("\n");
var outline_f32_20_33099=null;
var title_f32_20_33100="Classification neonate seiz";
var content_f32_20_33100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of neonatal seizures based upon electroclinical findings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical seizures with a consistent electrocortical signature (Pathophysiology epileptic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Focal clonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unifocal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multifocal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemiconvulsive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Axial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Focal tonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asymmetrical truncal posturing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limb posturing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sustained eye deviation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Myoclonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Generalized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Focal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Spasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extensor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mixed extensor/flexor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical seizures without a consistent electrocortical signature (Pathophysiology presumed nonepileptic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Myoclonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Generalized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Focal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fragmentary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Generalized tonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extensor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mixed extensor/flexor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Motor automatisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oral-buccal-lingual movements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ocular signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Progression movements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex purposeless movements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Electrical seizures without clinical seizure activity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mizrahi, EM, Clancy, RR. Neonatal seizures: early-onset seizure syndromes and their consequences for development. Ment Retard dev Disabil Res Rev 2000; 6:229. Copyright &copy; 2000 Wiley-Liss, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33100=[""].join("\n");
var outline_f32_20_33100=null;
var title_f32_20_33101="Contents: Drug Information";
var content_f32_20_33101=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Drug Information",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Drug Information",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"mobipreview.htm?43/6/44138\">",
"         General drug information",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?36/10/37025\">",
"         International drug information",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"mobipreview.htm?42/37/43610\">",
"         Patient drug information",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?25/27/26042\">",
"         Pediatric drug information",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"mobipreview.htm?12/27/12730\">",
"         What's new in drug therapy",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-DEB9B978C4-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f32_20_33101=[""].join("\n");
var outline_f32_20_33101=null;
var title_f32_20_33102="EST v TIPS mortality";
var content_f32_20_33102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mortality with TIPS versus endoscopic sclerotherapy for variceal bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 382px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effects of endoscopic sclerotherapy (EST) and transvenous intrahepatic stent shunt (TIPS) on mortality in published clinical trials of secondary prevention of variceal hemorrhage. There was no difference in mortality rate between the two groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Jalan, R, et al, Hepatology 1997; 26:1115; Rossle, M, et al, Lancet 1997; 349:1043; Merli, M, et al, Hepatology 1998; 27:48; Cello, JP, et al, Ann Intern Med 1997; 126:858; Cabrera, J, et al, Gastroenterology 1996; 110:832; and Sanyal, AJ, et al, Ann Intern Med 1997; 126:849.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33102=[""].join("\n");
var outline_f32_20_33102=null;
var title_f32_20_33103="FEV1 growth curves";
var content_f32_20_33103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79707%7EPULM%2F60080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79707%7EPULM%2F60080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    FEV1 growth curves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 316px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Growth curves FEV",
"    <sub>",
"     1",
"    </sub>",
"    for healthy boys showing increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    with increasing height.",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Wang X, Dockery DW, Wypij D, et al. Pediatr Pulmonol 1993; 15:75.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    FEV1 growth curves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 351px; background-image: url(data:image/gif;base64,R0lGODlhmAFfAdUAAP///wAAAO/y+Q8/n19/v9/l8h9Mpc/Z7AAzmX+ZzD9lsr/M5Z+y2e7u7i9ZrFVVVREREYiIiKqqqm+MxXd3d6+/3zMzM4+l0pmZmczMzE9yuSIiIru7u93d3URERGZmZtHa7cLO53eSyVl6vZWq1WiGw4aez7XE4cPP54ui0bPC4aS2232XywAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACYAV8BAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5RRwBEUUYAcEBHLrFxlgZEL2/G8fOz1IdEBgbvkTAwdbQ29xDHdUA4EfAGUbC593ps9jC2kXDTAHq87PgHfAPGAAYEA3x9ABf2YMXIdi0JvICKuyWcKFDZw0fSswVcaJFWhUvanyVcaNHVR0/iiwVcqRJUCVPqtyUciWqDh6CefBH4VwACWoe3HzU0qUp/wvDgD0gkiFAv5w7HfX0OaqBUSEQIBDR6c4pBKAbOuzbEGxozQcQKDTQGUzC2GAbzBqNCSFDwWAWlDIVGKBc1CESAjQjYnVfAA9F434IgKFmMApUh+iUcG9D34JDF/Oc60qCMq57AQDVx/dp4LfCKNS0pswfVJt980ZO2mgpZU4CjAzmXDBukccBHgQmMlpIYt+Eh6TODUAn59avTyVAEBvAWwucG3DFeduosplb2/UGcLZsd6PDhyYLYJuR6+SWCjhwcIBK31rn0U+6MCCBlfcY5X8qoMBA+4nx6dcIfRM0B6CAmgiggQELbBQggodUMECBSsAkk2mGpbWGZHJBSP+JggNUwARQHAjlXAAUhHNUGhwi56EkEmpgYBLv3SVZi1ZhpRU1XQHwVVjfmUVWWlax5ZYw5S3y4It+CDBBiE9wZZdUQJWD41PAAEYeALMZhuJvxd3UGG6rUecik4wsYICMUFiml15h4nSlVJ/ZJNoyAJQ2hDLnhBfnZGgq4uQAFzgxoxCznSjWBity9xRkuw2xHZjGCfeUamEexwcv7iSxZKB2HGCAAgU4sVxzzx2XoZmORvWXPzxms12Q3/VzKXHjJZnHeJ0i8SmocyRAqBPqsefeU6NIQ02vR/wK7BshrFdqE/TZVwV+oHzjizjv2OTss2yQgIAIxPb3XzHsZPP/D7h/CBuCEwQeegy3SnzL7hkE+NeEggymQ6+n9+4hgAIOyHuEhBQ6GHAe6hFgcBEgiviRvQt/ccAABDQR48MHVkyHhAwwMajEI1HssRYMQLmEmmyeZPLJVxAwwLlIDFroSi/DPIUABDgwbRKikupTzjpDIYADCnAshLA3TwFUn3n1iRSrShathqgZKxGtz1nUBkBeurLImnlWo3GxtUmIS+7ORkj5tTAHWXqVXjtyRdyPYpF1U3dErmXUkXB1WDYZDCAQshIyvzvFqbwRR4Q0AWglRF9Z7tZlaJSKqReZfwo+eBjC0mzEwFxLoaYCNDcQleREVCk3AHWecydpAZiW/ydqt5YJ6Odg5Ct6EQc44LAUNhuhU4pCUOCLNJm1eqJuW0qKZ+bH+Vmp57xvQbrSEqINRYw/D8FLo1H/VY7c18Fqdy+z6i0k3H7min32WDSsNH2HQ1GABipfga0sROPdxbKWBN9JIV5a+F8sAjg4kCnhaAWLwgH60yCPMNBqKSPZEQYoheV4T2H0i9nMlJCypjnhdL/TyAVPxrPSIeFJFTTUk0wokhVW7GhJS4KCjPUE8OEshFPAmhLU07Im7K9/KrHhvc6mhAVMCAoIHBoQoVC4/B2hik8IAQUpo8RnhQ5xI3SCCcaFBS9Fb1UbGlvVpsgEA9aMYEojAs8GoLgr1P8EeUIoSIoYZbsztIhsbNQhHIFmgOE1IXg5zIKXLGClncxJR9m5W26A5D6+qQUCRgJN2BDRRSbZLwnd6+ETvQCMZrhuTn7RkmAI4yXE4ClOY3oUcf74BtB0Kl3EWEInPcTBJAhLg0t4EjCpIK++3Ig1fYldaLajp9P0KXedo0Ne+kgNKOwSQQ6smRtFRrAURkEAjCsOTkykR+k0ikyRSt70Xnk952GqnXOIQPP8oq51BXIIGdQh0uI4hAHykwkpE5o6u4IhtLDKKumLJPvwRCu92UoqmJKfHO4Bj3HUxRzeuucQZOZNAPSSWgigYRD7M0woKPASRWHdO3JZL422MHz/RcDivjh6hUEl4J9KOOkkPECMvGTgHsTIxz4aBbBA4pBjMHQCInGaBPpoAKaxsCUAgHoio2iqqFMUYs004MIlIOwKC3BAv0AIxBPUB2gOKGIwkUg8mX3wItdkirhSkAQnTsBQ3bSCsAw5MSAWjgRNHYAVleDPKqjJATGsYQhTltgi0BSkIn3CESNrQfqlzJsQ/OccO7oEcE6IqUMYz1+0Ur5g9NEMtFREXE9yWSRolQlLpUIFRsVZJUTAF3nxwNs26Uc1qpZ3rb3isDQ2SimAQAGCzQIw4lK+uE3OKJCMlVcmmTdhvE8vl8wkkuYHs+Aa4ZdOECYVxigC0CbBTe6A/xzrKGe+LV3uMJljzOZkqTvuesy7cuxZbYVAuv0egT8OqOMVBuO41l30uXQiD2gOw8za7Ql3EJ2lbxOxWo/gdwjqSeQSCisFhJkXYoo5jKSWB4HmoTN66rQG9V73zuDYN2BfNIJZCbiEC4R0ZzIr6ROcxBzgnCMD5QNMZ1yFnVgt1BoNhR80JQpImD22CHOdaRglOKoPD8GzBICqE3Tqigpb5MlESNkKDrnPxd24CgwYVWOjwOVWeFkiYMbnlJXwVSkA2L9IUNNYO1axnhnswi9kqxM8TIUF9GewEnnzQvx8BPrst79tHcCaieVWK29D0QFhtBHivEGMfZhlVuZxwv8qGzBNO1ZfNT5zFJi2s71qGa6ljuCmZa1DTjOhWHiOqZqTeC9TE8HXGyxzFFJ2V9MZYM8uYxewhbDsItTZaPyb9MoOzRRMc2N7o1tPHMUbBVBHAQSVnou1oZHZbNP6CJBe9XChIAIElMDSRYjJ+Xxk0DRS7beBKjfEhLeEGZu3WK9Ga4CzUL7z6VFFpy1Daimcb2HLkd9KEBcLDnjWVSPgrd8sgk7Od0wz5YhukZwuWKrrnSFl92+afDF6jkbjK0M8sCr45oKkLfBc/5cAPQ7x+U6JTCy1d5WFwRw7NecY+kazyRBi+QYLuQRbN3EAam2CB61QAJxnWeMH7vjrlMn/YDw183bPjHB99yBVeyJI6Ub4KLqbrYQnIXrD67F5EaqOgKsb78Dl5OPrIIVieqt46NWDJjz5ME2z6wftwFs3urUNheB1VeoXrwLd7V6E0g6F3tgdckKNHIH2WbdW8VMGb+8gT4Qk/eVEuNjbMYx6alX8CY6XO4atHnA2IytZwWApEbw17lsgPvXJBRrGoI1syGPciLTnQps7kVLDv+b3Q8hmnoN/Qk83Pu5TmHzti8HTt80bq8lROz4NR0Lyy1DQS5i6nZMvCg50ngL37lo7TI8e8Qshn76cM9wFqlTsR0H7o8ABMXEOG3BVatB7smB/AABov6Z/SmBjx+dLkfd//+zXfnoRARnQAA2AATHBLGeAgLDAREbAgPzFVTg1MKjWfzz0BOBWd9u3CRLwAUfQeW4Agq6geo3mgC6nYV5lfU+gfuyGACPwgpyQcMJRg5SBg5umg0IQPC2nQ9ymgnIXVgPHChbggWxgg6ughKfWURdTbEwQLfxnfN80QwKBR3GghanAhb92bs5GfUsgLiZwfSt4QqNChKPgARYgGvAHB2p4Cmy4UW4YZnAIRgLGBEBoKPyzeqngFLLjhy4RiMw2iEMQY51FMHjoUf4nSlGnBewgZFMDBhIwiqOoUlm4Ek6EaPp2BNtEWIXEVIloRCTVBQbyAfqQJfYWBkDWAPF3gP8qIS6qyHjoNkhMEEpSGAVRpAV0dyjAgIYflxVVtQx4EyQZMIAe0AFFgnLb5QUEVhQG6IsmMQEIAFj79oQ7+E/gZSoTKFlbtAUAGFoGoVLs5QEHxxUd0EpgwkfA8AGcs3DI8Be1s4eQKBKncwLZZo5NyHQi04qEtYnqeFPuWIFFUBQm5hnkoTdl0WCmURTnYAHWM2FYkBf30AAC+QZ/6AnFc5DCF4FEkGE4FYuw5ZBX8I7xhhO8UJFSARkFIYPS83fawCjrJXgu1gVFURAF8Y1pcJKc4ENpp5DCxYjAh5BpJ5Od9SQsSYEumAQEZj6a9yrRWBeeVxbVKAwPEHp9twX/Wzl6aKCUmXBEOqaA94d+I2h+iLiOdjiGVCeRticVhiABnRcBZjGQE5GMiUdZAPAk/uV0wEOVDyQzhomVlHcsfEkITkEdJYmEEjFBxQd8jKhf3PR4SACTPdiJ2aeXnBABQGEBqokigrkQotlPhXhlxOiKfJUEW2NzEZMFNAkKZgRyJukQKKQEKxCb/JVW/GSMS0BeyOiDeZmVpUCSHKCBcsCWkJCSNSOO5Jh2w4eIcilHC3KIS8Afm2lcpplsAMGUSDBbCoACrvV6tZaChESa+TdqxNRuQ/gSYsGHotGLa0kPbjlEi5gEMjVEDtdUqkZmdShbowICqiCSdtKa3ECY/9/1WQIqabC1nQ+0ILkGTnZJBeKpY6TAi19DiowBoc+gmTQHAFSYooo5flCZkPJ5BKeTiTXjQfCGCfeon/tposfwmvzlmE0Hmku4Xzb2mBBjhlegnjT6CaUVGjyqC8FZoU/1QMIoSELqnfDpVXc4k7MIC7xIoqX4pL6HpK7VjvpUm0uHpk0ZoxDDPyBqKDYqCxzwfcKBlErAD8FwVbjkfLiAnqMjjlfpURgKSu6JBEX6BCnDphqzpbNgGZ0iAZf5BBSgDxEwmUJQTU9AnYHwn6DEqEqgAooXmt1ZglmaBOKZorJoAG/KCmexAQ8gGqlJp21iqfT0Si2lCxLaksi1qv8AwGPZqU2lCjxrglO5ajRxigsS4AF8coVW8A29SA4YZRO5gKJKICz0mZ6jwp4EyoONdqBasx6oWoyeWgzSaQXJYKcAUFG3ags+qqIGkKD/FaAbNqjopqFiREZU16UiIU/zRlVCxQ9G+A62EKVrF6qieq1XRJeuNaz70h/gaawXd6PdsD6EQVVv4VzrGgvWmYNqagQr2gQtCgCH2gRO1LE9NK73oql34KeLOZ4QA6SfWXv8gmdul6+qCjMqSwecim5W2QSJSoRYozSioqhCAHBVwKEQibOwUKxCICF4uUFm2oNXObIAVVxToKQPIRptkLNwoEUuCwAfKjKA+oOjOrP/Uhaupqqv9ICaqmkBG4CGSckKAlAC+BqaCICwRoC1MxWs/cSwsFVlxHSsAbFcqvm2W6sKWMageUZbt7arklWgRkC1qWakdIayAWEB1KG1p4gKaaYANHdEL7o0FOoEIUCvbcq3EGMuHqq2a4uum1sKepai9GGyRHBYG0q3v7qm/1SyoSa4l6sXFCCrh0sKhmYAUPmxnQWz+7JXimuo3poENXu1lgsQHPABfEKPaTgKVVcfHGNTrke7I7hrOmSvtyYt2ce6EoEBZAG3a8C1YiBqSvOzMfm1HntsqDq0/0RsrRaxHsGBIvabKOlqSnBcN1uVhdpE1Da5Zyu9T/sQHAAW/wbxAKbYvp7QuSk6t+NynAPQwDfHvZ1FvhsGuN+GvhPxNPQYsOCoCbH7QMzbuAUstnfLT/gLWVPQbuUlEg/wAcKLmZhQvC9qwZCHt6MjwEwguYKEuqa6Hg87Eijcn5ewvUm7uPQ7BAS7BEAsMiD8dOBrqAfsEaqpGRHgFOybwpMAvwhsvEYkr0ywwk0QAn67VqFrBOIpe5frkSgixmK6CFhWe1D8T7O7uwl8ayOAAHNYvlf6gKOrEqopxngMwJFwxdcZwyQLrsjnwSLTwlULhjs2c0zxNI/oyI7AxjWKMUTovTAsxBAjLFO6kBYaBYTWyd4yxnEbyoGMBJBsxVD3gv97vLwbjLYeJcKbPKojwQFmoYHlCsqJ0MdNZL9OQMC8uoDiC1DRXMTPW4xQJ7ELscisOZ16LI6orKK1PESDfMMrw8w++66+3KuqazRR+BraLMsUjAi7bKrhdmtW17x1Fc6disZPwLvd9sbJ8c7HzMOFcMt/Ksn27JxDVM/Txs9PEL07Rqby4clOisyBIMroRsThWZ5HitDTZrDhab6NN73uHMukxCeuKwTuW7v6rGuei3wKrUMaTVjIFcVOoL/qRrlzYczG/AWT6hy06iuCAG6WLMVou5sCOs30XNSGIjPp3IQirVHnFdTNAggY/G5nHMdIbdQw/c0Ly611Gaga5az/zZJRfuBU+CzHDE3PMZ3PDv1A4hiZxDLIOt2SjCnVRIGxGZsHh3XB3sxPW93BNj3Kcn1I97ycYq1R/Jqpe8AfxHllM40EgS3Hg+zVvSosqGM6Nf1v64zXSkCxKa2UPDbYLh2ukw08h13EvazZTA0viezZW3CSTlV7GC3ZHF0EhtbatqzUPitWF/Bh/PLUsM3YdTBbiJXVCV3YMrrZ5/zCiHpscXwwrz3csU0HmgmVRE3ac3fbYebbuytW0R1m0E1MbkrdYICAc6TdRTvIWL3Qbb3bb43cxrrBz5ye12ze5x0HkS1HmMzWyh2+8Z3Pus3Cq01M7YzfXWBt6klznrXK//6ty5hd30ek3pL9JBog3LgN0Aie4G1w3TJd4A9+ySC+0QMe4kcr0RvuBV6mzLv90u793y1p4b68AIMM4zf33lTGwSmuBas1z1eEzhuN49st5CPoAPWR1ivDPxOwpEfAajsuBnHVuR01WwE+5DZetNwN2e8a3kKQ2xQOe1H95PldBsULoj68BC145Sqq5EBrdcJdAcx9BQcwyIkt5lbQRVAs4EZaAIN8nx/95fiEXEs+bOONBbk9AUhu5yr+vnv1MBNU4lhed4nubHHOwtBtXmlW5VKQ6YCu6DweBlJu25AOtlkOzZo+5Bf+TRew5VgAToXu6WXAQGHl3C2Jc9982v/49Op0JuhL6lkuTnVP8uuwHutdMFmRbOO43qur7gChKwCrbrzm5esYnnZWR8fDfufasxx46+M3fuXSbs/0vX51Z+0sPSFMfu1YYDIBpWW+zlnJ/u1ehVxq7rGlLs0G0Ono/gX2MuvSRh/CrtZEHukEUFsCkOm/rerHlgDnzt+6nu+zTAUgwD+UZdBWvn0HkOUFEOz1nXo4pwEbb6rBPu0OX91U0G7trWu0XvEfPehNpAEBj24MYOQsbwUXP+4jb9EkOyoPO+tQmeycrjQFn/D/JjMKwOUCPvM3P7wRDdJnbuI12vByHOxGv4DyvvAoj+9JTwbxwbLgDOm4nvEjLqP/1f5/T8Ls2Ozqp571ZAyggjbhHIPrNT/wVixWWB99Li/39RPyak8HSyGh2f323H3ofCwszP5/CXBsB48FcU/uez/mQBO1QmCfAYfrP99Ebt5tl58Fgt/4XMCsv3AOuifUEvhWp7PEpE7kaP/DRq7wRvPsrJ8Flc/5WsALtnqp86RLi5vZcoTitU7kYP/vqczqjdfxH2/paS/7VYC9n19PuH+kBsv1Ah9wi09YmW8oMW/uyqj3yP8Fym9Rssp7b+jgRVve3R5wmy+gvK4/RD/1oHT3jL/9S9D9zRL6VT3+glaspx37GX3pVAQEigGhADAekUllsjAxGC6C5ZRatV6x/1ntltv1fsFhsdYTMXYCHMADA8BAGteA8TKYSJEHhWGxBBEQiKYEEp4YqgoANfq0mgYcGPDEBBiECBjHMjU3OTs9P0G5OAJINwDQ1CJIIdrk9PiUEhASlgREEEaKlhwVMJcqhCZ0syo0Ag80DwgeI0Odn6GjpaepqQJmlRYMFJCVGAYUQKaUj6kELgwlrwoKodTBzh3shqvr7e/x86kD3gUmBi4seVVhyoJg9JgsU0BQywJAlzRVUMRQX0WLFzFmnDIHSYUBGhAC8DcgwTsjDJ6UpAJsSEhz6AwkcNmFXcqZGnHm1LlTE0cABTQMoIikDkglhAyZQ+lOCzkNQ8NUCv/ki2dVq1exbqRjx+QCB7CSgPjXiwovqFUoyROW6cA/SCazxpU792KAV1RFLqOVxB+ubksWGBOUJRG4Q2PS2vlLl3Fjx/uwxRrSL0HLQUtVZqlkeYxDBAoOPxY9mjQnftkMOMCLkuyusaHXuW0mpmbMm6Vx59a9xKcRoABRg832cLGVYuXGHCdwdndz57t9EuKaxKAB2EgYfM28rl2UMY4ceH8+nnxujhW2FS+8/QiIypAaPsTbJTGB4uXx56cboICQ633vUCIRXOarBSaZOlNoNv0YbDCra9iTbjAkBpzQCqeY4+KcJ9Zy0MMPeToNu23wqvC2IxLrMIzjngLRxRf/NepNG+GOMBGLwkD7zgmmYOzRR3w4qu66nx468SRLjLSCEksK/NHJJ0HhT693bLQCvAW/UIYZuKDs0sueEAiQwiKvUO4+DS9QK8kv2WwzCxFrJLMK954QDwyJEGjRzT35/KK3KssCZIQmCWsHwT4RTRQLjgCdolEvpIJI0Ukp5e1RAeXMUjYuK+0U0Wss3CVT+rJTzNNTPYXT0VG58CxHVGGttDdMA1lTQENtjVXXJ2eNs9YvlMtw12Hb7PXSG92yk9hlXbTAjEXH/FXDUu1j1loXRwngWTl8YxULhwzj9Npx8SvjzWPRgklFctl10FzeSIkX1FwBwLDdez98Vw5x/wE7CN9/3d3Wil6rwIxfgBHGLdsATOH2CqSsS1jiLgmmcCxCJ87Yw4rrJU7jj38k2KB5QC65x1kNNlnlFzmCeMiVYWaQv4tjrvlDUM+0WWfyON7ZZ+d6/llo3IIe2ujHij5a6bmSXtrpq5p+Wmqdop7aaoyqvlrrfLLe2utquv5abGjCHtvsT8o+W+2e1m67nrTdjpsLuOWu22G78TYt773Z5ttvMOj+O+/ABf+5AwtIaeUIDORVY+DC237gAQAkCCCOxRt+E/K1IZDAiDSQYJwUga3ZXG3QAQhA8dADyCAJeWGPXfbZaa/d9ttxz1333Xnv3fffgQ9e+HgT7fxzx/+VQD0Uwud+23mw7WE+UckptxyVNdp44/Lln9+n+2mk3yL8Pg9P/BTQVQmAFbK/l2Z8aKFvX+737wZffvbvd5v+x+P3vn//8ba/KgiwdP9zX/RMl0AFLpCBDXTgAyEYQQlO0GwdgADyjkCBUriOExbEoBE8sIoPjsGDU1DFCMVQwiR8QF6dUOEKR+eJF54Bdh34WvpG+ADXUW8TOKQCBSzACR8qQXQoBMMQkfCBD3wCiUf4wAY42IkmJiECmfua8pRAgcl1AotJeMASuThCCXSui5koIwsZZsQwdLEBZTSNERuwvrG5EQAcgIANw7gExm0Aj29Mwig4cL08TuEDEPD/RBdHAYEYHtKIQDybGzEARbSpsYqMhGHjBrmEUVgSCRngSOX6uAk3CnKOjrueByywvUGi4nA2pIAhV6k8UorSlKCzgOs+4AFOXm99lVNlT2rpuAfocmzpC8ASWVnDHsYLmWlowANKoUYvGLOZyJvlGKh5PjVAMwC3FCIztVnHDahvdZnI5vVGEUUKrpOd7XTnO+EZT3nOk571tOc98ZlPfe6Tn/305z8BGlCBDpSgBW1T5bZ4BRZ6bhoZgEAQDdocaHqujZZbAuLUeQSEdrKbSqgcBaYZAJCGlHQRJc1EAVDRX15ho0fwJESR4AE4hHSkXtiAFU160gBQlBQNeGYp/zwHzR2uYqeVswDiUqlIUjDUCBAgJgAQx80IhDCVADBmBDwZrwZEkhSTM+pRM4A4UnCQhRnN6WO4Ka+fSgANphCqKiY30crpMoRY7SgS0ABGqKZhFKZgIQZUAdJxdiCwAHgpAP5aOVIcVXVU3OlZS4NSlSpVq0KFphnkGoDJadCuMKWhXjF6WM6mdamFNSYpKNBS0XXzcqpgKmTR+liVQnN1bxUpAEIogY1y1pM4BYBTjxDajnJWFXq16jENe1cjtDS4jUVs62A7Gsn29KerWEPrGhDChxZVswDg7HUfewSZXk64QfzuaTPQALFudZyjayll9XrT6IKoAYPdwkfroTOKks6XPBUlZxcWSg2Hepa/BTbwgRGcYAUvmMENdvCDIRxhCU+YwhW28IUxnGENbxgjQQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The smoothed percentiles of FEV",
"    <sub>",
"     1",
"    </sub>",
"    by height for white girls; six cities, United States.",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wang X, Dockery DW, Wypij D, et al. Pediatric Pulmonology 1993; 15:75.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_20_33103=[""].join("\n");
var outline_f32_20_33103=null;
